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1c e rv Ic a l c a nc e r
Cervical cancer is preceded by pre-malignant dysplastic changes in the epithelium known as 
cervical intraepithelial neoplasia (CIN) or squamous intraepithelial lesions (SIL). Affected 
cells comprising of more than one-third of the epithelium are called CIN 2/ 3 or high-grade 
SIL (HSIL). HSIL is caused by persistent infection with the human papillomavirus (HPV), a 
DNA virus infecting the basal cells of the cervical epithelium (1-3). There are over 100 types 
of HPV, which can be divided into low-risk (non-oncogenic) and high-risk (oncogenic) HPV 
(4). HPV is the most common sexually transmitted virus (5) with a lifetime risk of infection 
of 80% (6-8). In the majority of cases infection is controlled after approximately 2 years, but 
persistence of infection occurs in about 10% of the women (6- 7). These women are at risk 
of developing CIN, but other areas can be infected as well (vagina, anus, vulva, penis and/
or head and neck) with risk of progression to invasive squamous(adeno)carcinoma (5-7, 9, 
10). The HPV genome importantly encodes the two oncoproteins, the early antigens 6 (E6) 
and 7 (E7), which are expressed in HSIL and tumour cells which are required for the onset 
and maintenance of the malignant transformation (4).
I m m u nol o g y
The immune systems defense against hpv-induced cervical lesions.
Both the innate and adaptive immune system play an important role in the protection 
against HPV. Keratinocytes, the first line of defense express among other pathogen recep-
tors, Toll-like receptor (TLR)-9, which can recognize HPV DNA. Activation of TLR9 should 
lead to activation of NF-kB, which results in the up regulation of proinflammatory cytokines 
(eg GM-CSF, IL-1b, TNF-a, IL-10, Il-12) and chemokine’s, inducing the migration and the 
activation of antigen-presenting cells (APC’s) e.g. Langerhans cells (LC’s), Dendritic cells 
(DC’s) and macrophages. Activation of the adaptive immune system requires viral antigen 
to be cross-presented by activated APC’s (11). Cues in the microenvironment will evoke 
APC to differentiate and migrate to the local lymphoid organs in order to present antigens 
to locally present naive T cells. Depending on different co-stimulatory or -inhibitory mol-
ecules and cytokine production (e.g., IL-12 or IL-10), a T-cell response will be induced 
which may comprise various CD8+ cytotoxic T cells (CTLs), CD4+ helper T cells (Th cells) 
and/or CD25+FoxP3+ regulatory T cells (Tregs) (11). As HPV proteins are foreign to the 
body they should be able to trigger a strong immune reaction when presented in the cervical 
epithelium.
In the circulation of healthy individuals HPV-16 specific Th1, Th2 cells and CTLs are de-
tected against a broad array of epitopes of the viral early (E2, E6, E7) and late (L1) antigens. 
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These cells are able to leave the circulation and migrate to areas where the antigen is present 
(12-19). The importance of the adaptive immune system is shown by the high incidence of 
HPV infections, HSIL and cervical cancer in immune suppressed individuals (20) and at the 
time of spontaneous regression of HPV-infected genital warts, lesions are infiltrated with 
CTL, CD4+ T cells and macrophages (21). A broad HPV specific T-cell response, consisting 
of Th1, Th2 and CTLs, seems desired for viral control, yet in patients with HPV induced 
disease this response is often not present. It deems logical that restoration of this profile is 
one of the aims of immunotherapeutic strategies.
escape from the immune system
Failure of immune system to control infection is reflected by the fact that only one third 
of cervical cancer patients display a detectable systemic HPV-specific response against E6 
and E7, and when it is present, the response is generally not associated with the production 
of IFN-γ and consists of mostly Th2 cells, non-polarized T cells or Tregs (14, 22-26). In 
the course of HPV infection to cervical cancer, various factors seem to play an important 
role. Pathogen recognition receptor (PPR) signaling in keratinocytes is suppressed, human 
leukocyte antigen (HLA) expression is down regulated, immunosuppressive cytokines are 
produced, Tregs are induced while Th cells and CTLs may be rendered dysfunctional via the 
expression of co-inhibitory molecules. Furthermore, APC’s are hampered in their function.
- Viral recognition receptors
Keratinocytes are the first line of defense against invading pathogens. Viruses are recognized 
via several PRR. The viral DNA of HPV can be recognized by cells expressing TLR9. TLR9 
is expressed in differentiating keratinocytes, but not in the undifferentiated cells of the basal 
layer which is the port d’entree of HPV. During infection with high risk HPV, TLR9 expres-
sion in the epithelium is not affected (2, 27), but its downstream signaling, as well as that of 
several other PRR which might recognize parts of HPV, is suppressed by the upregulation 
of the cellular protein ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) that dampens 
the production of interferon’s, cytokines and chemokine’s needed for the attraction and full 
blown activation of the adaptive immune system (2, 28). This renders the virus less visible, 
allowing HPV to persist.
- HLA expression
Essential elements for successful recognition of infected (or transformed) cells by the im-
mune system is the presentation of viral peptides by HLA class I and II molecules. Down-
regulation of HLA class I on HPV transformed cells, possibly resulting in escape from CTL 
attack, is observed in cervical neoplasia (29, 30) and in patients with cervical cancer where 
the loss of HLA-A expression is associated with worse survival (31). HLA class II expression 






1cells, which are needed for the promotion of CTL recruitment and cytolytic function (32). 
In colorectal carcinoma HLA class II expression is a favorable prognostic marker (33) but 
its role in cervical cancer is less clear. Other non-classical HLA types have been described to 
play a role in the persistence of HPV induced lesions. HLA-G is found on cervical tumour 
cells (34-35) and might inhibit the function of NK cells (not frequently found in HPV 
induced lesions) and T cells through the binding of inhibitory receptors. The expression 
of HLA-G is associated with progression of pre-malignant to malignant lesions (34, 36). 
HLA-E is another non-classical HLA type which is over expressed in HPV induced lesions. 
HLA-E can inhibit the function CTL’s expressing the CD94/NKG2A receptor which are 
frequently found in HPV induced lesions (37). A third non-classical HLA molecule is the 
MHC class I chain related molecule A (MICA) which interacts with the stimulating NKG2D 
receptor on CTL’s and NK cells and enhances the effector function of these cell types (31, 
38). MICA is expressed on normal epithelium but is weak or absent in about 60% of cervical 
tumours and is associated with worse survival when analysed in combination with a low 
ratio of CTL/ Tregs (31).
- Tumour expressed inhibitory molecules
T cell infiltration and function can be hindered through tumour expressed molecules. 
Versican is expressed in cervical tumours and thought to prevent the homing of T cells 
into the tumour. High expression was associated with low numbers of tumour infiltrating 
T cells (TIL’s) in cervical tumours (39). Furthermore, co-inhibitory molecules expressed 
by chronically activated CD4+ and CD8+ T cells can interact with their ligands, when lo-
cally expressed. Examples are Cytotoxic T-Lymphocyte Antigen 4 CTLA-4, program death 
1 (PD-1) and T cell immunoglobulin mucin-3 (TIM-3) expressed on T cells (40-42). The 
interaction between PD-1 receptor on T cells and program death ligand 1 (PD-L1[B7-H1]) 
and/or PD-L2 (B7-DC) results in the induction of apoptosis, anergy or exhaustion of effec-
tor T cells (43-45). Many PD-1 positive T cells are found infiltrating cervical cancer, yet its 
ligand PD-L1 is found less frequently on the cancer cells (45, 46). Interaction of TIM-3 and 
its ligand Galectin-9 results in a decreased Th1 and CTL immunity by inducing apoptosis 
of Th1 cells as well as by inhibiting the function of CTLs and Th1 cells (40, 42, 47). Increase 
in Galectin-9, has been associated with malignant differentiation in cervical cancer (48).
- Antigen presenting cells
HPV has been reported to also regulate the function and migration of APCs present in 
the epithelia, thereby hampering the activation of the adaptive immune response. The 
L2 protein of HPV is able to suppress the maturation of LC’s causing inadequate antigen 
presentation to T cells (3, 49). Not only the function, but also the number of LCs seems 
reduced in HPV-infected epithelia (50-52). Furthermore, the absence of pro inflammatory 
signals in HPV-infected epithelia can result in inappropriately activated APCs (53). The 
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expression of HLA class II on tolerogenic APC’s in the tumour could have pro-tumoural 
effects by rendering Th cells anergic through the lack of stimulation via co stimulatory 
molecules (eg CD40) and/or by the production of inhibitory cytokines, or by the induction 
and activation of Tregs (54). Tumour associated macrophages (TAM), are a heterogeneous 
myeloid cell population originating from monocytes in the circulation, which are able 
to undergo specific differentiation depending on the different stimulatory signals within 
the tumour microenvironment. Macrophages display the flexibility to continuously adapt 
to such cues in the local microenvironment allowing them to differentiate into cells that 
phenotypically and functionally fit between the two extreme polarization states known: 
M1-like pro-inflammatory, tumoricidal macrophages (M1) and M2-like anti-inflammatory, 
tumor-promoting macrophages (M2). Both are frequently found infiltrating tumours, but 
opposed to M1, M2 have a poor antigen-presenting capacity, preventing T-cells to be prop-
erly activated, furthermore they can enhance angiogenesis and metastasis (55) and have 
been associated with worse survival in various tumour types (56).
- Regulatory T cells and cytokines
In addition to CTL and Th cells the tumour milieu may also comprise Treg. Tregs display 
a high expression of CD25 and express the forkhead box protein 3 (FOXp3). Tumour 
infiltrating FOXp3+ T cells have been studied extensively and have been correlated with 
a poorer prognosis in various cancer types (57-64). Tregs found in tumours can inhibit 
the proliferation and function of Th cells and CTL’s by preventing the expression of Il-2 
receptor or inhibiting Il-2 production (24). The ratio of tumour-infiltrating CD4+, CD8+ 
and tumour-infiltrating Tregs is strongly correlated to survival in patients with cervical 
cancer (24, 31, 65, 66) and HPV specific Tregs have been found infiltrating cervical cancer 
(24, 25). Tregs further suppress the antitumor response by the induction of suppressive M2 
macrophages, the up regulation of Il-10, the induction of tolerogenic indoleamine 2,3-di-
oxygenase (IDO)-positive APCs and the production of TGFβ (24). Il-10 and TGFβ can 
also be produced by tumour cells. Together, tumour cells, TAM and IDO+ APC may form 
a strongly immunosuppressive milieu. IDO, which is an immunosuppressive molecule, was 
found to be highly expressed in HSIL and cervical cancer on myeloid cells in the tumour 
stroma and the expression of IDO by tumour cells was correlated with an unfavourable 
survival in patients with cervical cancer (67-69). TGFβ is highly expressed in SIL and cervi-
cal cancer (70, 71), and prevents the infiltration of T cells into tumours, inhibiting their 






1I m m u not h e r a py of c a nc e r
With all evidence pointing in the direction that failure of the immune system leads to the 
development of cervical cancer, restoration of an effective anti-tumour immunity seems the 
logical way forward. Various modalities have been developed with limited success, affecting 
often a minority of patients with progressive disease. As discussed above a multitude of 
mechanisms can be responsible for the tumours escape from the hosts’ immune system. 
Therefore successful immunotherapy probably lies in multiple therapeutic strategies aiming 
at the enhancement of immune-mediated tumour destruction as well as simultaneously 
counteracting the tumour-induced immune suppression. Three main modalities have been 
developed to achieve this goal, but it is likely that this arsenal will increase tremendously in 
the coming years.
Therapeutic vaccination
Various therapeutic vaccines aiming at inducing and/or restoring the tumour-specific T-cell 
response have been investigated (73). Vaccines based on recombinant viral vectors, recom-
binant proteins, DNA, antigen-pulsed DC’s and peptides have been developed. For cervical 
cancer two promising vaccination strategies have been developed. One is a recombinant 
HPV16 E6E7L2 fusion protein (tissue antigen-cervical intraepithelial neoplasia, TA-CIN) 
(74) showing clinical responses when the vaccine was combined with Imiquimod treatment 
of the lesion. The other is a synthetic long overlapping peptide vaccine of HPV16 E6 and 
E7 (HPV16 SLP) which showed a good immunogenicity in cervical cancer patients (75, 
76) and a clinical response in patients with VIN (77). This clinical response was associ-
ated with the induction of a strong HPV-specific CD4+ T cell and CD8+ T cell response. 
Furthermore, unresponsive patients showed an increase in the numbers of HPV16-specific 
Tregs infiltrating the lesion.
antibodies and cytokines
Nonspecific immune stimulation with the use of monoclonal antibodies or recombinant 
cytokines can activate the immune system directly or counteract tumour induced immune 
suppression. Blocking or inhibiting immune inhibitory pathways are widely being inves-
tigated in cancer immunotherapy. CTLA4 blockade with Ipilimumab results in a broad 
enhancement of the immune system by T-effector stimulation and depletion of Tregs as 
reviewed by Blank et al (78). Blocking of CTLA-4 has been found to mediate a significant 
mean survival benefit in patients with advanced melanoma and an impressive long-term 
survival rate of a subgroup of patients (18% surviving longer than 2 years) (79). PD-1 is 
another immune checkpoint molecule, expressed by activated effector or Tregs within 
tumours (45, 80, 81), while its ligand, PD-L1, is expressed by tumour cells of many different 
tumour types and on macrophages and DC’s (44, 45). Interaction results in the inhibition 
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of T-cell function. Blockade of this pathway (Nivolumab) has been demonstrated to have 
success in pre-clinical studies (82). Phase 1 trials are showing promising response rates with 
Anti-PD-L1 and Anti-PD-1 antibodies with less toxicity that CTLA-4 (83, 84). Combining 
Ipilimumab and Nivolumab showed objective responses in more that 40-50% of melanoma 
patients (85). The stimulation of costimulatory receptors on the other hand is also a promis-
ing potential strategy. OX40 (CD134) and 4-1BB (CD137) are co stimulatory receptors of 
the TNF family that are expressed on activated CD4 and CD8 T-cells. Agonistic antibodies 
to these receptors have powerful capabilities to activate CD8+ T cells to produce IFN-γ (86, 
87). Various recombinant cytokine have found their way in to clinical trials with promising 
results. Examples are GM-CSF, inducing the proliferation of DC’s and macrophages, Il-2 
inducing T-cell activation and proliferation (88), Il-12 creating IFNγ producing T-cells (89) 
and type I Interferons which are known to have direct anti-viral properties, induce the 
differentiation of Th cells, generate CTL’s and prolong the survival of all T cells (90). Other 
potential candidate cytokines are Il-7, Il-15 and Il-21 able to stimulate T cells or chemokines 
(e.g. CXCL9 and CXCL10) to attract T cells to the tumour.
a d op t I v e c e l l t h e r a py
In adoptive cell therapy (ACT), lymphocytes are ex-vivo isolated from peripheral blood, 
tumour-draining lymph nodes or the tumour of cancer patients. Following an in vitro 
expansion the (partially) tumour-specific lymphocyte population is re-infused into the pa-
tient. This strategy may offer advantages over in vivo vaccination as the T cells are activated 
and expanded outside the cancer-induced immunosuppressive milieu, potentially allow-
ing them to acquire more potent anti-tumoural properties. Moreover, in vivo lymphocyte 
depletion prior to infusion may also deplete pre-existing Tregs. In melanoma patients ACT 
has led to significant and durable remissions as reviewed in Phan et al (91).
ou t l I n e of t h I s t h e sI s
This thesis firstly investigates the natural immune response against HPV in patients with 
(pre-) cancerous lesions of the cervix with an emphasis on the tumour microenvironment, 
by studying the local HPV-specific T-cell responses in HSIL and cervical tumours and 
draining lymph nodes, the presence of myeloid cells in cervical tumours, their interaction 
with the microenvironment and the effect on survival. The last two chapters describe two 
clinical trials in which patients with pre-cancerous lesions of the cervix are vaccinated with 






1In the face of developing therapeutic vaccination strategies, it is of vital importance to 
gain a better understanding of the local tumour environment and the pre-existing local 
anti-tumour response. In chapter 2 we investigated the systemic and local HPV16 T cell 
response in patients with HSIL. Only a minority of the patients with HPV16+ HSIL have 
an IFNγ associated HPV16 specific T cell response. Proliferative responses were more often 
found, especially in patients with persisting infections after previous surgical treatment. 
Moreover, we showed that these premalignant lesions could be infiltrated with HPV-specific 
Tregs. The results of this chapter formed a good basis for the design and interpretation of 
immunotherapeutic vaccine approaches as treatment modality for HPV-induced in pre-
cancerous lesions.
Previous work showed that HPV specific T cells can be found infiltrating the tumour and 
its draining lymph nodes. We wanted to know the potential of these cells to aid tumour im-
munity and, therefore, studied the properties of these T cells. In chapter 3 we comprehen-
sively analysed the spontaneous tumour-specific immune response in patients with cervical 
cancer by dissecting local HPV E6- and E7-specific CD4+ and CD8+ T-cell responses down 
to the level of the percentage, specificity, cytokine polarization and number of different 
responding T-cells. We describe a large polyclonal repertoire of HPV-specific T cells present 
in the tumour and lymph nodes of cervical cancer patients, whereby we distinguished four 
different cytokine signatures based on the production of IFNγ and Il-2. This work shows 
TIL’s can be isolated and cultured for use in ACT.
The focus of chapter 4 was to further improve our knowledge of the local microenviron-
ment by investigating the tumour infiltrating myeloid cells. The different types of myeloid 
cells, their clinical impact and their co-operation with T cells in the cervical cancer micro-
environment was analysed. A strong intraepithelial infiltration with CD14+CD33-CD163- 
myeloid cells associated with a large influx of intraepithelial T lymphocytes, improved 
disease-specific survival and formed an independent prognostic factor for survival. This 
study provided a profound insight on the role of myeloid cells in the microenvironment, 
how they can work side by side with T cells to control tumours and forms a major addition 
to the current discussion about the impact of tumour-infiltrating myeloid cells in human 
cancers.
The influence of human cervical cancer cells on myeloid cell (monocyte) differentiation is 
presented in chapter 5. It shows that the majority of cancer cells either hamper monocyte 
to DC differentiation, or skew their differentiation towards M2-like macrophages. Block-
ing studies revealed that M2-differentiation was caused by tumour-produced PgE2 and 
IL-6. Furthermore, upon cognate interaction with Th1 cells these tumour-induced M2-
macrophages could be switched back to activated M1-like macrophages. These data show 
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the plasticity of tumour-induced tolerogenic APC and suggest that increased numbers of 
tumour-infiltrating Th1 cells may stimulate a tumour-rejecting environment by switching 
M2-macrophages to classical pro-inflammatory tumouricidal M1 macrophages. Vaccina-
tion aimed at the induction of HPV specific Th1 cells could be beneficial.
The aim of chapter 6 was to investigate the capacity of the HPV16-SLP vaccine to stimulate 
the HPV16-specific T-cell response and to enhance the infiltration of HPV16-specific type 
1 T-cells into the lesions of patients with HPV16+ HSIL and HPV clearance. This was a 
placebo controlled randomized phase II study in patients with HPV16 positive HSIL. Vac-
cination of HSIL patients resulted in increased Th1 HPV16-specific T-cell immunity.
chapter 7 investigates the capacity of a low dose of the HPV16-SLP vaccine to induce an 
HPV16-specific T-cell response in patients with low grade abnormalities of the cervix, to 
determine the long term memory response after vaccination and finally to evaluate the need 
and potency of a booster vaccination after one year. We concluded that two low dose injec-
tions of HPV16-SLP can induce a strong and stable HPV16-specific Th1 T-cell response that 
lasts at least for 1 year. The booster injection resulted in increased Th2 responses.
In chapter 8 the contribution of our results to the current knowledge of the immune 
response to HPV induced lesions and cancer is discussed. In addition, the present and 
future of immunotherapeutic strategies in cervical cancer according to recent international 
literature is reviewed.
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a b st r ac t
Purpose: To characterize HPV16 E6- and E7-specific T-cell immunity in patients with high-
grade squamous intraepithelial lesions (HSIL).
Experimental design: PBMC isolated from 38 patients with HPV16+ HSIL were used to 
determine the magnitude, breadth and polarization of HPV16-specific T-cell responses by 
proliferation assays and cytokine assays. Furthermore, HSIL-infiltrating T-cells isolated 
from 7 cases were analyzed for the presence of HPV16 E6 and/or E7-specific T-cells, pheno-
typed and tested for the specific production of IFNγ and IL-10 as well as for their capacity 
to suppress immune responses.
Results: HPV16-specific T-cell responses were absent in the circulation of the majority 
(~60%) of patients who visit the clinic for treatment of an HPV16+ HSIL lesion. Notably, 
HPV16-specific T-cell reactivity was predominantly detected in patients returning to the 
clinic for repetitive treatment of a persistent or recurrent HPV16+ HSIL lesion after initial 
destructive treatment. The majority (>70%) of these HPV16-specific T-cell responses did 
not secrete pro-inflammatory cytokines, indicating that most of the subjects, although in 
principle able to mount an HPV16-specific immune response, fail to develop protective 
cellular immunity. This notion is sustained by our observation that only 3 HSIL-infiltrating 
T-cell cultures contained HPV16-specific T-cells, one of which clearly consisted of HPV16 
E7-specific regulatory T-cells.
Conclusions: The presence of HPV16-specific T-cells with a non Th1/Th2 cytokine and even 
suppressive signature in patients with HSIL may affect the outcome of vaccine approaches 
aiming at reinforcing HPV-specific immunity to attack HPV-induced lesions.






I n t rodu c t Ion
Cervical cancer is preceded by well defined stages of changes in the epithelium known as 
cervical intraepithelial neoplasia (CIN) or squamous intraepithelial lesions (SIL), which are 
caused by persistent infection with human papillomavirus (HPV). Changes that affect more 
than one-third of the epithelium are diagnosed as CIN 2 or 3 or high-grade SIL (HSIL). 
These HSIL have a high chance of progressing to cancer if left untreated (1). Most HSIL are 
associated with the presence of a high-risk HPV type, in particular HPV type 16 (2). The 
HPV genome encodes two oncoproteins, E6 and E7, which are constitutively expressed in 
high-grade cervical lesions and cancer since they are required for the onset and mainte-
nance of the malignant cellular phenotype (3).
The key role of the adaptive cellular immune system in the protection against HPV-induced 
lesions is indicated by the high incidence of persistent HPV-infections and subsequent 
HPV-related malignancies in immunosuppressed individuals (4) as well as by the fact that 
only a fraction of infected subjects develop progressing epithelial lesions or cancer (5). Since 
HPV proteins are foreign to the body, one would expect the immune system to mount a 
response against these antigens when expressed in the cervical epithelium. Indeed, HPV16 
E6, E7 and E2-specific Th1- and Th2-type CD4+ T-cell responses were frequently detected 
in PBMC cultures of healthy individuals (6-8) and both HPV16-specific CD4+ and CD8+ 
T cells are able to migrate upon antigenic challenge {van den Hende, 2008 176 /id} showing 
that successful defense against HPV16 infection is commonly associated with the install-
ment of a systemic effector T-cell response against these viral antigens.
The local microenvironment in an HSIL is associated with an increase in IL-10 produc-
tion and a decrease in proinflammatory cytokines (10-13), which poses a harsh milieu for 
the immune system and is likely to affect both the systemic and local immune response. 
Indeed, patients with HSIL show evidence of non-specific suppression of type 1 T-helper 
cell cytokine production (11;14) but how this affects the priming and the character of an 
HPV-specific immune response is only slowly elucidated. So far, the presence of HPV-
specific immunity has either been studied in a number of really small cohorts of patients 
with HSIL (7;15-21), or in somewhat larger cohorts that focused on a highly restricted set 
of antigenic peptides (22), and/or studies using only one single immunological parameter 
(23-26) to decide whether a response is present. Unfortunately, huge differences between 
these studies in design and outcomes complicate the development of a unifying picture on 
how HPV-specific immunity and HSIL co-evolve.
So-called therapeutic vaccines are being developed for the treatment of individuals who 
contracted a high-risk type of HPV and were unable to control the viral infection - as dem-
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onstrated by the presence of an HPV-induced (pre-)malignant lesion (27-31). A number of 
therapeutic vaccines have been tested in patients with cervical and non-cervical high-grade 
genital lesions, but with modest success (32-38). Since these therapeutic vaccines aim at 
reinstating an effective T-cell response against HPV16 E6 and/or E7 it will become very 
important not only to know the presence of pre-existing HPV16-specific T-cell immunity 
in patients with HSIL but also to understand the functionality, as this may bear impact on 
vaccine efficacy (39;40).
Here we have studied the presence and function of spontaneously induced HPV16-specific 
T cells in a large group of patients with HPV16+ HSIL. HPV16-specific proliferative T-cell 
responses were detected in less than half of the patients and the majority of the responses 
were not associated with the production of IFNγ or other pro-inflammatory cytokines. 
Notably, even HPV16-specific regulatory T-cells could be isolated from HSIL tissue. The 
induction of these HPV-specific T-cell responses most likely is the product of surgical treat-
ment with recurrence or persistence of disease.
m at e r Ia l s a n d m et hod s
patient inclusion and sample collection
Patients visiting the colposcopy clinic at the department of Gynaecology of the Leiden 
University Medical Centre or the Haga Teaching Hospital in The Hague were recruited in 
the CIRCLE study, which investigates cellular immunity against HPV16- positive cervical 
lesions. The study design was approved by the Medical Ethical Committees of the Leiden 
University Medical Center and the Haga teaching hospital. Patients were eligible for the 
current study if they had a histologically proven cervical intraepithelial neoplasia at the time 
of diagnostic colposcopy or loop electrical excision procedure (LEEP). Notably, patients 
with chronic HSIL were more motivated to participate in this study hence this group pf pa-
tients is somewhat overrepresented in our cohort. Informed consent was obtained from all 
patients. Seventy ml of blood was drawn on the day prior to LEEP. Serum was obtained and 
peripheral blood mononuclear cells (PBMC) were isolated from heparinised blood samples 
by Ficoll (Sigma) density centrifugation for the analysis of HPV-specific T-cell reactivity. In 
a number of cases tissue from the lesion was obtained for research purposes.
hpv typing
Patients with a HSIL were typed for HPV on paraffin-embedded sections of biopsies using 
3 general HPV primer sets (CPI/II [1], MY 9/11[2], GP 5+/6+ [3]) followed by sequencing. 
Sequencing results were analysed by the NCBI BLAST programme. As controls beta-globine 
PCR and a blank sample were included (41-43).







A set of 22 amino acid long peptides, overlapping by 12 amino acids, and indicated by the 
first and last amino acid in the sequence of the E6 and E7 protein of HPV16 (e.g. E6.1-
22 and the last peptides E6.137-158 and E7.77-98), were used for the screening of T-cell 
responses. The peptides were mixed into four pools of E6 peptides and two pools of E7 
peptides (i.e. E6.1 - E6.4, E7.1 and E7.2). These pools consisted of four 22-mer peptides. 
Notably, peptide pools E6.3 and E6.4 both contained peptide E6.111-132, whereas peptide 
pool E7.2 harbored the last five peptides of HPV16 E7. The peptides were synthesized and 
dissolved as described previously (44). Memory response mix (MRM) consisted of tetanus 
toxoid (0.75 Limus Flocculentius per ml; Netherlands Vaccine Institute, Bilthoven, The 
Netherlands), sonicated Mycobacterium tuberculosis (5 μg/ml; kind gift from Dr. P. Klatser, 
Royal Tropical Institute, Amsterdam, The Netherlands) and Candida (0.015%, HAL Aller-
genen Lab, Haarlem, The Netherlands). The response to MRM was used as positive control 
in the assays (8) to confirm the capacity of the antigen presenting cells that are present in 
PBMC to process and present antigens to memory T-cells.
proliferative capacity of hpv16-specific t-cells by lymphocyte stimulation test 
(lst)
The capacity of T-cells to proliferate upon stimulation with the antigen was determined by 
short-time proliferation assay as described earlier (6;8;45). Briefly, freshly isolated PBMC 
(1.5 x 105) were seeded into 8-replicate wells of a 96-well U-bottom plate (Costar, Cam-
bridge, MA) to which the indicated peptide pools were added at a final concentration of 10 
μg/ml. Medium without antigen served as background control and MRM was taken along as 
a positive control. The test was conducted in IMDM (BioWhittaker, Verviers, Belgium) con-
taining 10% autologous serum. On day 6, supernatant was harvested for cytokine analysis 
and subsequently the cells were pulsed with 0.5 μCi [3H]Thymidine (Pelkin Elmer, Boston, 
USA) per well and incubated for an additional 18 hours. Then, the cells were harvested onto 
filters (Wallac, Turku, Finland) using the Micro-cell Skatron harvester (Skatron Instruments 
AS, Lier, Norway) and counted on the 1205 Betaplate counter (Wallac, Turku, Finland). The 
average and standard deviation of the 8 medium only control wells were calculated and the 
cut-off was defined as this average plus 3xSD. The stimulation index (SI) was calculated as 
the average of tested 8 wells divided by the average of the medium control 8 wells. A positive 
proliferative response was defined as a stimulation index of at least 3 and the counts of at 
least 6 out of the 8-wells must be above the cut-off value (7).
cytokine analysis
The supernatants isolated on day 6 of the proliferation assay were subjected to a Th1/Th2 
inflammation cytokine bead array (CBA) kit (BD Biosciences, Erembodegem, Belgium). In 
this array the levels of IFNγ, TNFα, IL-10, IL-5, IL-4 and IL-2 were determined. According 
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to firm prescription the proposed detection limit was 20 pg/ml. However, for IFNγ the 
cut-off value was set to 100 pg/ml because the standard curve showed linearity starting at 
a concentration of 100 pg/ml. Positive antigen specific cytokine production was defined as 
a cytokine concentration above the cut-off value and >2x the concentration of the medium 
control (7).
culture of cIn Infiltrating lymphocytes
CIN Infiltrating Lymphocytes (CIL’s) were isolated and cultured as described previously 
(46). Briefly, CIL cultures were expanded using a mix of irradiated autologous Epstein-Barr 
virus transformed B cell lines (B-LCL) and 5 ug/ml cognate peptide in IMDM, supple-
mented with 10% human AB serum (PAA laboratories, Pasching, Austria), 10% T-Cell 
Growth Factor (TCGF, Zeptometrix, Buffalo NY, USA) and 5 ng/ml recombinant human 
IL-15 (Peprotech, Rocky Hill NJ, USA).
analysis of t-cell specificity
T-cell cultures (25,000-50,000 cells/well) were stimulated with autologous monocytes or 
irradiated autologous B-LCL’s pulsed with their cognate peptide (ID2 HPV16 E7.71-92; 
ID23 HPV16 E7.51-72; 5 μg/ml) (47) and protein (10 μg/ml) in triplicate wells in a 3-day 
proliferation assay. After 48 hours supernatant was harvested and stored at -20oC for cy-
tokine analysis. Antigen-specific IFN-γ and IL-10 production was measured by ELISA as 
described earlier (19).
detection of cd4+ cd25+foxp3+ t-cells
HPV16-specific CIL lines were stained 3 weeks after their last antigen-specific activation 
in vitro first for surface markers CD25 (anti-CD25 FITC; clone M-A251, BD Pharmingen), 
and CD4 (anti-CD4-APC; clone RPA-T4, BD Pharmingen) before the cells were fixed and 
permeabilized. Blocking was performed with 2% normal rat serum followed by the addition 
of anti-human Foxp3 (PCH101, eBiosciences, San Diego, CA) antibody or rat isotype IgG2a 
control. Then the cells were washed and analyzed by flowcytometry. As a positive control a 
previously isolated HPV16-specific CD4+CD25+Foxp3+ regulatory T-cell clone (C148.31) 
and as negative control an HPV16-specific CD4+CD25+Foxp3- T-cell clone (C271.9) (47) 
were used. The fluorescence intensity of these two control clones was used to set the gates 
for the other samples in which the CD25+Foxp3+ expression of the stimulated polyclonal 
T-cell populations were analyzed.
hpv16-specific t-cell suppression assay
T-cell suppression assay’s were performed as described previously (47). Briefly, the CIL 
lines were co-cultured with allogenic CD4+CD25- responder cells in the presence of 1 μg/
ml agonistic anti-CD3 (OKT-3; Ortho Biotech, Bridgewater, NJ) and APC mixture of 5 






different B-LCL cell lines. Suppression of the responder cells was analyzed on proliferation 
and IFNγ production as described previously (47). HPV16 antigen-dependent suppression 
was measured using a flowcytometry based proliferation assay. Responder cells were labeled 
with CFSE and co-cultured with PKH -26 labeled CIL lines at a 1:1 ratio. The responder 
cells were stimulated with a pool of 5 allogenic B-LCLs, the HPV-specific CIL lines were 
stimulated with 5 ug/ml cognate peptide and autologous B-LCL in the presence of IL-2 
(300 IU/ml). After 4 days of culture, the allo-specific proliferation of responder T-cells was 
analyzed by flowcytometry. HPV-specific CIL lines were treated with 50 μg/ml mitomycin 
C (Kyowa, Hakko, Japan) for 1 h followed by irradiation (2,000 rad) to prevent proliferation 
but not effector function.
statistical analyses
In order to evaluate the effect of a previous treatment for high-grade CIN and persistence of 
the lesion afterwards on HPV-specific immunity, the patients were divided into two groups. 
The group of patients with a persistent lesion after treatment consisted of patients who 
had already undergone a surgical treatment for a HSIL after which the lesion persisted at 
least for 8 months (range 8-72 months) as indicated by the detection of Pap3a or higher 
in follow-up smears, or a HSIL at follow-up colposcopy for which these patients all had to 
undergo a second surgical treatment at the time that blood was drawn for the detection of 
HPV-specific immunity. Patients without a persistent infection where defined as patients 
who had no prior treatment before the drawing of blood for the immunological assay. These 
groups were then subdivided into patients who did show an HPV-specific immune response 
or in whom no specific immune response was detected and analyzed by a two-sided Fisher’s 
exact test.
r e su lt s
patients and hpv distribution
During a period of 5 years a total of 74 patients with a HSIL were included in this study, 16 
patients who were diagnosed with a CIN2 and 58 with a CIN3 (Table 1). The median age 
was 38 years with a range of 24-68 years. HPV typing revealed that 60 patients (81%) were 
HPV 16 positive and 2 (3%) were HPV 18 positive. In 11 patients (15%) another HPV type 
was found (HPV 45, 33, 31) and 1 patient was HPV negative (Table 1).
patients with hsIl fail to induce a strong hpv16 e6- and e7-specific t-cell 
response
From 38 HSIL patients (Table 2) freshly isolated PBMC were stimulated with peptides 
derived from HPV16 proteins E6 and E7 as well as with a mix of common recall antigens 
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(MRM) in a short-term proliferation assay (Figure 1A). We have previously shown that this 
assay is geared towards the detection of CD4+ T-cell responses (7;8;14;22). HPV16-specific 
T-cell responses were detected in 15 (39%) of the 38 patients (Table 3). In 6 cases prolifera-
tion was detected against E6, in 3 cases to E7 and in 6 cases to both E6 and E7 (Table 3). 
Analysis of the supernatants of these T-cell cultures for the presence of type 1 and type 2 
cytokines revealed the secretion of the Th1 cytokine IFNg in 6/15 (40%) patients with a pro-
necrosis factor-a, IL-10, IL-5, IL-4, and IL-2 were determined. According
to manufacturer’s instructions, the proposed detection limit was
20 pg/mL. However, for IFN-g the cutoff value was set to 100 pg/mL
because the standard curve showed linearity starting at a concentration
of 100 pg/mL. Positive antigen-specific cytokine production was
defined as a cytokine concentration above the cutoff value and more
than two times the concentration of the medium control (7).
Culture of CIN-infiltrating lymphocytes. CIN-infiltrating lympho-
cytes (CIL) were isolated and cultured as described previously (45).
Briefly, CIL cultures were expanded using a mix of irradiated autologous
EBV-transformed B-cell lines (B-LCL) and 5 Ag/mL cognate peptide in
IMDM supplemented with 10% human AB serum (PAA Laboratories),
10% T-cell growth factor (Zeptometrix), and 5 ng/mL recombinant
human IL-15 (Peprotech).
Analysis of T-cell specificity. T-cell cultures (25,000-50,000 cells per
well) were stimulated with autologous monocytes or irradiated
autologous B-LCL pulsed with their cognate peptide (ID2 HPV16
E7.71-92; ID23 HPV16 E7.51-72; 5 Ag/mL; ref. 46) and protein
(10 Ag/mL) in triplicate wells in a 3-day proliferation assay. After 48 h,
the supernatant was harvested and stored at -20jC for cytokine analysis.
Antigen-specific IFN g and IL-10 production was measured by ELISA as
described earlier (19).
Detection of CD4+CD25+Foxp3+ T cells. HPV16-specific CIL lines
were stained 3 weeks after their last antigen-specific activation in vitro
first for surface markers CD25 (anti-CD25 FITC; clone M-A251; BD
Pharmingen) and CD4 (anti-CD4-APC; clone RPA-T4; BD Pharmingen)
before the cells were fixed and permeabilized. Blocking was done with
2% normal rat serum followed by the addition of anti-human Foxp3
(PCH101; eBiosciences) antibody or rat isotype IgG2a control. Then, the
cells were washed and analyzed by flow cytometry. A previously isolated
HPV16-specific CD4+CD25+Foxp3+ regulatory T-cell clone (C148.31)
was used as a positive control and a HPV16-specific CD4+CD25+Foxp3-
T-cell clone (C271.9; ref. 46) was used as a negative control. The
fluorescence intensity of these two control clones was used to set the
gates for the other samples in which the CD25+Foxp3+ expression of the
stimulated polyclonal T-cell populations was analyzed.
HPV16-specific T-cell suppression assay. T-cell suppression assays
were done as described previously (46). Briefly, the CIL lines were
cocultured with allogenic CD4+CD25- responder cells in the presence of
1 Ag/mL agonistic anti-CD3 (OKT-3; Ortho Biotech) and APC mixture
of five different B-LCL cell lines. Suppression of the responder cells was
analyzed on proliferation and IFN-g production as described previously
(46). HPV16 antigen-dependent suppression was measured using a
flow cytometry-based proliferation assay. Responder cells were labeled
with CFSE and cocultured with PKH-26-labeled CIL lines at a 1:1 ratio.
The responder cells were stimulated with a pool of five allogenic B-LCL;
the HPV-specific CIL lines were stimulated with 5 Ag/mL cognate
peptide and autologous B-LCL in the presence of IL-2 (300 IU/mL).
After 4 days of culture, the allospecific proliferation of responder T cells
was analyzed by flow cytometry. HPV-specific CIL lines were treated
with 50 Ag/mL mitomycin C (Kyowa) for 1 h followed by irradiation
(2,000 rad) to prevent proliferation but not effector function.
Statistical analyses. To evaluate the effect of a previous treatment
for high-grade CIN and persistence of the lesion afterwards on HPV-
specific immunity, the patients were divided into two groups. The
group of patients with a persistent lesion after treatment consisted
of patients who had already undergone a surgical treatment for a
HSIL after which the lesion persisted at least for 8 months (range,
8-72 months) as indicated by the detection of Pap 3a or higher in
follow-up smears or a HSIL at follow-up colposcopy for which these
patients all had to undergo a second surgical treatment at the time that
blood was drawn for the detection of HPV-specific immunity. Patients
without a persistent infection where defined as patients who had no
prior treatment before the drawing of blood for the immunologic assay.
These groups were then subdivided into patients who did show a HPV-
specific immune response or in whom no specific immune response
was detected and analyzed by a two-sided Fisher’s exact test.
Results
Patients and HPV distribution. During a period of 5 years, a
total of 74 patients with a HSIL were included in this study, 16
patients who were diagnosed with a CIN 2 and 58 patients with
a CIN 3 (Table 1). The median age was 38 years (range, 24-68
years). HPV typing revealed that 60 (81%) patients were
HPV16+ and 2 (3%) were HPV18+. In 11 (15%) patients,
another HPV type was found (HPV45, HPV33, and HPV31)
and 1 patient was HPV- (Table 1).
Patients with HSIL fail to induce a strong HPV16 E6- and
E7-specific T-cell response. From 38 HSIL patients (Table 2),
freshly isolated PBMC were stimulated with peptides derived
from HPV16 proteins E6 and E7 as well as with a mix of
common recall antigens (memory response mix) in a short-
term proliferation assay (Fig. 1A). We have shown previously
that this assay is geared toward the detection of CD4+ T-cell
responses (7, 8, 14, 22). HPV16-specific T-cell responses were
detected in 15 (39%) of the 38 patients (Table 3). In 6 cases,
proliferation was detected against E6, in 3 cases to E7, and in 6
cases to both E6 and E7 (Table 3). Analysis of the supernatants
of these T-cell cultures for the presence of types 1 and 2
cytokines revealed the secretion of the Th1 cytokine IFN-g in 6
of 15 (40%) patients with a proliferative T-cell response
(Fig. 1B; Table 3). Occasionally, low levels of tumor necrosis
factor-a and IL-5 were produced by the HPV16-specific
responding cells. Of all the proliferative responses measured
(n = 31) in these patients, only 9 (<30%) were associated with
the production of a proinflammatory cytokine (Table 3).
HPV-specific T-cell responses are correlated with the persis-
tence/recurrence of HSIL. The majority of HSIL lesions are
precancers that are destined to persist (1) and for that reason
are surgically removed. As a small percentage of HPV16+ HSIL
may spontaneously regress after a biopsy (47), we hypothesized
that the combination of HPV antigens and an invasive
(surgical) treatment may deliver sufficient antigenic stimulation
and danger signals to activate a HPV16-specific T-cell response.
Because several of our patients (Table 2) had already been
surgically treated in the near past for HSIL, the patients were
divided into two groups and analyzed with respect to the
absence and presence of HPV16-specific immunity. Group 1
(n = 28) consisted of those patients who were treated for the
first time for a HSIL at the time of testing for HPV-specific
immunity, whereas group 2 (n = 10) consisted of patients with
Table 1. HPV distribution in HSIL patients
Patients included N = 74
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HSIL that persisted/recurred after a first destructive treatment
and who were treated again at the time that their HPV-specific
immune status was assessed. The latter group displayed a
significantly higher respons ate to HPV16. The percentage of
positive systemic responses in the group with persistent/
recurrent lesions (group 2) wa 90% versus 21% in group 1
(P = 0.0002; Fig. 2). Altogether, our results suggest that a
systemic immune response, most often of a non-Th1/Th2 type,
develops against HPV16 E6 and/or E7 and is often induced if
the lesion persists or recurs after initial surgical treatment of
HSIL. For a high number of patients, clinical follow-up data
were available (Table 2). The potential clinical effect of the
immunologic response was analyzed by dividing the subjects
according to treatment and subdivision according to immune
status and either (a) the presence/absence of a Pap 3b or
CIN 2-3 score once within 12 months or, more stringently,
(b) the presence/absence of a Pap 3a score twice within 12
months. Neither this nor grouping only according to immune
status and clinical status in follow-up revealed any significant
relationship.
HPV16 E7-specific regulatory T cell infiltrate cervical HSIL
lesions. From 7 patients, we were able to receive a small piece
of cervical ti sue for research purposes to characterize HPV16-
specific T cells present in the HSIL lesion. As part of a larger
study, we established CIL cultures from all 7 cases (45). In 3 of
these cultures, T cells responding to HPV16 E7 were detected.
The percentages of CD3+ T cells in CIL after 3 weeks of culture
did not differ between HPV16-specific and nonspecific CIL
(54 F 16% versus 52 F 31%, respectively). From two of these
CIL cultures (ID2 and ID23), sufficient numbers of T cells were
obtained for a more in-depth analysis. On stimulation with
their cognate peptide, both CIL cultures produced IFN-g
(Fig. 3A). In addition, the culture of ID2 produced low levels
of IL-10 and a small population of the CD4+ CIL population
Table 2. Summary of patient characteristics and HPV16-specific immunity
ID Age Histology Treatment at time of analysis Previous treatment LST* CIL (antigen)c Follow-up
6 mo 12 mo
1 28 CIN 2 LEEP - Pap 1 Pap 1
2 36 CIN 2 LEEP - CIL (E7) Pap 1
3 45 CIN 2 LEEP - CIN 3
4 33 CIN 2 LEEP - Pap 1 Pap 1
5 40 CIN 2 Conization - Pap 2 Pap 2
6 61 CIN 2 LEEP -
7 41 CIN 2 LEEP - Pap 3a Pap 2
8 29 CIN 2 LEEP + Pap 1 Pap 1
9 35 CIN 2 no treatment + Pap 3a CIN 3
10 43 CIN 2 Conization LEEP 2 + Pap 2 Pap 2
11 35 CIN 3 LEEP - Pap 1 Pap 1
12 30 CIN 3 LEEP - Pap 1 Pap 2
13 31 CIN 3 Conization LEEP + Pap 1
14 33 CIN 3 LEEP LEEP + Pap 1 Pap 1
15 31 CIN 3 LEEP - Pap 1 Pap 1
16 35 CIN 3 LEEP - Pap 1 Pap 1
17 29 CIN 3 Conization - Pap 3b CIN 3
18 61 CIN 3 LEEP - CIL Pap 2 Pap 1
19 27 CIN 3 LEEP - Pap 1
20 43 CIN 3 LEEP - Pap 1
21 35 CIN 3 LEEP - CIL (E7) Pap 1
22 25 CIN 3 LEEP - Pap 3a Pap 3a
23 26 CIN 3 LEEP - CIL (E7) Pap 1 Pap 1
24 44 CIN 3 LEEP LEEP - Pap 1 Pap 1
25 35 CIN 3 LEEP - Pap 1 Pap 3b
26 41 CIN 3 LEEP - Pap 1
27 51 CIN 3 LEEP - Pap 1
28 41 CIN 3 LEEP LEEP + Pap 3a
29 42 CIN 3 LEEP -
30 34 CIN 3 LEEP LEEP + Pap 3a Pap 3a
31 52 CIN 3 Conization LEEP + Pap 3a Pap 1
32 36 CIN 3 Conization LEEP 2 + Pap 2 Pap 2
33 27 CIN 3 LEEP + CIL Pap 1 Pap 1
34 46 CIN 3 LEEP + CIL Pap 1
35 47 CIN 3 Conization LEEP + CIL Pap 1 Pap 1
36 45 CIN 3 LEEP + Pap 3b CIN 3
37 34 CIN 3 LEEP + Pap 3a Pap 1
38 39 CIN 3 No treatment LEEP + Pap 1 Pap 1
*Lymphocyte stimulation test; PBMC of patients failed to respond (-) or did proliferate (+) on stimulation with HPV16 E6 and/or E7 peptide
pools.
cFrom this patient, a biopsy from the HSIL lesion was cultured. When the infiltrating T cells were found to react to either HPV16 E6 or E7 in a
3-d proliferation assay, the antigen recognized (E6 or E7) is specified in parentheses. Diagnosis at 6 and 12 mo follow-up by Pap smear or by
histology is indicated, when available.
Dysfunctional HPV16-SpecificTcells in Persistent HSIL
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liferative T-cell response (Figure 1B & Table 3). Occasionally, low levels of TNFa and IL-5 
were produced by the HPV16-specific responding cells. Of all the proliferative responses 
measured (n=31) in these patients, only 9 (<30%) were associated with the production of a 
pro-inflammatory cytokine (Table 3).
hpv specific t-cell responses are correlated with the persistence/recurrence of 
hsIl
The majority of HSIL lesions are precancers that are destined to persist (1) and for that 
reason are surgically removed. As a small percentage of HPV16-positive HSIL may sponta-
neously regress after a biopsy (48) we hypothesized that the combination of HPV antigens 
and an invasive (surgical) treatment may deliver sufficient antigenic stimulation and danger 
signals to activate an HPV16-specific T-cell response. Because a number of our patients 
(Table 2) had already been surgically treated in the near past for HSIL, the patients were 
divided into two groups and analyzed with respect to the absence and presence of HPV16-
specific immunity. Group 1 (n=28) consisted of those patients who were treated for the 
first time for an HSIL at the time of testing for HPV-specific immunity, whereas group 
Figure 1, de Vos van Steenwijk et al, Clinical Cancer Reserch, 2008
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figure 1. Short-term proliferation assay (LST) and associated IFNg production. (A) Representative examples 
of the HPV16-specific proliferation following the stimulation of PBMC from two HSIL patients (ID30, ID37). 
Cultures were tested in a 7 day lymphocyte proliferation assay upon stimulation with HPV16 E6 and E7 peptide 
pools. ID 30 tested positive for HPV16 peptide pool E6.2 and E6.3; ID 37 was positive for HPV16 peptide pools 
E6.2, E6.3 and E7.2. (B) Analysis of cytokine production by Cytokine Bead Array showed that only the culture 
from ID 37 stimulated with peptide pool E6.2 was associated with the production of IFNg, whereas in ID 30 the 
HPV16-specific T cells did not produce this typical Th1 cytokine.
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2 (n=10) consisted of patients with HSIL that persisted/recurred after a first destructive 
treatment and whom were treated again at the time that their HPV-specific immune status 
was assessed. The latter group displayed a significantly higher response rate to HPV16. The 
percentage of positive systemic responses in the group with persistent/ recurrent lesions 
(group 2) was 90% versus 21% in group 1 (p=0.0002, Figure 2). All together our results 
suggest that a systemic immune response, most often of a non Th1/ Th2 type, develops 
against HPV16 E6 and/or E7 and is often induced if the lesion persists or recurrs after initial 
surgical treatment of HSIL.
hpv16 e7-specific regulatory t cells infiltrate cervical hsIl lesions
From seven patients we were able to receive a small piece of cervical tissue for research 
purposes in order to characterize HPV16-specific T cells present in the HSIL lesion. As 
part of a larger study we showed that 3 of the 7 of these cervical infiltrating lymphocyte 
(CIL) cultures contained T-cells which recognized HPV16 E7 (46). From two of these CIL 
cultures (ID 2 and ID23) sufficient numbers of T cells were obtained for a more in-depth 
analysis. Upon stimulation with their cognate peptide both CIL cultures produced IFNg 
before this immunologic analysis was done. This suggests that
the HPV16 E6/E7-specific immune response detectable in the
circulation of cervical cancer patients has developed as part of
long-term exposure to the HPV16 antigens in the persistent/
recurrent HSIL in combination with the danger signals
delivered by the previous invasive treatment and is less likely
to develop in patients who have failed to induce a detectable
response befor their tr atme t and show no sign(s) of a
persistent/recurrent HSIL lesion afterwards. This notion is
sustained by our observation that the cytokine profile of the
HPV16-specific immune response in persistent/recurrent HSIL
patients is similar to that of what we observed in cervical cancer
patients (7) as well as the fact that the majority of established
high-grade CIN lesions will evolve toward cervical carcinoma
when left untreated (1). As such, the group of patients with
recurrent/persistent HSIL may reflect our ‘‘missing link’’ with
respect to the absence of HPV16 E6/E7-specific immune
responses in first time diagnosed HSIL patients and the
presence of these responses in patients with cervical cancer.
As yet, it is unclear whether either the previously given
destructive treatment, the persistence of the lesion, and as such
HPV antigens, or the combination of both is responsible for the
activation of the HPV16-specific proliferative response. Nota-
bly, a previous study in HSIL patients showed that activation of
HPV16 E7-specific immunity shortly after a local invasive
procedure occurred only in 2 of 18 patients (26). In that study,
immunity was measured by IFN-g ELISPOT, whereas we
showed that most of the HPV16-specific proliferative responses
detected in our group of patients were not associated with the
production of IFN-g (Fig. 1; Table 3). The former study thus
may have underestimated the response rate after local invasive
procedures. Interestingly, a history of a long period (15-51
months) of persistent HPV16 infection is also associated with
the activation of HPV16 E7-specific immunity, albeit that these
responses are weak considering the fact that an indirect
measurement consisting of a highly sensitive cellular bioassay
for IL-2 production was needed to detect these responses (23).
Taken together, these studies build a strong case supporting the
idea that local danger signals and long-term exposure to
sufficient amounts of antigen are key in the development of the
weak and dysfunctional immune responses observed in HSIL
patients.
The number of circulating, regulatory T cells as defined by
CD4+CD25high T cells (48) or CD4+CD25high CTLA4+ T cells
(49) is increased in patients with HSIL when compared with
healthy controls. In addition, immunohistochemical analysis of
HSIL lesions revealed not only that HSIL lesions represent
immunosuppressive environments (13) but also that immune
cells possessing a suppressive phenotype, as defined by
CD25+TGF-h+ and CD4+TGF-h+ immune cells, may infiltrate
such HSIL lesions (12). However, the specificity of these
Table 3. Summary of HPV16-specific T-cell
responses in patients with HSIL
ID Specificity* SIc IFN-;b Tumor necrosis
factor-Ab
IL-5b
8 E6.4 4 <100 <20 <20
9 E6.2 11 299 <20 <20
10 E6.3 4 167 <20 <20
13 E6.2 4 <100 <20 <20
E6.3 4 <100 <20 <20
E7.2 3 <100 <20 <20
14 E6.3 6 <100 <20 <20
E6.4 10 <100 29.2 <20
E7.2 3 <100 <20 <20
28 E7.2 6 <100 <20 <20
30 E6.2 7 <100 <20 <20
E6.3 8 <100 <20 <20
31 E6.2 7 <100 <20 <20
E6.3 3 <100 <20 <20
E7.2 6 <100 <20 <20
32 E7.2 13 <100 <20 <20
33 E6.1 5 <100 <20 <20
E6.2 10 473 <20 31.2
E6.3 6 <100 <20 <20
E6.4 10 <100 <20 27.5
E7.2 8 112 <20 <20
34 E6.1 3 <100 <20 <20
E6.2 6 <100 <20 <20
E6.3 11 <100 <20 <20
35 E7.2 7 447 <20 <20
36 E6.2 5 <100 <20 <20
E7.2 5 <100 <20 <20
37 E6.2 16 210 <20 <20
E6.3 5 <100 <20 <20
E7.2 7 <100 <20 <20
38 E6.2 8 781 <20 60
*The peptide pool to which PBMC of the indicated patient
proliferated.
cThe magnitude of the response indicated by the stimulation
index (SI) is shown.
bThe amount of cytokine produced in the cultures with HPV16-
specific PBMC is depicted in pg/mL. Production of IL-4, IL-10, and
IL-2 was undetectable in the cultures. Cutoff values are 100 pg/mL
for IFN-g and 20 pg/mL for tumor necrosis factor-a and IL-5.
Positive antigen-specific cytokine production was defined as a
cytokine concentration above the cutoff value and more than two
times the concentration of the medium control (7).
Fig. 2. HPV16-specific immune responses are more frequently observed in
patients with previous treatment of HSIL than in patients treated for the first time.
Of the 28 patients scheduled with a diagnosed HSIL for the first time, only 6 (21%)
responded to HPV16 E6 and E7 peptide pools in a short-term lymphocyte
stimulation test, whereas a significant proportion of patients with persistence or
recurrence of the lesion after initial treatment (90%; P = 0.0002) displayed a
HPV16-specific immune response (IR).
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(Figure 3a). In addition, the culture of ID2 produced low levels of IL-10 and a small popula-
tion of the CD4+ CIL population co-expressed CD25 and FoxP3, as measured by flowcy-
tometry (Figure 3ab). As we had observed that the presence of HPV16-specific T cells with 
such a phenotype in cervical carcinoma represented regulatory T cells with the capacity to 








































































































































































































































Figure 3, de Vos van Steenwijk et al, Clinical Cancer Reserch, 2008
figure 3. HPV16-induced HSIL lesions can be infiltrated by HPV16-specific regulatory T cells. Cervical infil-
trating lymphocyte (CIL) cultures of ID2 and ID23 contained T-cells which recognized HPV16 E7 (46), and 
were analyzed for (A) their capacity to produce IFNγ and IL10 upon stimulation with cognate antigen, (B) the 
co-expression of the with regulatory T-cell associated markers CD25 and Foxp3. (C) Their capacity to suppress 
CD4+CD25- responder T-cells, cultured with the HPV-specific CIL lines at indicated different ratios, was mea-
sured by proliferation (left) and IFNg production (right). T-cells of ID2 suppressed both proliferation and INFγ 
production. (D) The antigen-dependency of the HPV16 E7-specific regulatory T cells of ID 2 to exert their sup-
pressive function was shown in a CFSE-based proliferation assay (47). Left and right panels depict responder 
cell proliferation in the absence or presence of their cognate peptide respectively.
LST negative 22 (79%) 1 (10%)



















Figure 2, de Vos van Steenwijk et al, Clinical Cancer Reserch, 2008
figure 2 . HPV16-specific immune responses are more frequently observed in patients with previous treatment 
of HSIL, than in patients treated for the first time. Of the 28 patients scheduled with a diagnosed HSIL for the 
first time, only 6 responded (21%) to HPV16 E6 and E7 peptide pools in a short-term lymphocyte stimulation 
test (LST) whereas a significant proportion of patients with persistence or recurrence of the lesion after initial 
treatment (90%; p=0.0002) displayed an HPV16-specific immune response (IR).
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CIL cultures in a classical suppression assay (Figure 3c). The CIL culture of patient ID2 
was able to suppress both proliferation and IFNg production of CD4+CD25- responder T 
cells, whereas the CIL culture of patient ID23 did not contain such suppressive capacity. In 
order to prove that the HPV16-specific T cells were responsible for this suppressive effect, 
a CFSE-based suppression assay was performed in which the suppressive action of the CIL 
culture in the presence and absence of HPV16 peptide was tested (47). As expected, the 
CIL culture of patient ID2 almost completely suppressed the proliferation of the responder 
cells (85%) dependent on stimulation with HPV peptide, whereas the CIL culture of patient 
ID23 did not show substantial suppression (32%) when stimulated with its cognate HPV 
peptide (Figure 3d). These data demonstrate that HPV-specific regulatory T cells not only 
are present in patients with cervical carcinoma, but can already develop earlier during the 
malignant transformation of a persistently HPV16 infected cervix.
dI s c u s sIon
In this study we show that a systemic proliferative T-cell response against HPV16 is often 
absent in the majority of patients who visit the clinic for treatment of an HPV16+ HSIL 
lesion. In a number of cases HPV16-specific T-cell reactivity can be detected in the form 
of proliferative responses which are not associated with HPV16-specific secretion of the 
pro-inflammatory Th1 or Th2 signature cytokines. Importantly, HPV16-specific T-cell 
reactivity is predominantly detected in patients returning to the clinic for repetitive treat-
ment of an HPV16+ HSIL lesion because of persistence or recurrence of the lesion after 
initial destructive treatment. This was not the case in patients visiting the clinic for a first 
treatment of their HPV16 HSIL lesion (Figure 2). The observation that these responses lack 
a clear pro-inflammatory signature indicates that this type of immune activation should 
not be regarded as beneficial, but rather as a reflection of the fact that most of the subjects, 
although in principal able to mount an HPV16-specific T-cell response, fail to develop a 
cellular immune response that is associated with protection against HPV-induced lesions 
(7;18;22;25). This notion is sustained by our data showing for the first time that already at 
this pre-malignant phase a population of regulatory T cells, which specifically recognize 
HPV16 E7 antigen, arises and infiltrates the HPV16+ HSIL lesion (Figure 3).
In a previous study, in which the immune response to HPV16 E6 and E7 was studied in 
patients with cervical carcinoma, we were able to detect an HPV16-specific proliferative 
response in about half of all patients, but only in 1 of the 8 tested subjects with an HPV16+ 
HSIL (7). Similar observations regarding the low frequency of responders were made in 
small cohort studies performed by others (18;22). The reason why fewer patients with HSIL 
mounted an immune response to E6 and E7 in comparison to cervical cancer patients at 
that time remained unclear. Our current study of a large group of 38 HPV16+ HSIL patients 






confirms that the majority of HSIL patients fail to mount an HPV16 E6/E7-specific T-cell 
response. The absence of an HPV16-specific immune response in patients with HSIL and 
the presence of such responses in about half of the patients with cancer previously led us 
to hypothesize that the long-term presence of the HPV16 E6 and E7 antigens in a develop-
ing tumor may eventually trigger the induction of a CD4+ T-cell response (7). Here, we 
identified a larger group of HPV16+ HSIL patients which was able to mount an HPV16 E6/
E7-specific immune response. Importantly, most patients within this group suffered from 
a persistent/recurrent HSIL lesion and had already been treated by destructive treatment 
before this immunological analysis was performed. This suggests that the HPV16 E6/
E7-specific immune response detectable in the circulation of cervical cancer patients has 
developed as part of long term exposure to the HPV16 antigens in the persistent/recurrent 
HSIL in combination with the danger signals delivered by the previous invasive treatment. 
This notion is sustained by our observation that the cytokine profile of the HPV16-specific 
immune response in persistent/recurrent HSIL patients is similar to that of what we ob-
served in cervical cancer patients (7) as well as the fact that the majority of established 
high-grade CIN lesions will evolve towards cervical carcinoma when left untreated (1). As 
such, the group of patients with recurrent/persistent HSIL may reflect our ‘missing link’ 
with respect to the absence of HPV16 E6/E7-specific immune responses in first time diag-
nosed HSIL patients and the presence of these responses in patients with cervical cancer. As 
yet, it is unclear whether either the previously given destructive treatment, the persistence 
of the lesion, and as such HPV antigens, or the combination of both is responsible for the 
activation of the HPV16-specific proliferative response. Notably, a previous study in HSIL 
patients showed that activation of HPV16 E7-specific immunity shortly after a local invasive 
procedure occurred only in 2 out of 18 patients (26). In that study immunity was measured 
by IFNg ELISPOT while we showed that most of the HPV16-specific proliferative responses 
detected in our group of patients were not associated with the production of IFNg (Figure 
1, Table 3). The former study, thus, may have underestimated the response rate after local 
invasive procedures. Interestingly, a history of a long period (15-51 months) of persistent 
HPV16 infection is also associated with the activation of HPV16 E7-specific immunity, 
albeit that these responses are weak considering the fact that an indirect measurement con-
sisting of a highly sensitive cellular bio-assay for IL-2 production was needed to detect these 
responses (23). Taken together, these studies build a strong case supporting the idea that 
local danger signals and long-term exposure to sufficient amounts of antigen are key in the 
development of the weak and dysfunctional immune responses observed in HSIL patients.
The number of circulating, regulatory T cells as defined by CD4+CD25high T cells (49) or 
CD4+CD25high CTLA4+ T cells (50), is increased in patients with HSIL when compared 
to healthy controls. In addition, immunohistochemical analysis of HSIL lesions not only 
revealed that HSIL lesions represent immunosuppressive environments (13) but also that 
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immune cells possessing a suppressive phenotype – as defined by CD25+TGFb+ and 
CD4+TGFb+ immune cells – may infiltrate such HSIL lesions (12). However, the specificity 
of these circulating and HSIL-infiltrating regulatory T-cells was never determined. Previ-
ously, we showed that the CD4+ subset of T cells infiltrating cervical carcinomas consisted 
of HPV16-specific regulatory T cells able to suppress proliferation and cytokine production 
of responder cells (47). Similar functional analyses of the T-cell populations infiltrating 
HSIL not only showed that indeed fully functional regulatory T cells can infiltrate pre-
malignant cervical lesions but also that these regulatory T-cells exerted their action upon 
recognition of their cognate HPV16-specific antigen (Figure 3). Interestingly, a higher 
number of circulating CD4+CD25high CTLA4+ regulatory T cells coincides with the pres-
ence of HPV16-specific T cells in the blood of patients with HSIL (50) indicating that such 
responses may co-evolve. Recently, we have developed an assay to measure the percentage 
of HPV16-specific regulatory T-cells in the circulation of patients with cervical cancer (27). 
Similar analyses in patients with HSIL may reveal to which extent the detected HPV16-
specific responses lacking a clear cut pro-inflammatory signature (Figure 2 and Table 3) 
may actually represent HPV16-specific regulatory T cells. The lack of PBMC precluded such 
an analysis in the current group of patients but this question will be addressed in a new 
study.
The detection of HPV16-specific T cells with a non Th1/Th2 cytokine and even immune sup-
pressive signature in patients with HSIL bears implications to immunotherapeutic vaccine 
approaches aiming at reinforcing HPV-specific immunity to attack HPV-induced lesions. 
Recently, we showed that such a vaccine also activates/boosts an unwanted pre-existing 
HPV16-specific T-cell repertoire in cervical cancer patients (27) suggesting that strategies 
to overrule or eliminate the responses of these subsets of T-cells in cancer patients should be 
considered for immunotherapeutic strategies against HPV-induced cervical lesions.
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Translational Relevance
In the face of developing therapeutic vaccination strategies, it is of vital importance to gain a better 
understanding of the local tumor environment and the preexisting local anti-tumor response. In this study 
we have comprehensively analyzed the spontaneous tumor-specific immune response in patients with 
cervical cancer by dissecting local HPV E6- and E7-specific CD4+ and CD8+ T-cell responses down to 
the level of the percentage, specificity, cytokine polarization and number of different responding T-cells, 
showing a large polyclonal repertoire of poised non-functional HPV-specific T cells. Addition of immuno-
activating compounds could be key in increasing the effector function of these T cells with beneficial effects 
for therapeutic strategies.
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a b st r ac t
The diversity and extent of the local tumor-specific T-cell response in a given individual 
is largely unknown. We have performed an in-depth study of the local T-cell repertoire 
in a selected group of cervical cancer patients, by systematic analyses of the proportion, 
breadth and polarization of HPV E6/E7-specific T cells within the total population of 
tumor-infiltrating lymphocytes (TIL) and tumor-draining lymph node cells (TDLNC). 
Isolated T cells were stimulated with sets of overlapping E6 and E7 peptides and analyzed by 
multiparameter flow cytometry with respect to activation, cytokine production and T-cell 
receptor Vb (TCRVb) usage. HPV-specific CD4+ and CD8+ T-cell responses were detected 
in TIL and TDLNC and their relative contribution varied between <1% to 66% of all T cells. 
In general, these HPV-specific responses were surprisingly broad, aimed at multiple E6 and 
E7 epitopes and involved multiple dominant and subdominant TCRVb’s per single peptide-
epitope. In most patients only few IFNg-producing T cells were found and the amount of 
IFNg produced was low suggesting that these are poised T cells, rendered functionally inac-
tive within the tumor environment. Importantly, stimulation of the TIL and TDLNC with 
cognate antigen in the presence of commonly used Toll like receptor-ligands, significantly 
enhanced the effector T-cell function. In conclusion, our study suggests that within a given 
patient with HPV-specific immunity many different tumor-specific CD4+ and CD8+ T cells 
are locally present and poised for action. This vast existing local T-cell population is await-
ing proper stimulation and can be exploited for the immunotherapy of cancer.






I n t rodu c t Ion
Our current knowledge on the diversity and extent of tumor-specific T-cell immunity is 
largely based on pooled T-cell response data of many different subjects (1-4), the T-cell 
response to a specific epitope (5;6) and/or studies of tumor-specific T-cell clones (7-9). 
However, very little is known about how extensively one individual’s immune system can 
simultaneously respond to one or more tumor antigens. Cervical carcinoma offers an excel-
lent opportunity to answer this question as these tumors are caused by the high-risk human 
papillomavirus (HPV) which encodes the two clearly defined tumor-specific viral antigens 
E6 and E7 that are constitutively expressed in each cancer cell (10). Notably, cervical cancer 
arises more frequently in immunocompromised individuals (11), illustrating the role of T 
cells in this type of cancer.
Low levels of circulating HPV E6- and E7-specific T cells in patients with cervical cancer 
or premalignant lesions (4;12-15) indicate that these oncoproteins activate an anti-tumor 
response. Indeed, cervical tumors are infiltrated by lymphocytes (16) and both CD8+ and 
CD4+ T cells isolated from such tumors are able to recognize the E6 and E7 tumor antigens 
(17;18). Furthermore, we showed that 43% of the isolated tumor-infiltrating lymphocyte 
(TIL) and tumor-draining lymph node cell (TDLNC) cultures from a large cohort of HPV16 
or HPV18 positive patients contained T cells specific only for the E6- and/or E7-peptides 
corresponding to the HPV type present in the tumor (3). When the tumor was negative for 
HPV16 or 18, the TIL did not react to these HPV16 or HPV18 peptides (3). While these 
studies clearly indicate that HPV-specific T cells can infiltrate HPV-induced cervical cancer 
in a substantial number of patients, they do not allow a full comprehension of the contribu-
tion and role of these HPV-specific TIL and TDLNC to the total tumor-specific immune 
response. The size of the HPV-specific T-cell pool in the TIL population, the polarization 
of these T cells as well as the breadth of this local HPV-specific response within a given 
individual with an HPV-specific response is unknown. It is important to gain such insights 
because of several therapeutic strategies under development (19-21). These include vaccines 
to enhance E6- and/or E7-specific T-cell reactivity (22-27) the results of which could be 
influenced by the presence of a preexisting HPV-specific local immune response.
Therefore, we performed a more in-depth study of the populations of TIL and TDLNC of 
patients for which we previously showed that they comprised HPV16- or HPV18-specific T 
cells (3) by a comprehensive analysis of the HPV-specific CD4+ and CD8+ T-cell responses 
down to the level of the percentage, specificity, cytokine polarization and number of dif-
ferent responding T cells.. Our study revealed that many different HPV-specific T cells are 
present, but need proper stimulation to become full effector cells.
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m et hod s
subjects
Women presenting with histologically proven cervical neoplasia (FIGO 1a2, 1b1 or 1b2) at 
the department of Gynecology of the Leiden University Medical Centre were enrolled in 
the CIRCLE study, which investigates cellular immunity against HPV16- positive cervical 
lesions after providing informed consent. The study design was approved by the Medical 
Ethical Committee. The subjects were tested for HPV status using HPV16 and HPV18 
specific primers on DNA isolated from surgical resection specimens (28).
antigens
A set of 22-mer peptides overlapping by 12 residues spanning both HPV16 and HPV18 E6 
and E7 protein were synthesized and dissolved as described earlier (13;27) and used for T 
cell stimulation assays.
Isolation and culture of t cells
Cervical tumor biopsies were obtained from patients scheduled for radical hysterectomy as 
described previously (3). Briefly, fresh cervical tissue was minced and cultured in IMDM, 
supplemented with 10% human AB serum (PAA laboratories, Pasching, Austria), 10% T 
Cell Growth Factor (TCGF, Zeptometrix, Buffalo NY, USA) and 5 ng/ml IL-15 (Peprotech, 
Rocky Hill NJ, USA). On the first day 5 ng/ml IL-7 (Peprotech) was added to cultures to 
drive homeostatic expansion of T cells. This does not alter the CD4/ CD8 T-cell composition 
of the TIL(3), but it allows the acquisition of sufficient numbers of T cells for immunological 
assays. After 2-3 weeks of T-cell expansion (mean 18x106 cells, range 4 - 40x106) the T cells 
were harvested and stored in liquid nitrogen.
TDLN derived from the pelvic region contained tumor cells, indicative of metastatic 
cancer. The TDLN were cut into pieces and incubated for one hour at 37 ºC in the presence 
of collagenase (200 IU/ml, Sigma) and DNAse (50 mg/ml, Sigma), then put through a cell 
strainer (BD, Erebodemgem, Belgium) to obtain single cells. TDLNC were not expanded 
but directly stored in liquid nitrogen.
analysis of t-cell specificity by proliferation assay
T cells (25,000-50,000/well) were stimulated with autologous monocytes or irradiated 
autologous Epstein-Barr virus transformed B cell lines (B-LCL’s) pulsed with HPV16 or 
18 E6 and E7 peptides (5 μg/ml) in triplicate wells in a 3-day proliferation assay. After 48 
hours supernatant was harvested and stored at -20ºC for cytokine analysis. During the last 
16 hours of culture 0.5 μCi/well [3H]thymidine was added to measure proliferation (27) The 
stimulation index (SI) was calculated as the average of test wells divided by the average of the 
medium control wells. An SI >2 was considered a positive response. Antigen-specific IFNγ 






and IL-10 production was measured by ELISA (29). Antigen-specific cytokine production 
was defined by a cytokine concentration above the cut-off value (IFNγ 100pg/ml; IL-10 20 
pg/ml) and >2x the concentration of the medium control (4).
analysis of t-cell specificity by multiparameter flow cytometry
T cells were examined directly ex-vivo (TDLNC) or after homeostatic expansion (TIL) to 
quantify the number of HPV-specific T cells. B-LCL were pulsed with 5 ug/ml HPV-16 or 
18 E6 and E7 peptide pools. TIL’s or TDLNC were thawed, rested in IMDM (BioWhittaker, 
Verviers, Belgium) containing 10% Fetal Calf Serum (FCS, PAA laboratories, Pasching, 
Austria) for 5 hours and seeded into a 96-wells round bottom plate at 200,000 cells per well 
and 40,000 antigen-pulsed B-LCL were added. After one hour Brefeldin A (10ug/ml) was 
added to the culture and left overnight. Cells were stained with antibodies to CD154-PECy5, 
CD137-APC, CD3-Pacific Blue, CD4-PECy7, CD8-APCcy7, IFNγ-FITC and IL-2-PE (all 
from BD Pharmingen, the Netherlands)(30).
In addition, TDLNC and TIL were stimulated with a mix of irradiated autologous B-LCL 
and 5 ug/ml HPV16 or HPV18 E6 or E7 peptide pools and irradiated allogeneic PBMC 
pool, in order to obtain enough HPV-specific T cells to measure the breadth of the response 
with respect to single peptide-antigens and for TCRVb usage analyses (8 sets of antibodies). 
After a 3 week rest period these cells were tested for their specificity by overnight incubation 
with each single peptide. Responses were considered positive when the percentage of HPV 
stimulated CD154 and/or CD137 positive cells was at least three times the medium control.
analysis of the breadth of the hpv-specific t-cell response
In vitro expanded T cells were stimulated with the indicated single peptides of HPV-16 or 
18 E6 and E7 (5 ug/ml). Per peptide 500.000 cells were analyzed by multiparameter flow 
cytometry as described above. One day later this analysis was repeated for those peptides 
found positive, but then the antibodies to the cytokines were replaced by antibodies to 
different TCRVb (Beckman Coulter, Immunotech, France). A TCRVb was considered 
dominant (>10% ), subdominant (3-10%) or minor (<3%) on basis of the percentage of 
HPV-specific cells using the same TCRVb.
rt-pcr
Expanded bulk cultures were enriched for CD8+ T cells by negative selection using CD4+ 
isolation dynal beads (Invitrogen, the Netherlands). After RNA was isolated with the 
RNAeasy mini isolation kit (Qiagen, the Netherlands), cDNA was synthesized using the 
iScript cDNA Synthese kit (Biorad). Vβ PCR was performed on amplicons as previously 
described (31). Primers were kindly provided by dr M.H. Heemskerk.
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In vitro stimulation with peptides and tlr ligands
TDLNC were thawed, rested for 5 hours and stimulated with 1ug/ml pool of E6 and E7 pep-
tides, TCGF 10% and IL15. Toll like receptor (TLR) 4 ligand LPS 250 ng/ml (Sigma-Aldrich, 
USA), TLR 3 ligand Poly(I:C) 12.5 mg/ml (InvivoGen, USA) and TLR 1-2 ligand Pam3CSK4 
20 mg/ml (InvivoGen, USA) were added at the start of culture where indicated. To stimulate 
TIL, monocytes were pulsed with 1 ug/ml of E6 and E7 peptide pool and the indicated TLR 
ligands. After 5 hours monocytes were washed and TIL were added. Supernatant was taken 
every 2 days and analyzed by human Th1/Th2 cytometric bead array (BD Pharmingen, 
USA). Cells were left to rest for 2-3 weeks before analysis of the percentage of activated and 
cytokine producing cells by flow cytometry.
r e su lt s
Quantification of hpv-specific t cells in tumor and lymph nodes
TDLNC and homeostatic cytokine-mediated expanded TIL isolated from a selected group 
of 16 cervical carcinoma patients, comprising 10 patients of whom it was known that their 
TIL (8 patients) or TDLNC (2 patients) contained T cells that specifically reacted to the 
peptides of the HPV type present in the tumor and 3 patients in whom we previously failed 
to detect HPV-specific immunity (3), and 3 patients with unknown reactivity.
The presence of HPV-specific T cells within the TIL cultures was analyzed by their capac-
ity to proliferate upon stimulation with HPV E6 and E7 peptides (Table 1). As expected 
proliferating HPV-specific T-cells were found in 8/12 tumors tested. All HPV-specific T-cell 
cultures produced IFNγ, yet the amount of production varied greatly (103 - >5000 pg/ml), 
irrespective of the proliferative capacity of the cells. In addition, 4/8 positive cultures pro-
duced IL-10 (45 – 836 pg/ml). The TIL all reacted to PHA and proliferation was associated 
with large amounts of IFNγ and IL-10 (not shown).
To type and enumerate HPV-specific T cells within the TIL or TDLNC populations, the 
percentage of CD4+ and CD8+ T cells specifically expressing the activation markers CD137 
and/or CD154 when stimulated with E6 and E7 peptides or proteins was analyzed. CD137 
is known as an activation marker for CD8+ T cells and CD154 for CD4+ T cells (32;33). 
The TIL cultures that were negative in the proliferation assay were taken along as control. 
In 7/10 TIL cultures tested and 2/4 TDLNC, HPV specific activated T cells were detected 
and comprised CD4+ or CD8+ T cells or both (Table 1). In two cases not enough TIL were 
available to perform this analysis. In one TIL culture – in which we previously failed to 
detect HPV-specific T cells by proliferation - an HPV-specific CD8+ T-cell response was 
detected. The percentage of HPV-specific T cells generally corresponded with the strength 
of proliferation. HPV-specific CD4+ T cells expressed both CD154 and CD137 (Figure 
1a), while HPV-specific CD8+ T cells predominantly expressed CD137, yet sometimes co-






expressed CD154 (Figure 1a). The percentage of HPV-specific T cells varied enormously 
between as little as 0.17% to as much as 66% (Table 1) of the CD4+ or CD8+ T cells present 
in TIL and from 0.63% - 24% in TDLN. This was independent of the total numbers of T cells 
isolated, indicating a great variability in the contribution of HPV-specific T cells to the total 
local anti-tumor response between patients.
The local hpv-specific response consists of a broad t-cell repertoire
To study the breadth of the HPV-specific TIL/TDLNC-repertoire the isolated cells were 
stimulated with pools of E6 or E7 peptides as otherwise there would not be enough cells 
to study the response to single peptides. This allowed the analysis of the breadth of the 
HPV-specific T-cell response to single peptides in 12 patients (Figure 1b; Supplemental 
Table 1). The three TIL cultures tested negative before remained negative excluding that 
the responses detected are primed in vitro. In most of the patients the HPV-specific CD4+ 
T-cell response was highly diverse as in 5/10 patients CD4+ T cells responded to 5 or more 
different peptides and in another 4 patients the CD4+ T cells recognized 2 different peptides 
(Supplemental Table 1). HPV-specific CD8+ T-cell reactivity was detected in 6 of the 12 
the indicated TLR ligands. After 5 h, monocytes were washed
and TIL were added. Supernatant was taken every 2 d and
analyzed by human Th1/Th2 cytometric bead array (BD
PharMingen). Cells were left to rest for 2 to 3 wk before the
analysis of the percentage of activated and cytokine-producing
cells by flow cytometry.
Results
Quantification of HPV-specific T cells in tumor and
lymph nodes. TDLNC and homeostatic cytokine-mediated
expanded TIL isolated from a selected group of 16 cervical car-
cinoma patients, comprising 10 patients with TIL (8 patients)
or TDLNC (2 patients) which contained T cells that specifically
reacted to the peptides of the HPV type present in the tumor,
3 patients in whomwe previously failed to detect HPV-specific
immunity (3), and 3 patients with unknown reactivity.
The presence of HPV-specific T cells within these homeo-
static cytokine-mediated expanded TIL cultures was ana-
lyzed by their capacity to proliferate upon stimulation with
HPV E6 and E7 peptides (Table 1). As expected, proliferating
HPV-specific T cells were found in 8 of 12 tumors tested. All
HPV-specific T-cell cultures produced IFNγ, yet the amount
of production varied greatly (103 to >5,000 pg/mL), irrespec-
tive of the proliferative capacity of the cells. In addition, four
of eight positive cultures produced IL-10 (45–836 pg/mL). All
TIL reacted to phytohaemagglutinin and proliferation was
associated with large amounts of IFNγ and IL-10 (data not
shown).
To type and enumerate HPV-specific T cells within the TIL
or TDLNC populations, the percentage of CD4+ and CD8+
T cells specifically expressing the activation markers CD137
and/or CD154 when stimulated with E6 and E7 peptides or
proteins was analyzed. CD137 is known as an activation
marker for CD8+ T cells and CD154 for CD4+ T cells (32,







T cell Overnight activation
analysis
Activated cells (%)‡
Reactivity§ SI∥ IFNγ¶ IL-10¶ Medium E6 E7
1 16 TIL 9 16E6 2.9 103 <20 CD4 0.16 0.58 0.26
2 18 TIL 13 18E7 5.4 763 45 CD4 0.04 0.03 0.17
3 16 TIL 15 — — — — —
4 16 TIL 26 16E6 104 >5,000 315 CD4 0.8 63 0.9
CD8 0 47 0.7
5 16 TIL 79 16E6 109 >5,000 836 CD4 3.1 66 2.7
6 18 TIL 25 — — — — —
7 16 TIL 12 — CD8 2.9 24 3.4
8 16 TIL 29 — — — — —
9 16 TIL 17 16E6 2.6 110 <20 CD8 0.4 4.5 0.6
10 16 TIL 27 16E6 4.8 >5,000 <20 CD4 0.13 0.52 0.14
11 18 TIL 30 18E7 8.9 244 66 NT**
12 16 TIL 68 16E6 4 276 <20 NT
13 18 LN 0 NT — — — —
14 16 LN 0 NT CD4 0.12 0.63 0.16
CD8 0.23 5.92 0.11
15 16 LN 0 NT CD4 0.51 24 20
16 16 LN 0 NT — — — —
*HPV type found in the tumor by PCR.
†Days of cytokine-mediated homeostatic expansion before immune assay.
‡Percentage of total CD4 or CD8 T-cell population expressing CD154 and/or CD137 after stimulation with the indicated antigen
corresponding to the HPV type present in the tumor. A response equal or more than three times the medium control was consid-
ered positive.
§Reactivity indicates the HPV type and protein to which the T-cell culture specifically reacted.
∥SI, stimulation index, average proliferation of test wells divided by the average proliferation of medium control wells. SI > 2 is
positive.
¶Antigen-specific cytokine production in pg/mL is indicated when test value was above cutoff level and at least more than two
times the background production (4).
**NT, not tested.
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figure 1. HPV-specific T cells in TIL and TDLNC.
(A) An example of a CD4 and a CD8 HPV-specific response measured by flow cytometry using the activation 
markers CD154 and CD137 in two TIL cultures tested before antigen-driven expansion in vitro (P4 and P9). (B) 
The breadth of the response was analyzed after antigen-driven expansion. TIL and TDLNC cultures were stimu-
lated with single peptides and analyzed for the expression of CD154 and CD137. P9 displayed a CD8 response 
against four different single peptides (notably 41, 51, 61 and 137). P12 displayed a CD4 response against six 
different single peptides (notably 21, 61, 71, 81, 91 and 101). (C) Summary of the number of different peptides 
recognized by each single culture (white bars) after antigen-driven expansion. The minimal number of epitopes 
recognized (black bars) was estimated by counting the response to two overlapping peptides as one, because the 
peptides used are 22-mers, overlapping in 12 amino acids.






tested patients, five of whom displayed CD8+ T-cell reactivity to 2-6 different peptides 
(Figure 1b; Supplemental Table 1).
The minimal number of T-cell epitopes recognized per patient was estimated by counting 
the response to two overlapping peptides as one because they overlapped in 12 amino acids. 
The majority of the patients (8/12) recognized 3 or more different T-cell epitopes (Figure 
1c). The TDLNC populations reacted against 4-9 different epitopes (Figure 1c). Thus the 
tumor-induced HPV-specific T-cell repertoire is directed against multiple T-cell epitopes.
As each individual T-cell epitope can be recognized by different T-cell clones, we stud-
ied the number of TCRVb families involved in the recognition of each epitope by using 
a commercially available TCRVb-specific antibody kit. The different T-cell clones were 
operationally defined as the cohort of activated HPV single peptide-specific CD4+ or CD8+ 
T cells expressing the same TCRVb-chain. Figure 2a shows a number of examples on the 
contribution of several T-cell receptor families reactive to one single peptide. Often one or 
two dominant TCRVβ’s were found (Table 2 and Figure 2b), as well as several sub-dominant 
and minor TCRVβ’s. For example, the HPV-specific CD4+ T-cell response of patient P14 
reacted to 9 different peptides and - on the basis of the different TCRVb’s present in the 
population of activated T cells - this involved the activation of at least 43 different T-cell 
clones (Table 2 and Figure 2b). In a number of cases not all TCRVb could be indentified as 
the available antibodies cover approximately 70-80% of the full TCRVb-repertoire (34). In 
one case (P7) of whom all the cells in the cultured T-cell population responded exclusively 
to one peptide - but for which only 22% of the HPV-specific T cells the TCRVb was ac-
counted for by antibodies (Figure 2a, fourth row and Table 2)- a semi-quantitative RT-PCR 
was applied revealing the presence of TCRVb24 (Figure 2c). In another case (P15) only 30% 
of the TCRVb were accounted for by flow cytometry. Here, three additional TCRVb 6C, 6D 
and 15 (not shown) were detected by RT-PCR. No skewing to a certain TCRVb within this 
patient group was found, nor was there any skewing of certain TCRVb families to individual 
peptides observed (Figure 2d). Thus the HPV-specific T-cell repertoire consists of a poly-
clonal T-cell population able to respond to many different CD4 and CD8 T-cell epitopes.
hpv-specific tIl generally lack type 1 polyfunctional t cells
The production of type 1 cytokines (IFNγ, IL-2) is essential for an effective anti-tumor 
response and instrumental to functionally characterize antigen-specific T cells (35-40). 
Therefore, the ex-vivo enumerated HPV-specific CD154+ and/or CD137+ T cells were 
simultaneously analyzed for their production of IFNγ and IL-2. Four distinct cytokine pro-
files were found (Figure 3ab). Profile 1 was found in one patient (P7). Despite the presence 
of a high percentage of HPV E6-specific CD8+ T cells (24%), only about 4% produced either 
one of the cytokines. The second profile comprised HPV-specific T cells of which the major-
ity produced both IFNγ and IL-2 (e.g. P4 and P5), HPV-specific T cells in the third profile 
mainly produced IL-2 (e.g. P1, P2, P10 and P15), whereas they produced mainly IFNγ in 
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figure 2. The T-cell response to a single HPV epitope involves the use of multiple dominant and subdominant 
TCRVb families.
(A) The TCRVβ families used by T cells responding to a single peptide were analysed in the T-cell population 
with high expression of activation marker(s) after peptide stimulation. Depicted is the response against one 
peptide for four different patients (P4, P7, P9 and P12). The letters (a-h) indicate the eight different antibody 
pools, each consisting of three differently labeled antibodies (FITC (FL1), PE (FL2) or FITC-PE combined) 
specific for three different TCRVb, plotted in separate quadrants. The involved TCRVb and the percentage of 
responding cells are indicated in the plots.






profile four (P14 and P9). These data indicate that while most of the HPV-specific TIL can 
produce either one of the type 1 cytokines, there are only few patients (2/9) in whom the 
majority of their HPV-specific TIL simultaneously produce IFNγ and IL-2 (Profile 2; Figure 
3ab).
activation of hpv-specific t cells in the presence of tlr ligands increases the type 
1 cytokine effector response
Our results showed that in many cases the HPV-specific T-cell response is not associated 
with strong production of IFNγ (Table 1 and Figure 3ab). In mouse models, the local injec-
tion of TLR2, TLR3 or TLR 4 ligands can augment the tumor response (41-43). To mimic 
the local delivery of antigen and TLR ligand, homeostatic expanded TIL from 2 patients 
were stimulated with HPV antigen-pulsed TLR-activated autologous monocytes whereas 
TDLNC from 2 other patients, which already contained APC, were activated with their 
cognate HPV-antigens in the absence or presence of TLR-agonist directly ex-vivo. Cytokine 
analyses revealed a faster and higher production of IFNγ during the first 7 days after activa-
tion in all four TIL and TDLNC cultures tested when PAM3CSK4 (TLR2) was added and 
in 3 out of 4 of the cultures with poly(I:C) (TLR3) (Figure 3c). The use of the TLR4 agonist 
LPS boosted the IFNγ-response in one patient (P14), but with somewhat slower kinetics. 
Notably, PAM3CSK4 (TLR2) also increased the production of the Th2 cytokine IL-5 in 3 
out of 4 cultures (not shown). Analysis of the constitution of the responding cell population 
after 14 days, allowing the activated T cells to come to rest which is needed to decrease 
background staining for the activation markers and cytokines, revealed no overt differences 
in the number of activated cells or the percentage of IFNγ, IL-2 or double- producing T cells 
after this period (not shown).
(B) The relative contribution of dominant and subdominant TCRVb families to the overall HPV-specific T-
cell response is depicted. The grey stacked bars indicate the percentage of HPV-specific T cells comprising a 
dominant TCRVβ(s) and the black stacked bars indicate the accumulated percentage of all the sub-dominant 
and minor TCRVβ families (individual percentages for each family not shown) of all T cells responding to one 
peptide-epitope. The white bars indicate the percentage of HPV-specific T cells for which we could not iden-
tify the TCRVβ families involved using the TCRVβ kit. Patient numbers and 22-mer peptides recognized are 
indicated by the protein name and the first amino acid in the sequence of this protein. The * identifies the two 
cultures for which an additional TCRVβ analysis was done by RT-PCR allowing the detection of other TCRVβ’s 
not present in the TCRVb kit. (C) RT-PCR for TCRVb in TIL of patient P7, revealing the presence of TCRVb24. 
The percentage of each TCRVb that was detected by flow cytometry is indicated on the left.
(D) A fingerprint overview of all TCRVβ’s detected upon response to a single peptide-epitope for the patients 
investigated. The black squares indicate that the TCRVβ (indicated at the left) was involved in response to that 
particular peptide (indicted at bottom). A white cross means that this TCRVβ was found in two independent 
patients responding to that peptide, the right column indicates in how many patients this particular TCRVb 
was found.
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dI s c u s sIon
We have comprehensively analyzed the spontaneous tumor-specific immune response 
in patients with cervical cancer by dissecting local HPV E6- and E7-specific CD4+ and 
CD8+ T-cell responses down to the level of the percentage, specificity, cytokine polariza-
tion and number of different responding T-cells. The expression of the two known tumor 
antigens E6 and E7 in all cervical cancer cells and the use of overlapping peptide arrays 
for immunomonitoring in combination with the activation markers CD154 and CD137, 
as well as in the control of chronic viral infections (41, 42). In
most of the ex vivo–tested TIL and TDLNC, the population of
IFNγ- and IL-2–producing T cells or IFNγ-producing T cells
among the total population of HPV-specific T cells as well as
the amount of IFNγ produced was low (Table 1; Fig. 3B), sug-
gesting that most of the HPV-specific TIL and TDLNC with
respect to the production of these cytokines are rendered
functionally tolerant within the tumor environment and
Table 2. Different TCRVβ families found within the HPV-specific T cell population
Responding* Peptides† Number of TCRVβ found per peptide by FACS‡
Patient T cell Antigen Dominant Subdominant Minor Total
TIL 2 CD4 E7 1 0 0 4 4
11 0 2 4 6
4 CD4 E6 41 1 0 0 1
51 1 0 0 1
CD8 E6 41 2 1 3 6
51 2 1 3 6
CD8 E7 21 3 2 0 5
7 CD8 E6 21 0§ 3 4 7§
9 CD8 E6 41 0 1 1 2
51 1 0 3 4
61 1 1 3 5
137 0 2 5 7
10 CD8 E6 131 2 0 0 2
137 2 0 0 2
CD4 E7 1 2 0 0 2
11 CD4 E6 21 1 2 0 3
71 2 0 1 3
81 0 1 1 2
101 1 3 0 4
12 CD8 E6 1 1 0 3 4
11 1 0 3 4
41 1 1 4 6
51 1 3 2 6
LN 14 CD4 E6 11 2 0 8 10
61 1 1 5 7
71 1 1 5 7
81 2 2 0 4
91 2 2 0 4
101 1 3 3 7
121 2 6 2 10
131 0 0 2 2
137 3 2 0 5
15 CD4 E6 21 2§ 0 0 2§
51 1 0 0 1
81 1 2 1 4
111 1 1 0 2
121 0 2 0 2
131 1 1 3 5
*Depicted are all patients of whom enough T cells were available for TCRVβ analysis after antigen-specific expansion by stimulation
with E6 or E7 peptide pool.
†The number indicates the first amino acid of the 22-mer peptide of the antigen that the culture specifically responds to by the
expression of the activation markers CD154 and/or CD137.
‡A dominant TCRVβ consists of >10% of the activated T cells. A subdominant TCRVβ consists of between 3% and 10% of the
activated T cells. A minor TCRVβ consists of <3% of the activated T cells.
§Additional TCRVβs were found by PCR analysis for P7 and P15.
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offered the advantage to study the complete cervical cancer-specific local T-cell repertoire 
- independently of the knowledge of defined T-cell epitopes and not restricted to particular 
HLA-types – in a quantitative manner. We used a selected panel of HPV16- and HPV18-
typed cervical cancer patients for whom we previously showed that their TIL comprised 
HPV type-specific T cells, indicating that the current set of data applies to about 40-50% of 
all patients with an HPV16- or HPV18-positive cervical carcinoma (3). Our data show that 
Figure 3, de Vos van Steenwijk et al. 2009

















































































































































figure 3. Functionality of HPV-specific TIL and TDLNC .
(A) The specific activity to HPV16 or 18 E6 and E7 peptide pools by simultaneous analysis of CD154, CD137, 
IFNg and IL-2 in homeostatic cytokine-mediated expanded TIL as well as directly ex-vivo in TDLNC. Four 
different cytokine profiles could be distinguished. Profile I: HPV-specific T-cells with few T-cells producing 
cytokines (P7). Prolife II: Predominant production of IFNγ and IL-2 (P4). Profile III: predominant produc-
tion of IL-2 (P15). Profile IV: mainly IFNγ producing HPV-specific T cells (P9). (B) Overview of the cytokine 
production. The percentage of activated HPV-specific T-cells is indicated on top of the bars. The stacked bars 
indicate the percentage and type of cytokines (black: IFNg, grey: IL-2, hatched: IFNg+IL-2 and white: no IFNg 
or IL-2 (none)) produced within the activated HPV-specific T-cell population. (C) The homeostatic expanded 
TIL of patients 7 & 9 as well as the TDLNC of patients 13& 14 were stimulated with HPV16/18 E6 or E7 pep-
tide pools and TLR-agonist when indicated (medium control indicates peptide stimulation without addition 
of TLR-agonist). After 2, 4 and 7 days supernatant was harvested and analyzed for cytokine production by 
cytokine bead array.
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while HPV-specific T-cell responses can be detected within the tumors and tumor draining 
lymph nodes of this group of patients with cervical cancer their relative contribution to the 
overall local anti-tumor response varied enormously, ranging from <1% to 66% (Table 1). 
While we can not exclude that the quantification of HPV-specific T cells among the total 
population of TIL is accurate as it likely to be biased due to the isolation procedure, the 
results obtained in the ex-vivo measurement of HPV-specific T cells among TDLNC still 
sustains this notion. Strikingly the HPV-specific response of most patients tested was broad 
as it targeted multiple peptide-epitopes within the E6 and E7 tumor-specific antigens and 
the T-cell response to each and every peptide-epitope involved multiple dominant and/
or subdominant TCRVb families (Table 2, Figure 2). One could argue that our analyzes 
concerning the breadth of the response is biased through the expansion of TIL by either 
homeostatic cytokines or peptide stimulation, as these rounds of expansion may not equally 
amplify all possible responding cells and less well proliferating HPV-specific T-cell clones 
may even become extinct. Yet in view of the broad responses observed already this would 
only mean that in reality the response is even broader and even now is still underestimated.
The broad and hierarchical responses closely resemble the published pattern of CD4+ and 
CD8+ T-cell responses to genetically stable viruses, such as CMV (34). This brings forward 
the question whether the HPV-specific T-cell responses observed in these cancer patients 
reflect a characteristic antiviral response or an anti-tumor response. As shown previously, 
patients with HPV-induced pre-malignant disease either fail to mount HPV-specific im-
munity (4;12) or induce a non-beneficial HPV-specific T-cell response during progression 
of disease (4;12). Therefore, we deem it more likely that the T-cell responses studied here re-
flect a typical tumor-specific T-cell response. Indeed, a similar hierarchy of the spontaneous 
T-cell response was observed in a study of two patients responding to NY-ESO-1 (44), as 
well as in the HLA-A*0201-restricted Melan-A/MART-126-35-specific CD8 T-cell response 
(6). The presence of single peptide-specific dominant and subdominant (based on TCRVb-
chain expression) T cells within the tumor tissue implies that subdominant TIL participate 
in the immune surveillance of tumors and not simply act as a reservoir. It is likely that the 
different dominant and subdominant HPV-specific T cells have different functions. This 
is illustrated by the isolation of both HPV-specific T-helper and T-regulatory cells from 
the same tumor in a group of cervical patients studied previously (45). Overall, the local 
HPV-specific immune response consists of a polyclonal T-cell population able to respond 
to many different CD4 and CD8 T-cell epitopes.
CD4+ and CD8+ T cells as well as the cytokines IFNγ and IL-2 play a key role in the 
protection against cancer (4;35-38) as well as in the control of chronic viral infections 
(39;40). In most of the ex-vivo tested TIL and TDLNC the population of IFNg and IL-2 
producing T cells or IFNg-producing T cells among the total population of HPV-specific T 
cells as well as the amount of IFNg produced was low (Table 1 & Figure 3b), suggesting that 
most of the HPV-specific TIL and TDLNC are rendered functionally tolerant within the 






tumor environment and implying that the local tumor-specific immune response in cervical 
cancer patients does not differ from others, such as melanoma (46). In vitro stimulation of 
these HPV-specific T cells with their cognate antigen resulted in an increase in the total 
population of HPV-specific T cells (e.g. P9 and P12, compare Figure 1a and Figure 1b) as 
well as in an increased IFNg production (P9; compare Table 1 & Figure 3c). We recently 
reported that the majority of patients vaccinated with a HPV16 E6 and E7 long peptide 
vaccine, showed a clearly detectable and broad vaccine-induced HPV-specific immune 
response as detected by IFNg-ELISPOT (23;24). Most likely this vaccine taps the broad 
available T-cell repertoire we identified in this study and either primes (in the group of 
patients without HPV-specific reactivity) or boosts their number. Interestingly, when TIL 
and lymph node derived T cells are ex-vivo stimulated with cognate antigen in the presence 
of TLR ligands, such as PAM3CSK4 or poly (I:C), an even more pronounced increase of 
effector function is observed (Figure 3c). This suggests that local delivery of these innate 
immune-derived stimulating factors can overcome functional tolerance in human cancers 
as was also observed in murine tumor models (41-43). Moreover, they are likely to assist 
therapeutic vaccines in driving T-cell responses with increased function as shown previously 
for a melanoma peptide vaccine in combination with CpG (47). Such type of responses is 
highly required as they do not only correlate with clinical efficacy in murine models (41), 
but also in human trials (48). Interestingly, the widely used TLR4 ligand LPS did not overtly 
increase IFNg production of TIL and TDLNC in our study.
In conclusion, the TIL or TDNLC isolated from 40-50% of patients with an HPV16 or 
HPV18-induced cervical tumor contain HPV type-specific T cells (3). Our study of the 
local T-cell repertoire within this group of patients suggests that within the tumor environ-
ment or tumor-draining lymph node of a given patient many different tumor-specific CD4+ 
and CD8+ T cells are poised for action but are awaiting proper stimulation.
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Supplemental figure 1.  
(A) Activated cells (CD154+ and/or CD137+) within CD3+ T cell population and within 
the CD3+ T-cell gated population expressing either CD4 or CD8. In these plots the 
homeostatic expanded TIL from two patients (P9 and P4) after stimulation with medium 
only, E6 or E7 peptide pools and E6 or E7 protein is shown. The peptide or protein-
activated CD154+ and/or CD137+ T cells as shown in Figure 1 where back-gated and 
indicated by a red color (activated CD8 T cells) or a blue color (activated CD4 T cells). 
Down regulation of CD8 is seen in the CD8+ T-cell population stimulated with the 
peptide pool and to a lesser extent in CD8 T cells stimulated with protein and this is not 
observed for CD4 on activated CD4 T cells.  
(B) An overview of all the single peptides used for analysis of the breadth of response 
after antigen-driven expansion for P9 and P12 (as partly shown in figure 1). Shown here 
are all the positive and negative responses as measured by the expression of CD154 and 
CD137. P9 displayed a CD8 response against four different single peptides (notably 41, 
51, 61 and 137). P12 displayed a CD4 response against six different single peptides 
(notably 21, 61, 71, 81, 91 and 101). 
 
 






Supplemental table 1.  Breadth of the HPV specific response detected in TIL and TDLNC 
Responding*  Activated Responding  Activated
Patient T-cell Antigen Peptides** Patient T-cell Antigen Peptides**
TIL 1 CD4 E6 medium 2 LN 13 CD4 E6 medium 0.1
E6 121 22 E6 1 1
E6 131 23 E6 41 1
2 CD4 E7 medium 2 E6 51 1
E7 1 10 E6 71 1
E7 11 10 E6 121 1
4 CD4 E6 medium 4 E6 131 1
E6 41 89 14 CD4 E6 medium 0.1
E6 51 65 E6 11 15
CD8 E6 medium 0,6 E6 61 78
E6 41 73 E6 71 78
E6 51 60 E6 81 2
CD8 E7 medium 2 E6 91 3
E7 21 15 E6 101 3
5 CD4 E6 medium 13 E6 121 9
E6 31 51 E6 131 6
E6 51 60 E6 137 2
E6 61 64 CD8 E6 medium 4
E6 71 56 E6 21 29
E6 81 60 E6 137 58
7 CD8 E6 medium 12 15 CD4 E6 medium 1
E6 21 47 E6 1 14
9 CD8 E6 medium 3 E6 21 2
E6 41 73 E6 41 6
E6 51 71 E6 51 6
E6 61 20 E6 71 2
E6 137 27 E6 81 4
10 CD4 E6 medium 9 E6 111 5
E6 1 33 E6 121 56
CD8 E6 medium 0.4 E6 131 38
E6 1 18 E6 137 20
E6 131 13 CD4 E7 medium 1
E6 137 14 E7 1 39
11 CD4 E7 medium 5 E7 11 37
E7 1 92 E7 41 4
E7 11 67 E7 51 5
12 CD4 E6 medium 2 E7 61 3
E6 21 16 E7 71 14











E6  71 3
* Depicted are all patients of whom T cells were tested after antigen specific expansion with E6 or E7 peptide pools
** HPV 16 or 18 (corresponding to the HPV type present in the tumor) E6 and E7 22-amino acid long overlapping peptides were 
used to test specificity  
Medium is activity present in cultures when no E6 or E7 22-mer peptide is added
The number indicates the first aminoacid of the peptide the culture reponded to or no peptide (medium) 
† The percentage of HPV-specific T cells that responded by upregulation of activation markers CD154 and/or CD137 
to the peptide depicted in the column on the left. A response is considered positive when the percentage is more 
than 3 times medium control
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Brief description: This study on the different types of myeloid cells, their clinical impact and their co-
operation with T cells offers a profound insight on the role of myeloid cells in the microenvironment and 
how they can work side by side to control tumors. As such, our data are a major addition to the current 
discussion about the impact of tumor-infiltrating myeloid cells in human cancers and offer potential new 
strategies to improve survival.
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a b st r ac t
One of the hallmarks of cancer is the influx of myeloid cells. In this study we investigated 
the constitution of tumor-infiltrating myeloid cells and their relationship to other tumor-
infiltrating immune cells, tumor-characteristics and the disease-specific survival of patients 
with cervical cancer. Triple color immunofluorescence confocal microscopy was used to 
locate, identify and quantify macrophages (CD14), their maturation status (CD33) and 
their polarization (CD163) in a cohort of 86 patients with cervical carcinoma. Quantifica-
tion of the numbers of myeloid cells revealed that a strong intraepithelial infiltration of 
CD14+ cells, and more specifically the population of CD14+CD33-CD163- matured M1 
macrophages, is associated with a large influx of intraepithelial T lymphocytes (p=0.008), 
improved disease-specific survival (p=0.007) and forms an independent prognostic fac-
tor for survival (p=0.033). The intraepithelial CD8+ T-cell and Treg ratio also forms an 
independent prognostic factor (p=0.010) and combination of these two factors reveals a 
further increased benefit in survival for patients whose tumor display a dense infiltration 
with intraepithelial matured M1 macrophages and a high CD8 T-cell/Treg ratio, indicating 
that both populations of immune cells simultaneously improve survival. Subsequently we 
made a heatmap including all known immune parameters for these patients, whereby we 
were able to identify different immune signatures in cervical cancer. These results indicate 
that reinforcement and activation of the intratumoral M1 macrophages may form an attrac-
tive immunotherapeutic option in cervical cancer.






I n t rodu c t Ion
Cervical cancer (CxCa) is caused by high risk human papilloma virus (HPV) (1). Studies on 
HPV-specific T-cell response in patients with premalignant disease suggest that spontane-
ous regression occurs when circulating HPV early antigen-specific CD4+ and CD8+ T-cells 
are present and when the lesions are infiltrated with effector T-cells that outnumber regula-
tory T-cells. Moreover, the presence of circulating HPV-specific CD4+ T-cells is associated 
with T-cell infiltration in the lesion and favorable clinical outcome in high-grade squamous 
intraepithelial lesion (HSIL) after treatment (2;3). The development of CxCa is associated 
with a weak systemic and local immune response to HPV, reflected by low numbers of 
tumor-infiltrating T-cells comprising CD8+ cytotoxic T-cells, CD4+ T-helper cells and 
regulatory T-cells (4-6). The T-cells present often lack cytotoxicity (7) and/or express co-
inhibitory molecules such as programmed cell death protein 1 (PD-1), CD94 and NKG2a 
(8;9). Tumors also down regulate Human Leukocyte Antigen (HLA) class I and MHC class I 
chain-related molecule A (MICA) and up regulate HLA-E and PD-L1 to further restrain the 
CD8+ T-cell response (2;8-10). The presence of circulating HPV-specific T-cells associates 
with better survival and high numbers of T-cells correlate with the absence of metastases or 
a relapse (2;6;11;12). Importantly, the ratio between tumor-infiltrating CD8+ and Foxp3+ 
T-cells was found to be the first immune-associated independent prognostic factor in CxCa 
(2).
Tumors mediate systemic and local effects, altering the accumulation and differen-
tiation of myeloid cells and redirecting their function to sustain tumor outgrowth. Three 
groups of terminally differentiated myeloid cells are essential for innate and adaptive im-
munity – macrophages, dendritic cells (DC) and granulocytes – and monocytes are the 
major precursor of the first two populations in humans. Macrophages are a heterogeneous 
population of tissue-resident monocytes, which display different functions depending on 
the microenvironment. Roughly two types are recognized; the classically activated type 1 
macrophages (M1) which are tumoricidal and produce IL-12 and the alternative activated 
type 2 macrophages (M2) which sabotage immunity by producing IL-10, prostaglandin E2 
(PgE2), TGFb and CCL22 (13-15). Extensive literature demonstrates that high numbers of 
tumor associated macrophages (TAMs) facilitate tumor growth, disease progression and 
poor prognosis (reviewed in (16)). The development from premalignant cervical lesions 
towards carcinoma is associated with high numbers of infiltrating CD68+ macrophages 
(17;18). However, in CxCa TAM were never associated with clinical parameters (12;19;20) 
or clinical outcome. It is conceivable that differences in macrophage subsets exist between 
patients, as some CxCa produce PgE2 and IL-6 (21;22), shown to be important for M2 
macrophages differentiation (23). Furthermore, there are vast differences between patients 
concerning density and type of tumor-infiltrating T-cells (2;6), which may also effect the 
type of macrophages present (24;25).
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This study uses a unique cohort of CxCa patients, for which many immune parameters 
are known, to investigate the presence of infiltrating myeloid cells and their relationship 
to other tumor-infiltrating immune cells, tumor characteristics and patient survival. We 
used fluorescence confocal microscopy to quantify macrophages (CD14), their matura-
tion status (CD33) and their polarization (M2; CD163). CD14 is a specific monocyte/
macrophage marker, although it can also be found on subsets of dendritic cells (26). CD33 
is expressed on non-terminally differentiated myeloid cells (27) and CD163 is linked to 
macrophage anti-inflammatory functions (26;28;29). We demonstrate that the density of 
tumor-epithelium infiltrating CD14+CD163- cells is an independent prognostic factor for 
prolonged disease-specific survival. Furthermore, unsupervised clustering of patients based 
on 40 known immune markers suggested that a tumor microenvironment that allows the 
accumulation of high numbers of CD14+CD33-CD163- myeloid cells forms a prerequisite 
for tumor-infiltrating CD8+ T-cells to exert their antitumor effect.
m at e r Ia l s a n d m et hod s
patient material
Formalin-fixed, paraffin-embedded tissue blocks from 86 CxCa patients undergoing a radi-
cal hysterectomy type III with pelvic lymphadenectomy (1985-2000) were retrieved from 
the Pathology Department (Leiden University Medical Center, Leiden, the Netherlands). 
Patients had not received radio- or chemotherapy before surgery. A trained pathologist 
reviewed all H&E-slides. All material was used according to Dutch Federation of Medical 
Research Associations guidelines.
Immunohistochemistry
Characterization of tumor-infiltrating myeloid cells (TIM) was carried out with triple 
immunofluorescent staining and confocal microscopy. Anti-CD33 (1:50, mouse-IgG2b, 
clone PWS44, LeicaMicrosystems, Rijswijk, the Netherlands), anti-CD14 (1:100, mouse-
IgG2a, clone 7, Abcam, Cambridge, UK) and anti-CD163 (1:400, mouse-IgG1, Clone 
10D6, LeicaMicrosystems) mixture was applied after EDTA (pH 9) pretreatment. CD68 
(Mouse-IgG2a, Clone 514H12, Serotec, Düsseldorf, Germany)/CD163 double-staining was 
also performed. The following fluorescently-labeled antibodies were used: goat-anti-mouse 
IgG2b-AlexaFluor546, goat-anti-mouse IgG2a-AlexaFluor488 and goat-anti-mouse IgG1-
AlexaFluor647 (MolecularProbes, Bleiswijk, the Netherlands). Images were captured with 
a confocal laser-scanning-microscope (Zeiss LSM 510, Germany) in a multitrack setting. 
Per slide, five randomly selected images were captured. Negative control slides, omitting 
the primary antibody, were included. Tumorcell-nests and stroma were measured using the 






Zeiss LSMImageExaminer and myeloid subsets were manually counted and presented as 
number/mm2.
In vitro differentiation assay of m2 macrophages
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy donors (29). 
CD14+ monocytes were isolated using MACS cell-separation (Miltenyi Biotec). Mono-
cytes were cultured with 25 ng/ml M-CSF (R&D systems, United Kingdom) to induce M2 
macrophages (23). On day 0 and 8, one sample was taken for FACS analysis and another 
was paraffin-embedded and stained with CD14 AF700 (clone M5E2, BD Biosciences, the 
Netherlands), CD33 PEcy7 (clone P67.6, BD Biosciences, the Netherlands) and CD163 
APC (clone 215927, R&D systems, United Kingdom) .
statistical analysis
Patients were divided into groups based on the median of the infiltrating cells. Cumulative 
disease-specific survival rate was calculated by the Kaplan-Meier method and analyzed by 
the log-rank test (Statistical Package for the Social Sciences software package 17 (SPSS)). 
A Cox regression analysis was used for the univariate and multivariate survival analyses 
of lymph node status, tumor size, tumor infiltration depth, vasoinvasion and parametria 
involvement as well as the different types of tumor-infiltrating immune cells. A p-value 
of <0.05 was considered statistically significant. The two-sided χ2 and the Fisher’s exact 
tests were used to associate TIMs, clinical variables, tumor-infiltrating lymphocytes (TILs) 
and expression of other tumor ligands. The Bonferroni correction was applied for multiple 
analyses. The Pearson’s correlation was used within the myeloid cells group.
For the creation of a heatmap, immune cell counts were divided into quartiles, except 
the CD3+CD8+CD57+ cells which were displayed in two groups due to low positive cell 
number. Tumor ligand expression was divided into two or three groups: positive or negative 
(HLA-E (9), HLA-G (unpublished), HLA-class II (2;10;30), MICA (2), PD-L1 (8), Serpin 
A1/A3 (31)) or negative, weak, strong (Chemokine (C-X-C motif) ligand (CXCL)12 , C-X-
C chemokine receptor (CXCR)4 (32), Indoleamine2,3-dioxygenase (IDO) (unpublished), 
CXCR7 (32), HLA-class I (2;10;30) and epidermal growth factor receptor (EGFR) (33)). 
The function ‘heatmap’ of the ‘stats’ package in R (Development Core Team, a language 
and environment for statistical computing, reference index version 2.14.0. 2005 Founda-
tion for Statistical Computing, Vienna, Austria) was used. Standard settings were used: 
euclidean distance and complete-linkage clustering (34). Data on the different lymphocitic 
sub-populations was previously generated (2;6). Tumor expression of the various ligands 
was measured by the Ruiter-system (35). Changes from the lowest to the highest quartile are 
reflected by a darker color, white blocks are missing data.
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r e su lt s
The cxca microenvironment comprises 
a large variety of myeloid cells
Patient characteristics are displayed in table 
1. To evaluate the infiltration of TIMs within 
the tumor-epithelium and stroma 86 tumors 
were analyzed for CD14, CD33 and CD163. 
Vast differences in the number and type of 
myeloid cells was found between tumors 
(Figure 1 and Table 2). In general, the stroma 
was more densely infiltrated with TIMs. 
The most common TIMs within the tumor-
epithelium were CD14+CD33-CD163-, 
CD14+CD33+CD163+ and CD14-CD33-
CD163+. These were also abundantly found 
in the stroma (Table 2). To confirm that the 
CD14+ cells were macrophages a staining 
was performed with the macrophage specific 
marker CD68 as well as CD163 in 10 CxCa. 
About 70% of the CD68+ cells expressed 
CD163 (M2 macrophages) (Supplementary 
Figure S1a). Additionally, in vitro M-CSF-
mediated differentiation of monocyte to M2 
macrophages showed that these cells clearly 
expressed CD14 and high levels of CD163 
(Supplementary Figure S1b). All together, 
we showed that tumors are infiltrated with 
variable M2 (CD14+CD163+) and M1 
(CD14+CD163-) macrophage numbers. In 
both our analyses using CD68 or CD14 as a 
macrophage marker we observed CD163+ cells that were CD68- (Supplementary Figure 
S1a) or CD14-, suggesting the presence of non-macrophage CD163+ myeloid cells, also 
observed by others (29).
induce M2 macrophages.23 On days 0 and 8, one sample was
taken for fluorescence activated cell sorting (FACS) analysis
and another was paraffin-embedded and stained with CD14
AF700 (clone M5E2, BD Biosciences, Breda The Nether-
lands), CD33 PEcy7 (clone P67.6, BD Biosciences) and
CD163 APC (clone 215927, R&D Systems).
Statistical analysis
Patients were divided into groups based on the median of the
infiltrating cells. Cumulative disease-specific survival rate was
calculated by the Kaplan–Meier method and analyzed by the
log-rank test [Statistical Package for the Social Sciences soft-
ware package 17 (SPSS)]. A Cox regression analysis was used
for the univariate and multivariate survival analyses of lymph
node status, tumor size, tumor infiltration depth, vasoinva-
sion and parametria involvement as well as the different
types of tumor-infiltrat ng immun cells. A p-value of <0.05
was considered statistically significant. The two-sided v2 and
the Fisher’s exact tests were used to associate TIMs, clinical
variables, tumor-infiltrating lymphocytes (TILs) and expres-
sion of other tumor ligands. The Bonferroni correction was
applied for multiple analyses. The Pearson’s correlation was
used within the myeloid cells group.
For the cr ation of a heatmap, immune cell c unts were
divided into quartiles, except the CD31CD81CD571 cells,
which were displayed in two groups because of low positive
cell number. Tumor ligand expression was divided into two
or three groups: positive or negative [HLA-E,9 HLA-G
(unpublished), HLA-class II,2,10,30 MICA,2 PD-L18 and Serpin
A1/A331] or negative, weak, strong [chemokine (C-X-C motif)
ligand (CXCL)12, C-X-C chemokine receptor (CXCR)4,32
indoleamine 2,3-dioxygenase (IDO) (unpublished), CXCR7,32
HLA-class I2,10,30 and epidermal growth factor receptor
(EGFR)33]. The function “heatmap” of the “stats” package in
R (Development Core Team, a language and environment for
statistical computing, reference index version 2.14.0. 2005
Foundation for Statistical Computing, Vienna, Austria) was
used. Standard settings were used: Euclidean distance and
complete-linkage clustering.34 Data on the different lympho-
cytic subpopulations was previously generated.2,6 Tumor
expression of the various ligands was measured by the Ruiter
system.35 Changes from the lowest to the highest quartile are
reflected by a darker color, and white blocks are missing data.
Results
The CxCa microenvironment comprises a large variety of
myeloid cells
Patient characteristics are displayed in Table 1. To evaluate
the infiltration of TIMs within the tumor epithelium and
stroma 86 tumors were analyzed for CD14, CD33 and
CD163. Vast differences in the number and type of myeloid
cells were found between tumors (Fig. 1 and Table 2). In
general, the stroma was more densely infiltrated with TIMs.
The most common TIMs within the tumor pithelium
were CD141CD332CD1632, CD141CD331CD1631 and
CD142CD332CD1631. These were also abundantly found
in the stroma (Table 2). To confirm that the CD141 cells
were macrophag s a staining was performed with the
macrophage-specific marker CD68 as well as CD163 in ten
Table 1. Patient characteristics
N (%)
No. of patients 86






















<4 cm 44 (51)
4 cm 36 (42)
Unknown 6 (7)
Infiltration depth
<15 mm 43 (50)









Mean follow-up time (months) 49.3
5-year survival rate 65 (76)
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figure 1. Immunofluoresence staining of cervical carcinoma with antibodies against CD14 (green), CD33 
(red) and CD163 (blue). (a) The tumor-epithelium (TE) and tumor stroma (S) are marked. The left panel de-
picts an example of an adenocarcinoma with dense infiltration of the stroma by CD14+CD33-CD163- (green), 
CD14+CD33-CD163+ (turquoise) and CD14-CD33-CD163+ (blue) cells. In the middle, a squamouscarcinoma 
with dense infiltration of the tumor-epithelium by various myeloid cells is shown. In the right panel is an exam-
ple of CD14+CD33-CD163- cells (green) infiltrating the tumor-epithelium. (b) An example of CD14+CD33-
CD163- (green) and CD14+CD33-CD163+ cells (turquoise; number 1) staining; CD14-CD33-CD163+ cells 
(blue; number 2); various myeloid marker combinations found in close proximity (number 3).
intraepithelial M2 macrophages (p 5 0.063). Pearson’s correla-
tion test showed that the numbers of CD141CD1632 and
CD141CD1631 cells were strongly related in both tumor epi-
thelium (p 5 0.002) and stroma (p 5 0.008), suggesting that
the observed trend between M2 macrophages and disease-
specific survival could be a confounder. The nonmacrophage
CD142CD1631 myeloid cells were not correlated to any of
the other groups of myeloid cells in epithelium or stroma
(0.086 and 0.083, respectively).
Further subdivision based on CD33 expression revealed
that especially the number of intraepithelial
CD141CD332CD1632 cells (mature M1 macrophages),
which made up 75% of all cells in the CD141CD1632
group (Table 2), was associated with improved disease-
specific survival (p 5 0.003; Fig. 2). Notably, the trend
between intraepithelial M2 macrophages and disease-specific
survival was lost. No associations with survival were found
for cells present in stroma.
M1 macrophages and T-cells act together to improve
disease-specific survival
Previously, we have shown that CxCa can be abundantly
infiltrated by CD81 T-cells and also by Foxp31 T-cells.2,6
Therefore, the relationship between the infiltration of the dif-
ferent types of TIMs and the other previously enumerated
tumor-infiltrating immune cells in this group of patients was
studied. The presence of high numbers of intraepithelial
CD141CD1632 cells (predominantly CD141CD332
CD1632 cells) correlated with a high influx of intraepithelial
T lymphocytes (p 5 0.008; Table 3). There was no correla-
tion with any specific lymphocyte subset. In contrast, the
intraepithelial population of nonmacrophage CD1631 mye-
loid cells, irrespectively of CD33 expression, was positively
correlated to the number of intraepithelial CD31CD82
Foxp31 Tregs (p 5 0.006; Table 3). No correlations were
found between stromal TIMs and intraepithelial immune
cells (data not shown).
We have previously shown that it is not a single popula-
tion of TIL that is associated with survival, but specifically
the ratio between the tumor-infiltrating CD81 and Foxp31
T-cells.2 Therefore, we assessed the influence of the intraepi-
thelial CD141CD332CD1632 myeloid population and the
intraepithelial CD81/Foxp31 T-cell ratio by dividing the
patients into four groups based on the median number of
both cell types. The best disease-specific survival was seen in
the group of patients with high numbers of intraepithelial
CD141CD332CD1632 myeloid cells and a high CD81/
Foxp3 T-cell ratio (n 5 19, p 5 0.005; Fig. 2b). Conversely,
patients with low numbers of these myeloid cells and a low
CD81/Foxp3 T-cell ratio displayed the worst survival (n 5
23). Interestingly, the groups with only high numbers of
CD141CD332CD1632 myeloid cells or a high CD81/
Foxp31 T-cell ratio did equally well (Fig. 2b), suggesting
that M1 macrophages and CD81 T-cells have an additive
antitumor effect.
We also assessed the association between TIM and expres-
sion of HLA-class I/II, MICA,2,30 IDO36,37 and PD-L18 by
the tumor cells, factors that may also play a role in the local
immune response to tumors, all of which have been studied
previously in this group of tumors. Although there was no
association with the macrophage populations, the intraepithe-
lial subpopulation of nonmacrophage CD142CD332
CD1631 myeloid cells correlated to strong HLA-class II
expression (p 5 0.005; Table 3).
M1 macrophages form an independent prognostic factor
for disease-specific survival
The clinical pathological factors known to influence CxCa
prognosis are lymph node status, tumor size, tumor infiltra-
tion depth, vasoinvasion and parametria involvement.38–41 To
further analyze the correlation between myeloid cells and
prognosis, we investigated their correlation with these clinical
pathological factors. Intraepithelial CD141CD332CD1632
myeloid cells (p 5 0.006) as well as CD141CD1631 myeloid
cells (p 5 0.005) and specifically the CD141CD331CD1631
subpopulation (p 5 0.007) were associated with lack of
metastasis (Table 3). The intraepithelial population of non-
macrophage CD142CD1631 myeloid cells was not corre-
lated to any clinical pathological factors, again indicating that
these cells form an unrelated group of TIM cells.
Because of the relationships found between M1 macro-
phages, lymph node status and T-cell infiltration, we assessed
their prognostic impact in a multivariate analysis. First, strati-
fication of all patients based on the known histopathological
risk factors showed that lymph node metastasis (p < 0.001),
tumor size (p < 0.001), infiltration depth (p 5 0.011) and
parametrial involvement (p < 0.001) were all associated to a
worse disease-specific survival by Cox regression analysis. A
multivariate Cox regression analysis of these clinical parame-
ters identified only lymph node status (p 5 0.004) and tumor
size (p < 0.001) as independent predictors of disease-specific
survival.










CD141CD332CD1632 12 (4–28) 40 (20–69)
CD141CD331CD1632 4 (0–16) 13 (2–38)
CD141CD332CD1631 9 (2–21) 39 (14–84)
CD141CD331CD1631 10 (1–49) 59 (14–198)
CD142CD331CD1632 3 (0–15) 19 (7–42)
CD142CD331CD1631 8 (1–26) 31 (7–72)
CD142CD332CD1631 10 (2–26) 52 (15–113)
1The identification of different myeloid cell subsets on the basis of the
expression of CD14, CD33 and CD163.
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Figure 2. de Vos van Steenwijk et al
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figure 2. Myeloid cell populations were divided into two groups based on the median number of intraepithelial 
myeloid cells. (a) Kaplan Meijer curves of the total CD14+ cells showed a significant survival benefit for patients 
with more than median CD14+ tumor-infiltrating cells. When these cells were divided adding the expression 
of CD163, the survival benefit was seen in the group of patients with more than median CD14+CD163- infil-
trating cells, yet a trend was still seen for the CD14+CD163+ myeloid cells. The main sub-population of the 
CD14+CD163- cells was CD33- (75%), which was again significantly correlated to a prolonged survival. (b) The 
ratio of CD8+ and Foxp3+ T-cells infiltrating the tumor-epithelium was previously identified as an independent 
factor of disease-specific survival in cervical carcinoma patients. The Kaplan Meijer of this ratio combined with 
the CD14+CD33-CD163- myeloid cells, showed a greatly increased 5-year disease-specific survival for patients 
with high numbers of both cell types and the poorest disease-specific survival in patients with low numbers of 
both cell types.






Intraepithelial m1 macrophages are associated with a better disease-specific 
survival
While on average CxCa is well infiltrated by the three major subsets of myeloid cells, a clear 
difference exists between individual patients as indicated by the interquartile ranges pro-
vided for each cell population (Table 2). To assess the prognostic impact of these myeloid 
populations, the 5-year Kaplan-Meier estimate and log-rank test were used. Patients were 
divided into two groups based on the median number of myeloid cell subset per mm2 in the 
tumor-epithelium or in stroma.
Firstly the patients were analyzed according to the total myeloid cell population expressing 
CD14+, CD33+ or CD163+. Patients with tumors displaying high numbers of intraepithe-
lial CD14+ myeloid cells, showed a better 5-year disease-specific survival (p=0.03; Figure 
2). No survival benefit was seen based on the number of intraepithelial CD33 or CD163 
expressing cells (Supplementary Figure S2). Further division of the CD14+ myeloid cell 
population based on CD163 expression revealed that patients with high numbers of in-
traepithelial CD14+CD163- cells (M1 macrophages) displayed a survival benefit (p=0.015). 
Unexpectedly a trend towards a better survival was seen in the patients with high numbers 
of intraepithelial M2 macrophages (p=0.063). Pearson’s correlation test showed that the 
numbers of CD14+CD163- and CD14+CD163+ cells were strongly related in both tumor-
epithelium (p=0.002) and stroma (p=0.008), suggesting that the observed trend between 
M2 macrophages and disease-specific survival could be a confounder. The non-macrophage 
CD14-CD163+ myeloid cells were not correlated to any of the other groups of myeloid cells 
in epithelium or stroma (0,086 and 0,083 respectively).
Further subdivision based on CD33 expression revealed that especially the number of 
intraepithelial CD14+CD33-CD163- cells (mature M1 macrophages), which made up 75% 
of all cells in the CD14+CD163- group (Table 2), was associated with improved disease-
specific survival (p=0.003; Figure 2). Notably, the trend between intraepithelial M2 macro-
phages and disease-specific survival was lost. No associations with survival were found for 
cells present in stroma.
m1 macrophages and t-cells act together to improve disease-specific survival
Previously we have shown that CxCa can be abundantly infiltrated by CD8+ T-cells, but 
also by Foxp3+ T-cells (2;6). Therefore, the relationship between the infiltration of the 
different types of TIMs and the other previously enumerated tumor-infiltrating immune 
cells in this group of patients was studied. The presence of high numbers of intraepithelial 
CD14+CD163- cells (predominantly CD14+CD33-CD163- cells), correlated with a high in-
flux of intraepithelial T lymphocytes (p=0.008; Table 3). There was no correlation with any 
specific lymphocyte subset. In contrast, the intraepithelial population of non-macrophage 
CD163+ myeloid cells, irrespectively of CD33 expression, was positively correlated to the 
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number of intraepithelial CD3+CD8-Foxp3+ Tregs (p=0.006; Table 3). No correlations were 
found between stromal TIMs and intraepithelial immune cells (data not shown).
We have previously shown that it is not a single population of TIL that is associated 
with survival, but specifically the ratio between the tumor-infiltrating CD8+ and Foxp3+ 
T-cells (2). We therefore assessed the influence of the intra-epithelial CD14+CD33-CD163- 
myeloid population and the intra-epithelial CD8+/Foxp3+ T-cell ratio by dividing the 
patients into 4 groups based on the median number of both cell types.. The best disease-
specific survival was seen in the group of patients with high numbers of intraepithelial 
CD14+CD33-CD163- myeloid cells and a high CD8+/Foxp3 T-cell ratio (n=19, p=0.005; 
Figure 2b). Conversely, patients with low numbers of these myeloid cells and a low CD8+/
Foxp3 T-cell ratio displayed the worst survival (n=23). Interestingly, the groups with only 
high numbers of CD14+CD33-CD163- myeloid cells or a high CD8+/Foxp3+ T-cell ratio, 
together with various immature CD331 myeloid cells) and a
high CD81/Foxp31 T-cell ratio, both independent prognostic
factors. Subgroup analyses provided new insights in the type of
immune responses key in the protection against progressive
CxCa. We observed that all groups of patients with few M1
macrophages and with l w numbers of tumor-infiltrating Tregs
(subgroups 2–5) displayed a similar intermediate percentage of
disease-specific survival independent of the level of CD81 T-
cell infiltration. This implies that the tumor-infiltrating T-cells
are less likely to exert a proper antitumor effect within a tumor
microenvironment that does ot allow the accumulation of
high numbers of M1 macrophages. Indeed, in subgroups 6–8,
reflecting patients who do very well, the tumors were infiltrated
with relatively high numbers of M1 macrophages and displayed
a high CD8/Treg ratio (Fig. 3).
Previous studies on the number of macrophages in CxCa
did not reveal any relationship with clinical par meters,12,19,20
most likely because differences in function were not taken
into account. Here, we quantified the number of immature
and mature M1 and M2 macrophages. A few recent studies
analyzing M2-type macrophages indicated that a dense M2
macrophage infiltration is associated with poor survival in















CD141CD1632 0.382 0.183 0.15 0.32 0.925 0.008 (0.048)2
CD141CD332CD1632 0.037 0.24 0.26 0.51 0.82 0.012
CD141CD331CD1632 0.33 0.036 0.69 0.38 0.97 0.038
CD141 CD1631 0.017 0.089 0.859 0.65 0.877 0.03
CD141CD332CD1631 0.27 0.35 0.42 0.32 0.32 0.19
CD141CD331CD1631 0.98 0.87 0.59 0.062 0.59 0.27
CD142CD1631 0.083 0.28 0.006 (0.036)2 0.021 0.062 0.519
CD142CD331CD1631 0.49 0.05 0.15 0.059 0.02 0.99




class 2 MICA IDO PDL1
CD141CD1632 0.887 0.928 0.475 0.586 0.22
CD141CD332CD1632 0.43 0.62 0.52 0.27 0.078
CD141CD331CD1632 0.22 0.64 0.33 0.52 0.62
CD141 CD1631 0.194 0.594 0.18 0.726 0.734
CD141CD332CD1631 0.032 0.81 0.38 0.15 0.96
CD141CD331CD1631 0.027 0.12 0.47 0.57 0.26
CD142CD1631 0.78 0.093 0.478 0.44 0.071
CD142CD331CD1631 0.2 0.88 0.26 0.73 0.087











CD141CD1632 0.081 0.632 0.504 0.744 0.165
CD141CD332CD1632 0.009 (0.045)2 0.73 0.58 0.12 0.043
CD141CD331CD1632 0.7 0.7 0.91 0.48 0.93
CD141 CD1631 0.005 (0.03)2 0.685 0.513 0.133 0.143
CD141CD332CD1631 0.86 0.27 0.82 0.74 0.54
CD141CD331CD1631 0.007 (0.035)2 0.84 0.38 0.019 0.039
CD142CD1631 0.519 0.77 0.513 0.745 0.191
CD142CD331CD1631 0.758 0.543 0.827 0.22 0.38
CD142CD332CD1631 0.86 0.68 0.82 0.57 0.52
1For the assessment of relationships between histopathological parameters and myeloid subpopulations, the latter were divided based on the 50th
percentile.
2The values in bold indicate the p-values that are considered to be significant, the values between the brackets indicate the p-value after Bonferroni
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did equally well (Figure 2b), suggesting that M1 macrophages and CD8+ T-cells have an 
additive anti-tumor effect.
We also assessed the association between TIM and expression of HLA-class I/II, MICA 
(2;30), IDO (36;37) and PD-L1 (8) by the tumor cells, factors which may also play a role 
in the local immune response to tumors, all of which have been studied previously in this 
group of tumors. While there was no association with the macrophage populations, the 
intraepithelial sub-population of non-macrophage CD14-CD33-CD163+ myeloid cells cor-
related to strong HLA-class II expression (p=0.005; Table 3).
m1 macrophages form an independent prognostic factor for disease-specific 
survival
The clinical pathological factors known to influence CxCa prognosis are lymph node status, 
tumor size, tumor infiltration depth, vasoinvasion and parametria involvement (38-41). To 
further analyze the correlation between myeloid cells and prognosis, we investigated their 
correlation with these clinical pathological factors. Intraepithelial CD14+CD33-CD163- 
myeloid cells (p=0.006), as well as CD14+CD163+ myeloid cells (p=0.005) and specifically 
the CD14+CD33+CD163+ subpopulation (p=0.007), were associated with lack of metas-
tasis (Table 3). The intraepithelial population of non-macrophage CD14-CD163+ myeloid 
cells was not correlated to any clinical pathological factors, again indicating that these cells 
form an unrelated group of tumor-infiltrating myeloid cells.
Because of the relationships found between M1 macrophages, lymph node status and 
T-cell infiltration, we assessed their prognostic impact in a multivariate analysis. Firstly, 
stratification of all patients based on the known histopathological risk factors showed that 
lymph node metastasis (p<0.001), tumor size (p<0.001), infiltration depth (p=0.011) and 
parametrial involvement (p<0.001) were all associated to a worse disease-specific survival 
by Cox regression analysis. A multivariate Cox regression analysis of these clinical param-
eters identified only lymph node status (p=0.004) and tumor size (p<0.001) as independent 
predictors of disease-specific survival.
Secondly, a Cox regression analysis of the tumor-infiltrating immune cells identified 
a significant correlation between survival and the total CD14 population (p=0.038), 
CD14+CD163- cells (p=0.016) and CD14+CD33-CD163- cells (p= 0.007). Finally, the 
independent clinical pathological risk factors, the number of myeloid cells, as well as the 
CD8+/ Foxp3+ T-cell ratio were analyzed in a multivariate Cox regression analysis. We 
confirmed that lymph node status (p<0.001), tumor size (p=0.001) and the CD8+/Foxp3+ 
intraepithelial T-cell ratio (p=0.015) were all independent survival factors. Furthermore 
we found that dense M1 macrophages (CD14+CD163-) tumor-epithelial infiltration is 
an independent survival factor (p=0.011). Analysis with the matured M1 macrophages 
(CD14+CD33-CD163-) did not reach significance (p=0.053).
76 Chapter 4
unsupervised clustering based on immune parameters identifies different immune 
microenvironments associated with survival
This cohort of 86 patients has been extensively studied for the total lymphocyte infiltration, 
as well as the various lymphocytes sub-populations CD3+CD8-Foxp3-, CD3+CD8-Foxp3+, 
CD3+CD8+Foxp3-, CD3+CD8+CD57+, CD3-CD8+CD57+, CD3+CD8-CD57+ and CD3-
CD8-CD57+ (2;6). Furthermore, this group has been studied for the expression of CXCR7, 
CXCL12, CXCR4 (32), EGFR (33), MICA (2), HLA-E (9), HLA-G (unpublished), PD-L1 
(8) IDO (unpublished), Serpin A1/A3 (31) as well as HLA-class I/II (2;10). To gain a better 
insight in the immunologic make-up of CxCa, a heatmap of all parameters including the 
ratio between intraepithelial CD8+ and Foxp3+ T-cells (2) and the intraepithelial myeloid 
cell populations identified in this study, was constructed. Unsupervised clustering divided 
the patients into two major groups (Group I and II) that are both subdivided into two 
subgroups (Ia and Ib, IIa and IIb) and then further into nine smaller subgroups (Figure 3a).
A clear difference between group I and II was the much denser matured M1 macrophage 
(CD14+CD33-CD163-) infiltration in group II, which co-clustered with different types of 
immature (CD33+) myeloid cells. Within group I, the tumors of group Ia generally expressed 
both HLA-class I/II, displayed a strong infiltration of all types of lymphocytes, as well as 
strong CD33-CD163+ myeloid cells infiltration, irrespective of CD14 expression. Group Ib 
distinguishes itself from group Ia by a lower lymphocytic infiltrate as well as loss or weak 
expression of HLA-class I/II in a substantial number of patients. The tumors in group IIa 
have less intraepithelial T-cell infiltrate and less infiltration of the above mentioned CD33-
CD163+ (CD14+ or CD14-) myeloid cells, which are all abundantly present in group IIb. 
Kaplan-Meier survival curves and log-rank analysis for these groups of patients revealed a 
significantly better survival for group II (p=0.045; Figure 3b), yet no differences were found 
between subgroups (Ia versus Ib or IIa versus IIb; Supplementary Figure S2b).
Subsequently, survival of the nine small subgroups was analyzed. The clustering of these 
groups seemed to be based mainly on 4 parameters: HLA-class I/II expression, number of 
CD8+ T-cells, CD8+/Foxp3+ T-cell ratio and matured M1 macrophages number, indicated 
by the red boxes in Figure 3a. Subgroup 1 includes tumors with low matured M1 macro-
phages infiltration and a low CD8+/ Foxp3 T-cell ratio (despite good HLA expression and 
moderate numbers of CD8+ T-cells). Patients in this group had the worse survival (Figure 
3c). Subgroup 2 reflects tumors strongly infiltrated with CD8+ T-cells with a beneficial 
CD8+/Foxp3+ T-cells ratio, but lacking matured M1 macrophages. This group displayed 
better survival (Figure 3c). Group 1b (subgroups 3-5) included tumors with low HLA 
expression, few CD8+ T-cells, a low CD8+/Foxp3+ T-cell ratio and few matured M1 macro-
phages. The survival in these groups was generally poor (Figure 3c). Group IIb was divided 
into the small subgroups 7, 8 and 9. They were all abundantly infiltrated with CD14+CD33-
CD163- myeloid cells. The main difference was a lower CD8+/Foxp3 intraepithelial T-cell 
ratio in subgroup 9 and the strongest intraepithelial CD8+ T-cell infiltration in subgroup 
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Figure 3, de Vos van Steenwijk et al
figure 3. A heatmap was created based on all immunological parameters determined in this patient cohort, 
followed by unsupervised clustering. The changes from the lowest to the highest quartile are reflected by a 
darker color, the white boxes are missing data. Along the Y-axis are the 86 patients, with all the immunological 
parameters indicated to the right. Each column is the unique fingerprint of one patient. The brackets to the left 
and along the top indicated the unsupervised clustering. Patients are clustered into two groups (Group I and 
II) based mainly on the CD33+ expressing cells, which co-cluster together with the CD14+CD33-CD163- cells. 
Both groups can be subdivided into two major groups (Ia, Ib, IIa and IIb) and then further into nine subgroups 
(indicated along the bottom). The red boxes indicate the parameters which seem important in determining the 
sub-group clustering. (b) Survival analysis by Kaplan Meijer method and log-rank test of the two major groups, 
shows a significant disease-specific survival benefit for Group II versus Group I (p<0.05). (c) Disease-specific 
survival analysis by Kaplan Meijer method of all the subgroups 1-9.
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7. Analysis of these subgroups revealed that subgroup 9 had the worst survival (similar 
to patients in subgroups 1-5), whereas patients in subgroup 7 had a 100% 5 year survival 
(Figure 3c). Subgroup 6 showed a similar survival to patients in subgroup 8, the main dif-
ference being the lower numbers of CD8+ T-cells, although a good CD8+/Foxp3 T-cell ratio 
was maintained.
In conclusion, the unsupervised clustering of patients based on several immune param-
eters confirmed our earlier observations that M1 macrophages, CD8+ T-cells and Foxp3+ 
Tregs are tightly associated with the disease-specific survival of CxCa patients.
dI s c u s sIon
Here we investigated the constitution of tumor-infiltrating myeloid cells in relationship to 
other tumor-infiltrating immune cells, tumor-characteristics and the disease-specific sur-
vival of CxCa patients. Quantification of myeloid cell populations based on the expression 
of CD14, CD33 and CD163, revealed that a strong intraepithelial infiltration of CD14+ 
cells, and specifically CD14+CD33-CD163- matured M1 macrophages, is associated with 
significantly improved disease-specific survival and is an independent prognostic factor as 
determined by multivariate analysis. The other independent prognostic immune-related 
factor in CxCa found so far is the intraepithelial CTL/Treg ratio (Figure 2c). Combina-
tion of these two factors revealed a substantial increase in survival in the group of patients 
with tumors displaying dense intraepithelial matured M1 macrophage infiltrate and a high 
CD8+/Foxp3+ T-cell ratio. Furthermore, immune profiling by unsupervised clustering 
of 40 different immune parameters revealed a fingerprint that was clearly associated with 
improved disease-specific survival. The main determinants were the presence of matured 
M1 macrophages (clustering together with various immature CD33+ myeloid cells) and a 
high CD8+/Foxp3+ T-cell ratio, both independent prognostic factors. Subgroup analyses 
provided new insights in the type of immune responses key in the protection against pro-
gressive CxCa. We observed that all groups of patients with few M1 macrophages and with 
low numbers of tumor-infiltrating Tregs (subgroups 2-5), displayed a similar intermediate 
percentage of disease-specific survival independent of the level of CD8+ T-cell infiltration. 
This implies that the tumor-infiltrating T-cells are less likely to exert a proper antitumor 
effect within a tumor microenvironment that does not allow the accumulation of high 
numbers of M1 macrophages. Indeed in subgroups 6-8, reflecting patients who do very well, 
the tumors were infiltrated with relatively high numbers of M1 macrophages and displayed 
a high CD8/Treg ratio (Figure 3).
Previous studies on the number of macrophages in CxCa did not reveal any relationship 
with clinical parameters (12;19;20), most likely because differences in function were not 
taken into account. Here, we quantified the number of immature and mature M1 and M2 






macrophages. A few recent studies analyzing M2-type macrophages indicated that a dense 
M2 macrophage infiltration is associated with poor survival in different carcinomas (43-46). 
In our study, we did not observe this association, finding instead that the number of tumor-
infiltrating M1 macrophages was positively associated with survival. Similar observations 
correlating M1 macrophages to better survival were made in non-small lung cancer (42;43) 
and breast carcinoma (44).
Studies on colorectal carcinoma also demonstrated that CD14+ TAM were associated with 
a favorable prognosis and that these CD14+ cells expressed CD40 and often CD80/CD86 
(45;46), which can be considered markers of matured antigen presenting cells. In our study, 
the strongest correlation was found between survival and fully matured (CD33 negative) 
M1 macrophages, suggesting that the accumulation of matured M1 macrophages reflects a 
tumor-rejecting microenvironment. The group of M1 macrophages comprised about 25% 
of cells that expressed CD33+, however, these cells did not provide any disease-specific 
survival advantage, possibly, because these cells are still not fully activated. Alternatively 
these CD33+ cells may reflect myeloid derived suppressor cells if they also display a low 
expression of HLA-DR (14), but this was not tested in our study.
Apart from M2 macrophages a group of myeloid cells was found in vivo that was CD163+ 
but CD14-. The numbers of these cells did not correlate with the other two myeloid sub-
groups, yet correlated to intraepithelial Foxp3+ lymphocytes. Based on our in vitro data, 
showing CD14 expression on monocytes and macrophages, as well as the presence of 
CD68-CD163+ cells in vivo, we conclude that these non-macrophage CD163+ myeloid cells 
are likely to reflect immunosuppressive DC’s or DC-derived macrophages (29;47).
Our results are important for the development of new strategies to combat cancer. We 
show that tumor-infiltrating matured M1 macrophages are associated with better survival, 
irrespective of CD8+ T-cells infiltration. Therapies to block macrophage infiltration – for 
instance by blocking chemokines or their receptors - thus are not warranted per definition. 
Furthermore, our data suggest that the density of tumor-infiltrating M2 macrophages does 
not have an impact on overall survival. Therefore, selective inhibition of M2 macrophages 
without stimulation of M1 macrophages may also prove to be unsuccessful. Therapies 
should rather aim at reprogramming the abundantly present M2 macrophages towards an 
M1 phenotype. This can be achieved via multiple pathways (14), including blocking of IL-6 
and cyclooxygenase-2  (COX2), both of which are associated with poor survival in CxCa 
and are known to induce M2 macrophages (21-23), or by using taxoids (48). Activation of 
the tumoricidal function of M1 macrophages can be achieved through ligation of CD40. In 
pancreatic ductal adenocarcinoma combining gemcitabine and agonistic CD40-antibody 
induced tumor regression due to the activation of tumoricidal macrophages and subsequent 
depletion of tumor stroma (49). Here, the myeloid derived suppressor cells (MDSC) were 
probably effectively removed by the use of gemcitabine (50). Notably, CD4+ type 1 helper 
T-cells are well equipped to reprogram CD14+CD163+ macrophages towards activated M1 
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macrophages via CD40-CD40L interaction and the production of Interferon (IFN)g (23). 
Our observations that patients whose tumors are infiltrated with a dense T-cell population 
comprising relatively low numbers of Foxp3 regulatory T-cells and a dense population of 
mature CD14+CD163- myeloid cells, have the best clinical performance, suggest that these 
two populations collaborate to resist tumor cells. These results should be validated by pro-
spective trials. Current immunotherapy trials aim at reinforcing the tumor-specific T-cell 
response to CxCa, but our data argue that these therapies are most likely to have success if 
the tumors are infiltrated with matured M1 macrophages. Therefore, pre-selection of pa-
tients based on dense CD14+ cells infiltration may help to improve success rates. However, 
therapy combining the induction of tumor-specific IFNg-producing CD4+ T-helper cell 
and cytotoxic CD8+ T-cell responses, the attraction of M1 macrophages or reprogramming 
of resident myeloid cells, may be beneficial to a larger group of patients.
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CD68 CD163 Overlay
Supporting information 1, de Vos van Steenwijk et al
supporting information 1. Immunohistochemical staining for CD68 and CD163 showing CD68+CD163- 























































Supporting information 2, de Vos van Steenwijk et al
supporting information 2. 76% of freshly isolated monocytes show intermediate expression of CD163, while 
cultured M2 macrophages express up to 1000x more. Immunohistofluorescence staining of monocytes shows 
mainly CD14+CD163- (green) cells, whole most of the M2 cells were positive for both markers (CD14+CD163+, 
turquoise).
























































high numbers of myeloid cells
low numbers of myeloid cells
supporting information 3. (a) Kaplan Meijer curves of intraepithelial myeloid cell populations based on the to-
tal CD14+, CD33+ and CD163+ cells shows a significant survival benefit for the total CD14+ cells. (b) Survival 
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a b st r ac t
Monocytes attracted by tumor-induced chronic inflammation differentiate to antigen-
presenting cells (APC), the type of which depends on cues in the local tumor milieu. Here, 
we studied the influence of human cervical cancer cells on monocyte differentiation and 
showed that the majority of cancer cells either hampered monocyte to DC differentiation or 
skewed their differentiation towards M2-like macrophages. Blocking studies revealed that 
M2-differentiation was caused by tumor-produced PgE2 and IL-6. TGFb, IL-10, VEGF or 
M-CSF did not play a role. Notably, these CD14+CD163+ M2-macrophages were also detect-
ed in situ. Activation of cancer cell-induced M2-like macrophages by several TLR-agonists 
revealed that when compared to DC these M2-macrophages displayed a tolerogenic pheno-
type reflected by a lower  expression of co-stimulatory molecules, an altered balance in IL-
12p70 and IL-10 production and a poor capacity to stimulate T-cell proliferation and IFNγ 
production. Interestingly, upon cognate interaction with Th1 cells these tumor-induced 
M2-macrophages could be switched to activated M1-like macrophages that expressed high 
levels of co-stimulatory molecules, produced high amounts of IL-12 and low amounts of 
IL-10, as well as acquired the lymphoid homing marker CCR7. The effects of the interaction 
between M2-macrophages and Th1 cells could partially be mimicked by activation of these 
APC via CD40 in the presence of IFNγ. Our data on the presence, induction and plasticity 
of tumor-induced tolerogenic APC in cervical cancer suggest that tumor-infiltrated Th1 
cells can stimulate a tumor-rejecting environment by switching M2-macrophages to classi-
cal pro-inflammatory M1 macrophages.






I n t rodu c t Ion
Cervical cancer (CxCa) is induced by human papilloma virus (HPV) (1). In many cases, 
the development of CxCa is associated with a weak systemic and local immune response 
to HPV, reflected by low numbers of tumor-infiltrating T cells that comprise functionally 
impaired T-helper cells and regulatory T cells (2-7).  When the tumor-specific immune 
response is stronger and more in favor of a Th1/CTL response, this is associated with an 
improved prognosis (4,8-10). 
Tumors foster a tolerant microenvironment by the activation of a plethora of immuno-
suppressive mechanisms, including the modulation of antigen presenting cells (APC) that 
otherwise may stimulate adaptive immunity against cancer (11). Monocytes are attracted 
by the chronic inflammation caused by tumors and differentiate into a variety of tumor-
associated macrophage (M2) and dendritic cell (DC) subtypes depending on local media-
tors (12-14).  Factors secreted by tumor cells that have been implicated in the  prevention 
or modulation of  DC differentiation and/or function are vascular endothelial growth factor 
(VEGF), macrophage colony stimulating factor (M-CSF),  transforming growth factor 
(TGFβ), IL-10, IL-6 and prostanoids(e.g. PgE2) (12). Cervical cancers are known also to 
secrete immunomodulatory compounds but their effect on APC is yet unknown (15-19).
Therefore, we studied the effect of cervical cancer cells on monocyte differentiation and 
function. We found that DC differentiation was hampered or even skewed towards the 
tolerogenic M2 macrophages by tumor-derived PgE2 and IL-6. Subsequently, we assessed 
the effects of APC activation by several different Toll like receptor (TLR)-agonists, which are 
currently used or tested for the treatment of cancer in human beings (20), CD40 stimulation 
or cognate interactions with Th1 cells. Notably, the interaction with Th1 cells resulted in 
a switch to activated M1-like macrophages expressing high levels of co-stimulatory mol-
ecules and producing high amounts of IL-12p70. Our data suggests that a highly immune-
stimulatory local microenvironment might be achieved by utilizing COX-inhibitors and 
IL-6 blocking antibodies to prevent M2-differentiation and vaccine-mediated stimulation 
of Th1 cells to switch M2 macrophages to tumor-rejecting M1 macrophages. 
m at e r Ia l a n d m et hod s
Immunofluorescent staining of tumor tissue
Ten patients with cervical cancer with FIGO stage I and II underwent radical hysterectomy 
(type III) in our hospital. Patients had not received radiotherapy or chemotherapy before 
surgery. Tumors were HPV typed by PCR and sequencing, as described previously (21). 
The use of clinical material was approved by the institutional review board according to the 
guidelines of the Dutch Federation of Medical Research Associations.
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Staining was performed on 4 mm tissue-sections of formalin-treated and paraffin em-
bedded tumor material. Immunostaining was performed with a monoclonal antibody mix 
of anti-CD14 (clone 7, Abcam USA) and anti-CD163 (clone 10D6, Novocastra United 
Kingdom) and after incubation overnight stained with fluorescent antibody conjugates 
(IgG2a-Alexa Fluor 488 and IgG1- alexa Fluor 647, Invitrogen USA )(22). Control staining 
with only secondary antibodies were included to ensure specificity. Images were captured at 
25 X magnification with a confocal laser scanning microscope (Zeiss LSM 510, Germany) 
in a multitrack setting. 
media and reagents
APC and tumor cell-lines were grown in RPMI (Invitrogen) supplemented with 10% 
Fetal Calf Serum (Greiner bio-one Germany), penicillin/streptomycin (Invitrogen) and L-
glutamine (Cambrex USA). Adherent cell-lines were treated with trypsin/EDTA 1x (PAA, 
Austria). T cell clones were grown in IMDM (Lonza Switserland) supplemented with 10% 
FCS (PAA), P/S and L-glutamine. The following factors and final concentrations were used 
to generate APC: 500 U/ml IL-4, 800 u/ml GM-CSF (Gibco, USA), ,10-100 ng/ml M-CSF 
(R&D systems USA), 50-1000 pg/ml TGFb1 (BD biosciences USA), 1-50 ng/ml prosta-
glandin E2 (Sigma-Aldrich Germany). TLR ligands used for activation: 25 mg/ml Poly(I:C), 
10 mg/ml R848/CL097 (all from Invivogen, USA) and 0.25 mg/ml LPS (Sigma-Aldrich). 
Optimal concentrations were used based on maximal cytokine release in mo-DC. To mimic 
T-cell interaction APCs were stimulated with irradiated CD40-L expressing mouse fibro-
blasts (23). 
Blockade of TGFβ signaling was achieved with 1μM SB431542 hydrate (Sigma-Aldrich) 
after optimization of the dose. IL-6 was blocked by adding 2.5 ug/ml antibody to IL-6 recep-
tor (clone B-R6) and 2.5 ug/ml antibody to IL-6 (B-E8) (Abcam, USA) to the culture. 
supernatant of cervical cancer cell-lines
To confirm the origin of the  established lines HeLa and CaSKi, lines were tested for the pres-
ence of integrated HPV 16 or 18 DNA using the INNO-LiPa HPV Genotyping procedure 
(Innogenetics). CSCC-1, CSCC-7, CC-8 , CC-10B and CC-11- were typed and cultured as 
described earlier (24). Stock ampoules were thawed and cultured for 10 passages and tested 
for the presence of mycoplasma monthly.
Cell-lines were grown in flasks at 80-90% confluence, harvested with trypsin/EDTA. 
100.000 cells were plated in 2 ml/well of 6-well culture plate and cultured for 5 days. Su-
pernatant was stored at -20 degrees. In case cultures were treated with COX-inhibitors, 
250.000 cells in 2 ml were plated in 6-well plates in the presence of 25mM Indomethacin 
or 5 mM NS-398 (Cayman Chemical, USA) dissolved in DMSO or as a control only with 
the corresponding concentration of DMSO. Medium was replaced after 24 hr and then 
harvested after 24 hours of culture. 







PBMC were obtained from buffy coats of healthy donors. CD14+ monocytes (>95% purity) 
were isolated using the MACS cell separation (Miltenyi Biotec Germany) and stored in 
liquid nitrogen until further use. Monocytes were thawed and cultured in 48- or 24-well 
plates in a density of 0.25 or 0.5 million cells/well respectively in the presence of IL-4 and 
GM-CSF (mo-DC). After 2 days fresh medium with cytokines was added. At day 5-6 the 
cells were analyzed for differentiation by flow cytometry and activated in the culture me-
dium or harvested, washed and activated in fresh medium. Tumor supernatant (TSN)-APC 
are cultured as described above but 20% supernatant of tumor cell-lines or medium was 
added. Titrations showed that 20% supernatant gave the best reproducible results between 
donors. DC were activated at day 6 and after 48 hr the supernatant was harvested and stored 
at -200 C for cytokine analysis and cells were stained for flow cytometric analysis. 
mixed lymphocyte reaction
Naïve CD4 cells were isolated from PBMC by CD25+ cell depletion using MACS and sub-
sequently isolation of CD4+ cells with the DynalBead system (Invitrogen) to a purity of > 
99%. These CD4+CD25- cells were plated in a 96-well plate at 50.000 cells per well. Matured 
DCs were added at different doses up to 10.000 cells/well in triplicate. T-cell proliferation 
was measured after 5 days by [3H]thymidine incorporation (0.5 uCi/well). Supernatant was 
taken at several time points and stored at -200C for cytokine analysis.
cd4+ t cell helper clones
HPV specific CD4+ T cell clones were obtained by limited dilution of LN cells of a patient 
with a HPV16+ cervical tumor. Clones were stimulated every 2 weeks with B-LCL loaded 
with the cognate HPV peptide, feeder-cells, TCGF and IL-15. Clones were used for DC 
activation after 2.5 weeks resting period.
Clone 214 recognized HPV16E6 aa61-82, clone 238 recognized HPV16 aa61-82 and clone 
16 recognized HPV16E6 aa 11-32 and all clones produced IFNγ and IL-2 but only clone 238 
produced IL-10 upon antigen-specific activation. HLA-class II matched APC were loaded 
with an irrelevant or the cognate peptide for CD4+ Th1 clones and co-cultured at different 
DC:T-cell ratio’s in medium containing 20% TSN. After 48 hours supernatant was analyzed 
and APC were phenotyped.
flow cytometry
Mouse monoclonal antibodies to human CD80, CD86, HLA-DR, CD206, CD1c(FITC) and 
CD83, CD86, CD14, CD16, CD163 (PE) and CD14, HLA-DR (PERCP) or CD11c, CD1a, 
CD4 (APC) (all from BD-biosciences) and CD163 (R&D systems) and PD-L1 (Ebioscience) 
were used. Cells were recorded (20.000/live gate) using a BD-FACS calibur with Cellquest 
software (BD-biosciences) and analyzed by Flowjo software (Tree star, inc. USA). 
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cytokine analysis
IL-12p40 and IL-12p70 were analyzed using ELISA kits from BD-biosciences or by inflam-
matory CBA (BD-biosciences). Il-10 and IFNγ was measured with ELISA (Sanquin, the 
Netherland). To evaluate the cytokines present in supernatant of tumor cells IL-6, IL-8 and 
IL-10 were determined by CBA, M-CSF by Bioplex (BioRad). PgE2 was measured with 
the prostaglandin E2 parameter assay kit (R&D systems), TGFb-1 with the human TGFβ1 
ELISA from Ebioscience. Samples were tested with and without acidic treatment to deter-
mine active and latent TGFb1 in the cultures.
r e su lt s
DC differentiation is altered by cervical carcinoma cells
To explore the effects of soluble factors secreted by CxCa on the differentiation of mono-
cytes, in vitro cultures were set up to analyze the direct effect of tumor supernatant (TSN) 
derived from five early passage CxCa cell lines (Table 1) (17,24) and the two well known cell 
lines CaSKi and HeLa. GM-CSF and IL-4 differentiated monocyte-derived DC (mo-DC) are 
defined as antigen presenting cells that lack the expression of CD14 but display the lineage 
marker CD11c, HLA-class I and II and CD1a. Healthy donor-derived monocytes were dif-
ferentiated in the presence of 20% TSN of the 7 tumor cell cultures. The presence of TSN had 
a striking effect on their differentiation as shown by evaluation of surface marker expression 
typical for monocytes, DC, MDSC and macrophages. Mo-DC cultures typically contain 
>80% CD1a+ cells but when monocytes were differentiated in the presence of TSN from 
CC11-, CSCC1 or CaSKi this percentage dropped, reflecting poor DC-differentiation (Fig. 
1a). TSN of the cell lines CCSC-7, CC-8 and HeLa did not only hamper CD1a expression 
but skewed the differentiation of monocytes towards the macrophage lineage as reflected 
table I Immuno-suppressive factors produced by CxCa cell-lines
 
(‡)number of passages since origin - HeLa and CaSKi not known
(§)integraded DNA found to be present in the tumor (24)
(*)100.000 cells/2ml cultured for 5 days in RPMI/10%FCS
(**)latent form of TGFβ-1 measured by ELISA after acidic treatment






by the high expression of CD14. Further evaluation of these CD14+ cells revealed that they 
expressed CD163 and CD206 as well. Notably these TSN induced cells expressed all human 
Fcγ-receptors (CD16, CD32 and CD64) as well as PD-L1  and HLA-class II, while CD1b 
and CD1c were absent (Fig.1b and not shown). This profile is highly similar to that of in 
vitro M-CSF-induced M2-macrophages and distinct from monocyte derived DC (Supple-
mental Fig. 1) (13,25). TSN of cell line CC-10B did not overtly alter the differentiation of 
monocytes to DC, indicating that CxCa supernatant does not per se result in phenotypical 
changes. Analysis of CD33, CD11b and CD124 expression revealed no evidence for skewing 
of monocytes to MDSC (data not shown). 
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figure 1. CxCa-secreted factors skew monocyte differentiation towards M2 macrophages.
Monocytes were cultured for 6 days with GM-CSF and IL4 in culture medium with 20% tumor supernatant 
(TSN) of indicated CxCa cell lines or 20% control medium (mo-DC) and (A) analyzed for expression of CD14 
and CD1a. TSN reduced CD1a expression and in 3 cases induced CD14+ expression. (B) The cultures of mono-
cytes differentiated with CD14+ cell-inducing TSN were analyzed for the expression of typical M2-macrophage 
markers. Numbers in quadrants represent percentage of cells within live gate. One representative of 5. (C) In situ 
immunofluorescence stainings of cervical tumor tissue of 3 out of 10 different patients for CD14 (green) and 
CD163 (blue) and measured by confocal microscopy (25 x magnification). CD14+CD163+ display as turquoise, 
white arrows indicate M2 macrophages.
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To verify that these different cell types reside in the tumors of patients, paraffin embed-
ded tissue sections of 10 patients with FIGO stage I or II  CxCa were stained for mac-
rophages (CD14+) and M2-macrophages (CD14+CD163+) (26,27). Figure 1c shows the 
presence of CD14 single positive cells (macrophages), CD163 single positive cells but also 
CD14+CD163+ M2-polarized macrophages. 
functional impairment of apc by tsn
Next we assessed the capacity of these tumor-modulated APC to respond to 5 different 
TLR agonists or CD40-L expressing fibroblast cells (CD40-L) to mimic T-cell interaction. 
Since the supernatant of CSCC-7, CC-8 and HeLa induced strikingly induced these M2-
macrophages (TSN-M2), which are known to foster immune tolerance, we focused on these 
cell lines for further evaluation and compared the results to those obtained with normal 
differentiated mo-DC. 
Stimulation of mo-DC  with LPS or R848 for 48 hours resulted in a strong increase in the 
expression of CD86, CD80, CD83, HLA-DR and PD-L1 (Fig. 2a and not shown). PolyI:C 
was the least potent TLR-agonist. TSN-M2 expressed higher basal levels of CD86, HLA-DR 
and PD-L1 but stimulation with R848 or PolyI:C did not raise their expression level to that 
of mo-DC (Fig. 2a and not shown). 
For the induction and polarization of cytotoxic T cells and Th1 cells the secretion of 
IL-12p70 by APC is essential (28,29). Mo-DC produced the biologically active IL-12p70 
upon stimulation with LPS, R848, or CD40-L cells. The amounts varied per donor of whom 
the mo-DC were prepared (Fig. 2b, Supplemental Fig. 2). Relatively to stimulated mo-DC, 
the TSN-M2 almost completely lacked the ability to produce IL-12p70 when stimulated 
with TLR agonists. The strong activation signal induced by CD40-L cells allowed TSN-M2 
to produce IL-12p70, albeit at significantly lower concentrations than CD40-stimulated 
mo-DC. In contrast, the production of the cytokine IL-10 – which varied greatly between 
donors -was at least 2-fold increased when TSN-M2 were stimulated with TLR agonist or 
with CD40-L cells  in 2 out of 3 experiments (Fig. 2b, Supplemental Fig. 2). The alterations in 
APC function were imprinted during the differentiation of the monocytes since activation 
of TSN-M2 cells in fresh medium without additives gave similar results (data not shown). 
Subsequently, the capacity of TSN-M2 to induce proliferation and cytokine production 
of T cells was compared to mo-DC. Graded doses of APC were co-cultured with a fixed 
number of allogeneic CD4+CD25- T cells. Clearly, the activated TSN-M2 displayed a 
lower capacity to induce T-cell proliferation and/or concomitant IFNγ release (Fig. 2c). 
The percentage of CD25+Foxp3+ T cells, which can be increased upon stimulation with 
immature APC (30), was not clearly altered  after 10 days of culture with TSN-M2 (data 
not shown). These results indicated that TSN-skewed APC were both phenotypically and 
functionally shifted towards that of M2 macrophages and that TLR mediated activation of 
TSN-M2 reinforced their tolerogenic profile. 
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figure 2. TSN-differentiated monocytes are phenotypically and functionally different from mo-DC.
(A) Monocytes were differentiated in the presence of the indicated TSN and activated with single TLR-ligands 
or CD40-L cells for 48 hr. TSN-M2 cells express higher basal levels of CD86 and PDL-1. R848 or Poly-IC can 
not induce equal expression of CD80 and CD86 in all APC types. (B) Supernatants of the cultures described 
in (A) were tested for the presence of IL-12p70 and IL-10 revealing that TSN-M2 produce more IL-10 and less 
IL12 than mo-DC. (C) CD4+CD25- allogenic responder T cells were cultured with activated mo-DC or TSN-
M2 (obtained with TSN from HeLa cells) at indicated ratio’s (DC:T cell). Top row shows the higher prolifera-
tion of T cells when stimulated with upon activated mo-DC at day 5 as measured by [3H]-thymidine uptake. 
Test performed in triplicate, shown is mean with SEM. Means were compared by unpaired t-test, *p < 0.05, 
**p<0.005. Bottom row shows the IFNγ production within these cultures measured in the supernatant isolated 
at day 4 by ELISA. One representative of 3 experiments (A-C).
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mediators of altered apc differentiation
Numerous mediators may cause the altered differentiation of monocytes to DC, including 
TGFβ, PgE2, IL-6, IL-8, IL-10 and M-CSF (12). TSN of CxCa cell cultures were analyzed 
for these compounds. Latent TGFβ was produced by almost all cell lines, except for CC-
10B. Three cell-lines produced high amounts of PgE2, and significant amounts of IL-6 were 
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figure 3. Cox-inhibition blocks PgE2 production and prevents M2-macrophage differentation.
(A) Tumor cell lines were treated for 24 hr with DMSO (control) or Cox-inhibitor (NS398 or Indomethacin) 
followed by culturing in fresh medium without additives for 24 hrs. PgE2 levels were measured by ELISA. 
Inhibition of COX totally abrogates PgE2 production. P<0.005 for all comparisons of PgE2 production by cells 
treated or not with indicated COX-inhibitor in 2 separate experiments (B) Culturing mo-DC (black fill) in the 
presence of 10 ng/ml PgE2 (dotted line) induce CD14+CD163+ expressing APC. (C) Flowcytometric analysis 
of CD14 and CD163-associated M2-macrophage marker expression on monocytes differentiated in the pres-
ence of TSN of Indomethacin-treated (black) tumor cells or TSN from non-treated tumor cells (white). (D) 
Comparison of CD1a and CD14 expressing populations following the differentiation of monocytes in the pres-
ence of TSN of Indomethacin-treated or non-treated tumor cells shows that TSN of COX-inhibitor treated cell 
lines induce less CD14+ cells and more CD1a+ DCs. Representative of 3 experiments (B-D).






produced by 5 cell lines. IL-8 was present in all TSN, of which CC-10B produced the highest 
levels (Table 1). Since the tumor supernatant of CC10B did not affect monocyte to DC 
differentiation, IL-8 was not further evaluated. IL-10 and M-CSF were not detected in the 
tumor supernatants. 
The three likely candidates, TGFβ, PgE2 and IL-6 were further evaluated. The addition 
of TGFβ during differentiation of monocytes to DC did not induce the expression of CD14 
but resulted in higher expression of CD1a. Likewise, blocking of the TGFβ pathway in TSN-
APC cultures did not restore the phenotype to that of mo-DC, indicating that TGFβ was not 
responsible for the observed effects of TSN (Supplemental Fig. 3).
Skewing of APC to a macrophage phenotype can occur at concentration of > 2 pg/ml 
PgE2 (31). In fact, mo-DC differentiated in the presence of 1-50 ng/ml PgE2 resulted in 
CD14+ macrophages that are polarized to CD163+ M2-like macrophages (Fig 3b). To test 
if PgE2 was the M2-inducing factor in the TSN, the tumor cells were treated with specific 
COX-enzyme inhibitors. After treatment, the tumor cells were washed and incubated with 
fresh medium to obtain COX-blocked tumor supernatant. This procedure was chosen to 
avoid interaction of the inhibitor with COX in APC. Indeed, PgE2 production was totally 
abrogated by inhibition of COX 1 and 2 using Indomethacin or COX-2 by NS-398 (Fig. 3a). 
Depletion of PgE2 in TSN by preventing its production revealed a striking effect on the 
DC-differentiation of monocytes. The expression of CD14 and CD163 was completely 
reversed (Fig. 3c) but the phenotypic differentiation towards DC was only partly restored 
as indicated by the percentage of CD14-CD1a+ APCs that was still lower than observed in 
mo-DC cultures (Fig. 3d). Furthermore, the capacity to produce IL-12p70 upon activa-
tion was restored while that of IL-10 was lowered (Fig. 4ab). The most pronounced effect 
of COX-inhibition was shown for CSCC-7 as the resulting APC from this COX-blocked 
tumor supernatant were completely comparable to mo-DC. The effects of COX-inhibition 
in lines CC-8 and HeLa on the function of TSN-altered APC was predominantly shown in 
CD40-activated APC.  The functional restoration was reflected also by partial up regulation 
of their T-cell stimulatory capacity (Fig. 4c). As a control, TSN of Indomethacin treated 
CaSKi cells - which hardly produce PgE2 - was tested and neither clear differences in the 
hampered differentiation of the APC nor in LPS-induced IL-12 production were observed 
(Supplemental Fig. 4ab).
Since restoration of the phenotype and function of APC induced by PgE2 producing 
cell lines treated with Indomethacin was not complete and the cell lines CC-8 and HeLa 
produced significant amounts of IL-6, we explored the possibility that IL-6 mediated 
also an effect. Mo-DC were cultured with or without 20% TSN of the non-treated or the 
COX-inhibitor treated HeLa cell line in the presence of monoclonal antibodies to IL-6 
and IL-6-receptor (32,33). The differentiation of mo-DC, nor the production of cytokines 
was altered by the presence of these antibodies (Fig. 5). However, blocking of IL-6 showed 









































































































































figure 4. Restored cytokine production when PgE2 production by tumor cells is blocked.
(A) The production of IL-12 and IL-10 by APC differentiated in the presence of TSN of Indomethacin-treated 
(black) tumor cells or TSN from non-treated tumor cells (white) upon 48 hr activation with LPS, R848 or 
CD40-L as measured by ELISA. Top row shows the cytokine production of untreated mo-DC. One representa-
tive experiment of 3. The block of PgE2 production by tumor cells alters the balance in IL-12 and IL-10 towards 
that observed in the corresponding mo-DC.
(B) Comparison of the cytokine production by APC differentiated in the presence of TSN from non-treated 
tumor cells (white) to Indomethacin-treated (black) tumor cells that where activated for 48 hours (combined 
data of LPS, R848 and CD40-L stimulated cells; n=3 experiments). IL-12, all p<0.003. IL-10, TSNcscc7 p=0.015; 
TSNcc8 p=ns; TSNhela p=0.026.
(C) Mo-DC or TSN-M2 obtained with TSN of untreated (+DMSO) or Indomethacin-treated HeLa cells (+In-
domethacin) were activated with LPS or R848 for 48 hours and used to stimulate allogeneic responder cells. 
APC differentiated in TSN of Indomethacin-treated cells induce better T-cell proliferation at day 5 of culture 
as measured by [3H]-thymidine incorporation. Test performed in triplicate, shown is mean with SEM. Means 
were compared by unpaired t-test. Comparison of non versus indomethacin treated HeLa cells (1:5 ; 1:10) for 
LPS p=0.009; p =0.024, and for R848 p=0.0003; p =ns. Comparison of mo-DC versus indomethacin treated 
HeLa cells (1:5 ; 1:10) for LPS p=0.004; p =ns, and for R848 p =0.009; p =ns. One representative out of 2 experi-
ments.






percentage of CD14-CD1a+ APC. IL-6 blocking acted synergistically with the inhibition 
of COX since the combined treatment resulted in a complete phenotypical restoration of 
TSN-M2 to mo-DC (Fig. 5a). Blocking of IL-6 during the culture resulted in TNS-altered 
APC that after CD40-activation produced more IL-12p70 although this was not significant 
(p=0.079, n=3 experiments). There were no significant alteration in cytokine production 
(p>0.05, n=3 experiments) when the APC were activated by the TLR agonists (fig 5b). No 
major synergistic effect of IL-6 blocking on IL-12p70 and IL-10 production was found when 
COX-inhibited TSN was used. Since the supernatant of CaSKi cells, which hampered DC 
differentiation and function (Supplemental Fig. 4), also contained high levels of IL-6 we 
blocked this cytokine during the differentiation of monocytes to DC with TSNcaski. Block-
ing of IL-6 restored both CD1a expression and the balance between IL-12p70 and IL-10 to 
what is found for mo-DC (Supplemental Fig. 4c). Together, these data showed that PgE2 
predominantly influenced the expression of the macrophage markers, whereas IL-6 altered 
CD1a expression. While both pGE2 and IL-6 affect the balance between IL-12p70 and IL-
10, PgE2 had a more dominant negative effect. Blocking of these two mediators prevents 
M2-skewing and restores normal monocyte to DC differentiation.
cd4+ Th1 t cells can switch tumor-induced m2 to activated m1 macrophages
Initially, we had used CD40-L cells to mimic the interaction between T cells and TSN-M2. 
Since CD40-activation was the best stimulus to induce IL-12p70 production by  APC we 
investigated the phenotypical and functional changes in TSN-M2 following cognate inter-
actions with CD4+ T cells. Co-cultures of TSN-M2 and Th1 cells were performed in the 
same TSN-containing culture medium since tumor secreted factors may  directly suppress 
T-cell function (34). Three different CD4+ Th1 clones were clearly able to fully activate 
mo-DC and TSN-M2 in an antigen dependent manner (Fig. 6). Notably, Th1-mediated 
activation of TSN-M2 resulted in a number of changes that suggested a shift from M2-like 
to M1-like macrophages. The levels of the co-stimulatory molecules readily increased to the 
same level as mo-DC (Fig. 6a). In addition, the expression levels of PD-L1 increased. The 
strong activation was also reflected by the high amounts of IL-12p70 produced reaching 
IL-12 levels similar to that of mo-DC, as there is no significant difference (p>0.05, n=3 
T-cell clones)  between mo-DC or TSN-M2 (Fig. 6b and not shown) and much higher than 
previously observed after TLR- or CD40-activation (compare Fig. 2b and 6b). Strikingly, 
the production of IL-10 remained low and around the same level as the corresponding mo-
DC cultures (p>0.05 for TSNcscc7 and TSNcc8, p=0.03 for TSNhela; n=3 T-cell clones). 
After the interaction with Th1 cells,  the typical M2-like macrophage markers CD206 and 
CD163 were lost. This was also observed when TSN-M2 were stimulated with LPS, R848 
and CD40-L cells indicating that this is a reflection of APC activation (Supplemental Fig. 
1bc).  Furthermore, high amounts of T-cell produced IFNγ, TNFα and IL-2 were detected in 



















































































figure 5. Blocking IL-6 and PgE2-induced altered differentiation restores monocyte to DC differentiation com-
pletely.
(A) Monocytes were differentiated in the presence of control(+DMSO) or COX-inhibited HeLa 
cells(+Indomethacin) without or with blocking antibodies against IL-6 and IL-6 receptor. A combination of tu-
mor cells treated with Indomethacin and blocking IL-6 during differentiation results in full DC differentiation 
reflected by high expression of CD1a and lack of CD14. (B) Blocking IL-6 during differentiation did not affect 
the production of IL-12 (ng/ml) and IL-10 (pg/ml) of mo-DC upon activation by indicated agonists. CD40-
activated TSN-M2 cells of which the IL-6 in TSN was blocked during differentiation, produced more IL-12. 
One representative experiment out of 3.






their cognate peptide (Fig. 6b and not shown). Apart from IL-12p70 and IFNγ for which it is 
clear that they are only produced by the APC or T cells, respectively, IL-10 may be produced 
by both cell types and this can not be distinguished by ELISA. It is likely that the IL-10 
detected in co-culture with clone 238 is produced by the T cell clone as mo-DC stimulated 
with the other 2 clones do not produce IL-10. Our previous experiments indicated that 
ligation of CD40 could not switch M2 to M1 macrophages, therefore, we analyzed if one of 
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figure 6. CD4+ T cells switch TSN-M2 to M1-like macrophages and activate them to produce IL-12p70.
(A) Mo-DC or TSN-M2 were pulsed with the cognate Th1-peptide and co-cultured with HPV-specific CD4+ 
T-cell clones (2 DC:1 T cell) or CD40-L cells. T-cell interaction results in high expression of co-stimulatory mol-
ecules and PDL-1. One representative experiment out of 3. (B) Top row: Cognate interaction of Th1 cells with 
TSN-M2 results in high IL-12 production. Stimulation with CD40-L cells in combination with 500 pg/ml IFNγ 
induces IL-12p70 production in TSN-M2 cultures to the level of mo-DC. Middle row: Cognate interaction with 
Th1 cells induced the production of IL-10 in TSN-M2 cultures at similar low levels detected for mo-DC. The ad-
dition of IFNγ to CD40-stimulation results in similar production of IL-10 as after CD40-L cell stimulation. Bot-
tom row: The Th1 clones produce IFNγ when stimulated with peptide-pulsed mo-DC and TSN-M2. Shown are 
the results of the experiment in which all conditions and 3 clones were combined. Similar results were obtained 
in experiments where individual clones and TSN-M2 combinations were tested (C) APC cultured in the pres-
ence of M2-inducing TSN or PgE2 were activated with CD4+ T-cell clone 16, CD40-L expressing fibroblasts or 
IFNγ and analyzed for the expression of CCR7 at 48 hr after activation. Cognate Th1 cell interaction induces 
high CCR-7 on TSN-M2 and this can be mimicked by activating DC with IFNγ. The level of CCR7 is enhanced 
when PgE2 is present during the differentiation of monocytes. One representative experiment out of 3.
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M2 to M1-like macrophages. TSN-M2 were activated with CD40-L and IFNγ or TNFα. 
This revealed that the combination of CD40-L cells with IFNγ but not CD40-L cells or 
IFNγ alone resulted in high levels of IL-12 not only in mo-DC but also in TSN-M2 cultures 
(Fig. 6b right and not shown). This capacity of Th1 cells or CD40-L cells + IFNγ to switch 
M2-like macrophages to M1-like macrophages could be reproduced in co-cultures with 
M-CSF-induced M2 macrophages (not shown).
TSN-M2 expressed higher levels of CCR7 than mo-DC following their cognate interac-
tion with CD4+ Th1 cells (Fig. 6c). As we had already found that IFNγ synergized with 
CD40-activation to switch M2- to M1-like macrophages we tested the hypothesis that IFNγ 
or TNFα secreted by the T-cell clone either alone or in combination with PgE2 present in 
TSN was responsible for the high levels of CCR7. Indeed, incubation with IFNγ but not 
TNFα induced the expression of CCR7 on mo-DC and a very high expression on TSN–M2. 
Furthermore, pretreatment of mo-DC with PgE2 during the differentiation phase resulted 
in similar high expression of CCR7 as found on TSN-M2 (Fig. 6c). 
Thus, cognate interaction with IFNγ-producing T cells can switch the tumor-promoting 
M2-like polarized macrophages to activated classical M1-like macrophages that express 
high levels of co-stimulatory molecules, produce high amounts of IL-12 and gain the ex-
pression of the lymphoid homing receptor CCR-7.
dI s c u s sIon
Our analysis on the effect of tumor-secreted factors from 7 different cervical cancer cell 
lines on the differentiation of monocytes to dendritic cells and their functional capacity 
revealed that these cancer cells can be sorted into two major categories; -1- cancer cells 
that hamper DC differentiation and function and -2- cancer cells that induce M2-like 
macrophages. These two categories comprised similar HPV types ruling out that the effects 
seen were HPV type specific. Tumor secreted PgE2 and /or IL-6 were clearly responsible for 
these effects while no role was found for TGFβ, IL-8, IL-10 or M-CSF.  In vivo, such APC are 
present at different levels of differentiation in stroma and epithelial compartments of HPV-
induced cervical cancer and these include next to immature DC, mature DC, macrophages 
and type II macrophages (Fig. 1)(10,35). 
Category 2 cancer cells stimulated the differentiation of CD14+, CD16+, CD206+, CD163+ 
M2-like macrophages. Consequently, these TSN-M2 displayed an altered cytokine profile 
and a poor capacity to stimulate T cells when compared to mo-DC. Careful evaluation 
of the expression of co-stimulatory molecules, cytokine production and T-cell stimulatory 
capacity of these TSN-M2 showed that stimulation with a number of clinical applicable 
TLR-agonists or CD40-L cells could not provoke the same phenotypical and functional 
activity as found for mo-DC. Interestingly, unstimulated TSN-M2 cells expressed PD-L1 






at higher levels than mo-DC. While stimulation of mo-DC and TSN-M2 resulted in an 
increased expression of PD-L1, the expression on TSN-M2 remained higher on TSN-M2, 
suggesting that TSN-M2 display an altered co-stimulatory/inhibitory molecule ratio on the 
cell surface as compared to mo-DC. High levels of PDL-1 expression on monocytes have 
been shown to effectively suppress tumor-specific T cell immunity and to contribute to the 
growth of human hepatocellular carcinoma cells in vivo(36). Furthermore, knockdown of 
PD-L1 in activated DC has been shown to increase the IFNγ and IL-2 production of reacting 
T cells (37). We are currently investigating the role of PD-L1 expression level with respect 
to the lack of responsiveness of naive T cells in our experiments. Notably, comparison of 
the two different agonists R848 and LPS to stimulate TSN-M2 revealed clear differences in 
their effects on co-stimulatory molecule expression and cytokine production, indicating 
that previous results reported with the TLR4 agonist LPS – most often used to stimulate 
tumor-induced DC in vitro (16,38)– can not be translated to other TLR agonists. Earlier 
studies identified macrophages (CD68+) within the CxCa microenvironment and showed 
that an increase in macrophages is inversely correlated with survival (39). The presence of 
macrophages correlated with a high production of IL-6 by tumor cells, the latter of which 
was associated with poor survival (19). IL-6 was shown in vitro to hamper the DC differen-
tiation and allogeneic T-cell stimulatory capacity and could even switch monocyte differ-
entiation from DC to macrophages (32,33,40-42). Others showed that the over-expression 
of COX-enzymes in HPV-induced lesions is associated with a loss in CD1a+ cells and PgE2 
was suggested to mediate this effect (16). Under our experimental conditions IL-6 alone was 
able to hinder DC-differentiation and function but PgE2 was responsible for the conversion 
of monocytes to M2 macrophages.  Differentiation of monocytes to M2 macrophages could 
be prevented by inhibition of the production of PgE2 in tumor cells and blocking IL-6 
during the differentiation period of the monocyte.
Importantly, when fully polarized M2 macrophages present antigen to Th1 cells within 
the context of a M2-polarizing milieu – as represented by the M2-inducing tumor super-
natant – this interaction not only results in re-polarization of M2- to M1-macrophages but 
it also activated these M1 macrophages to express high levels of co-stimulatory molecules, 
to produce IL-12 and to express the lymph node homing marker CCR7. The switch from 
M2- to M1-macrophages is in concordance with the plasticity of macrophages to change 
their functional phenotype from classically activated macrophages to wound-healing or 
regulatory macrophages and vice verse (43,44). This switch could be reproduced by stimu-
lating TSN-M2 with CD40-L cells and IFNγ. While activation via CD40 was enough to 
induce changes in the typical M2 markers, IFNγ provided the necessary signals for the 
macrophages to produce IL-12 without additional IL-10 production. Mouse models have 
elegantly demonstrated the importance role of the Th1-macrophage axis in anti-tumor im-
munity. Tumor-resident macrophages were shown to process and present tumor antigen 
to Th1 cells which in return activated these macrophages – through the local release of 
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IFNγ - to become tumoricidal and to induce a CD4+ T-cell dependent tumor protection 
(45,46). Our data suggest that alteration of the suppressive tumor microenvironment by 
tumor-infiltrating Th1 cells - which change the tolerogenic M2-macrophage phenotype 
to that of activated M1-macrophages- could be one of the underlying mechanisms of this 
tumor protection system. 
The local presence of IFNγ-producing T cells responding to antigen presented by these 
altered APC may restore proper tumor-rejecting immune function, but such T cells are 
often absent in tumors. (47,48). COX-inhibiting drugs are widely used in the clinic for 
treatment of auto-immune diseases and trials are now ongoing, with the aim to determine 
the effect of low dose NSAID on tumor prevention by disrupting the COX-2 meditated 
oncogenic pathways (49). Furthermore, monoclonal antibodies to IL-6 receptor are already 
in clinical use for the treatment of autoimmune diseases (50). It can be envisaged  that a 
combination therapy consisting of COX-inhibition,  IL-6 blocking and the induction of a 
strong Th1 T cell response by currently available vaccines may form the next generation of 
immunotherapy for the treatment of cervical cancer(51,52). 
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Supplementary fig 1. Phenotype of in vitro differentiated DC and M2 macrophages.
(A) Monocytes were cultured for 6 days with GM-CSF+IL-4 to obtain imm DC or M-CSF to obtain M2 macrophages and 
analyzed by flowcytometry for the expression of phenotypical markers. M2-differentiated macrophages typically display 
high expression of  the scavenger receptor CD163 and the mannose receptor CD206. In contrast to monocyte derived DC 
M2-macrophages express all FcγReceptors (CD32, CD64 and CD16). (B+C) Stimulation of TSN-M2 for 48 hr with (B) 
indicated TLR-ligands and (C) Th1 cells or CD40-L cells results in a lowered expression of CD14 and CD163 as detected 
by flowcytometry.
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Supplementary fig 2  Function of DC is hampered by TSN.
Compared to mo-DC, TSN-M2 cultures produce less IL-12 and more IL-10 upon depicted stimulus. We 
observed  large variation in  the amounts of cytokines produced by each donor to the different TLR-
ligands, especially for IL-10. To compare 3 different donors with respect to the amounts of cytokine 
produced; the relative production of cytokines of each condition within one experiment was calculated. 
The amount of cytokines produced by mo-DC to the indicated stimulus was set to 100%.  Three 
experiments combined, mean with SEM.  For each stimulus means were compared to mo-DC by 








supplementary fig 2 function of dc is hampered by tsn.
Compared to mo-DC, TSN-M2 cultures produce less IL-12 and more IL-10 upon depicted stimulus. We ob-
served large variation in the amounts of cytokines produced by each donor to the different TLRligands, espe-
cially for IL-10. To compare 3 different donors with respect to the amounts of cytokine
produced; the relative production of cytokines of each condition within one experiment was calculated. The 
amount of cytokines produced by mo-DC to the indicated stimulus was set to 100%. Three experiments com-
bined, mean with SEM. For each stimulus means were compared to mo-DC by paired t test. * indicates p<0.05, 
** indicates p<0.005.























   
   
   
   
 
B -- +SB431541
Heusinkveld et al. supplement fig 3
CD86 CD80 CD83
 1 ng/ml  0.05 ng/ml 0.5 ng/ml+  TGFβ: A C













Supplementary fig 3  Blocking of the TGFβ pathway in TSN differentiated APC.
(A) Mo-DC were cultured  with increasing concentration of TGFβ and activated for 48 hrs 
with LPS.  Flowcytometric  analysis show that high levels of TGFβ make APC unresponsive 
to LPS as reflected by a failure to upregulate the expression of co-stimulatory molecules. 
One representative experiment of 3. (B) Mo-DC or APC differentiated in the presence of 500 
pg/ml TGFβ-1 (TGFβ) or 20% TSN (obtained from HeLa or CaSKi) were treated without 
(white) or with the ALK-inhibiting compound SB431542 (black) during culture and activated 
with LPS for 48 hr. Although the effect of TGFβ on the unresponsiveness to LPS is com-
pletely abrogated by compound SB431541, no effect of this compound is found on the 
expression of CD1a, CD86 and CD83 by APC in TSN cultures. (C) The production of 
IL12p70 upon 48 h LPS stimulation of control (white) or compound SB431542 treated 
(black) cultures. The compound restores the IL12p70-production by TGFβ-treated cells to 
the same level as mo-DC, but does not restore IL-12 production by TSN-differentiated APC.
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(A) Mo-DC were cultured with increasing concentration of TGFβ and activ te for 48 hrs with LPS. Flow-
cytometric analysis show that high levels of TGFβ make APC unresponsive to LPS as reflected by a failure to 
upregulate the expression of co-stimulatory molecules. One representative experiment of 3. (B) Mo-DC or APC 
differentiated in the presence of 500 pg/ml TGFβ-1 (TGFβ) or 20% TSN (obtained from HeLa or CaSKi) were 
treated without (white) or with the ALK-inhibiting compound SB431542 (black) during culture and activated 
with LPS for 48 hr. Although the effect of TGFβ on the unresponsiveness to LPS is completely abrogated by 
compound SB431541, no effect of this compound is found on the expression of CD1a, CD86 and CD83 by APC 
in TSN cultures. (C) The production of IL12p70 upon 48 h LPS stimulation of control (white) or compound 
SB43154  treated (black) cultures. The compound rest res t e IL12p70-production by TGFβ-tr ted cells to the 
same level as mo-DC, but does not restore IL-12 production by TSN-differentiated APC.
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Supplementary fig 4 Blocking IL-6 in the TSN of CaSKi cells abrogates the suppressive 
effect on DC differentiation and function.
(A) A lower percentage of monocytes differentiated in the presence of 20% supernatant of caski-
cells expresses CD1a after 6 days of culture, reflecting poor DC differentiation. Addition of IL-6 
and IL-6Receptor blocking antibodies to the culture does not influence normal monocyte to DC 
differentiation but increases the percentage of CD1a expressing cells in cultures with TSNcaski. 
Treating the CaSKi-cells with COX-inhibitor indomethacin does not affect the effect on monocyte 
differentiation. Depicted is the percentage of all cells in live gate. One representative of 2 experi-
ments. 
(B) Monocytes were differentiated in the presence of control (+DMSO) or COX-inhibited CasKi 
supernatant and activated with LPS. Cytokine production was analyzed after 48 hr. (C) APC 
differentiated in the presence of TSNcaski produce more IL-10 and less IL-12 upon activation by 
TLR-ligands or CD40-L when compared to fully differentiated mo-DC. Blocking of IL-6 in the 
supernatant during differentiation of monocytes restores the capacity of the resulting cells to 
produce IL-12 while reducing the production of IL-10. To compare different donors,  the amount of 
cytokine produces is depicted as a percentage of the cytokine when produced by mo-DC 
activated by the same stimulus without blocking of IL-6. Three experiments combined. Means 
were compared by the two-tailed unpaired t-test using Graphpad software. * indicates p<0.05, ** 
indicates p<0.005 . 
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supplementary fig 4 blocking Il-6 in the tsn of caski cells abrogates the suppressive
effect on dc differentiation and function.
(A) A lower percentage of monocytes differentiated in the presence of 20% supernatant of caskicells expresses 
CD1a after 6 days of culture, reflecting poor DC differentiation. Addition of IL-6 and IL-6Receptor blocking an-
tibodies to the culture does not influence normal monocyte to DC differentiation but increases the percentage 
of CD1a expressing cells in cultures with TSNcaski. Treating the CaSKi-cells with COX-inhibitor indomethacin 
does not affect the effe t on monocyt  differentiation. Depicted is the percentage of all cells in live gate. One 
represe ta iv of 2 experiments. (B) Mo ocy es were differentiated in the pr sence of con r l (+DMSO) or 
COX-inhibited CasKi supernatant and activated with LPS. Cytokine production was analyzed after 48 hr. (C) 
APC differentiated in the presence of TSNcaski produce more IL-10 and less IL-12 upon activation by TLR-
ligands or CD40-L when compared to fully differentiated mo-DC. Blocking of IL-6 in the supernatant during 
differentiation of monocytes restores the capacity of the resulting cells to produce IL-12 while reducing the 
production of IL-10. To compare different donors, the amount of cytokine produces is depicted as a percent-
age of the cytokine when produced by mo-DC activated by the same stimulus without blocking of IL-6. Three 
experim nts combined. Means were compared by the two-tailed un ire  t-test using G aphpad software. * 
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a b st r ac t
The capacity of a low-dose HPV16 synthetic long-peptide vaccine (HPV16-SLP) to induce 
an HPV16-specific T-cell response as well as to establish long-term immunologic memory 
in patients with low-grade abnormali-ties of the cervix was determined in a placebo-
controlled, double-blinded phase II study. In addition, the effect of a booster vaccination 
after 1 year was evaluated. Patients received either the HPV16-SLP or a placebo at the 
start of the study. After 1 year, the vaccinated patients were again randomized to receive 
the HPV16-SLP or a placebo. Patients were followed for 2 years. HPV16-specific T-cell 
responses were determined in pre- and post-vaccination blood samples by ELISPOT, pro-
liferation assay and cytokine assays. We show that the HPV16-specific T-cell responses 
detected after vaccination are clearly due to vaccination and that reactivity was maintained 
for at least 2 years. Interestingly, a booster vaccination after 1 year especially augmented the 
HPV16-specific Th2 response. Furthermore, pre-existing immunity to HPV16 was associ-
ated with a stronger response to vaccination and with more side effects, reflected by flu-like 
symptoms. We conclude that two low-dose injections of HPV16-SLP can induce a strong 
and stable HPV16-specific T-cell response that lasts for at least 1 year. If booster vaccination 
is required, then polarizing adjuvant should be added to maintain the Th1 focus of the 
vaccine-induced T-cell response.






I n t rodu c t Ion
The development of (pre)cancers of the anogenital tract is associated with persisting human 
papillomavirus (HPV) infections [1]. The risk of progression of squamous intraepithelial le-
sions (SIL) is related to the severity of dysplasia. Up to 40 % of low-grade cervical squamous 
intraepithelial lesions (LSIL) will not spontaneously regress [2]. Small lesions can easily be 
treated by loop electrosurgical excision procedure (LEEP), yet LEEP of larger lesions can 
leave positive margins causing lesion recurrence requiring repeated surgery [3]. For the 
group of patients with a child wish, this can pose a problem due to distortion of the cervix 
and pre-term delivery [4].
Vaccines have been developed to prevent persistent infection with HPV but these prophy-
lactic vaccines are not effective in patients already infected with HPV16 or HPV18 [5]. 
Virus-specific, interferon-γ (IFNγ)-producing CD4+ T helper (Th) cells and CD8+ cyto-
toxic T lymphocytes (CTL) are essential components in controlling chronic viral infections 
[6, 7].
Healthy donors display relatively robust proliferative T-cell responses against the viral early 
proteins E2, E6 and E7, characterized by Th cells that produce IFNγ and IL-5 [8–10]. In 
addition, the majority of subjects who clear HPV16 display HPV16 E6-specific CTL re-
sponses [11, 12]. These findings suggest that successful defense against HPV16 infection 
is associated with a systemic HPV-specific T-cell response. Therapeutic vaccination can 
be clinically effective in patients with histologically confirmed HPV16+ vulvar epithelial 
neoplasia grade 3 (VIN3). Complete regression of lesions was seen after vaccination with 
a protein vaccine [13] or an HPV16 E6/E7 synthetic long-peptide vaccine (HPV16-SLP) 
[14]. Clinical success correlated with the induction of strong and broad HPV16-specific Th 
responses and HPV16-specific CD8+ T-cell activity [13–15]. In patients with high-grade 
cervical squamous intraepithelial lesions (HSIL), immunization with 300 μg per peptide of 
the HPV16-SLP vaccine-induced robust immune responses [16].
In addition to women with high-grade lesions, also women with persistent low-grade lesions 
may be treated by therapeutic vaccination. As low-grade cervical lesions are not considered 
a severe disorder, we decided to immunize such individuals with the lowest dose (50 μg/
peptide) previously shown to be immunogenic in patients with cervical cancer [17]. To this 
end, patients with LSIL or persistent mild cytological cervical abnormalities received either 
placebo or were vaccinated twice. The group of vaccinated patients was then randomized to 
receive a placebo or a booster vaccination after 1 year. All patients were followed for 2 years 
and their HPV-specific immune response was tested at several time points during the study. 
The aim of this phase II study was threefold. (1) To study the capacity of a low-dose vaccine 
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to induce HPV16-specific T-cell responses in patients with LSIL or persistent mild cytological 
cervical abnormalities, (2) to evaluate the long-term memory response after vaccination and 
(3) to study the effect of revaccination after 1 year on the HPV16-specific T-cell response.
pat I e n t s a n d m et hod s
patients
In this placebo-controlled, double-blinded study, 50 patients with histological evidence of 
LSIL or persistent mild cytological cervical abnormalities were included from the out-patient 
departments of the Leiden University Medical Center (Leiden, the Netherlands), the Haga 
Teaching Hospital (the Hague, the Netherlands) and the Medical Centrum Haaglanden (the 
Hague, the Netherlands). Patients were included between May 2007 until March 2010 after 
oral and written informed consent. Eligibility required pre-treatment laboratory findings of 
leukocytes >3 × 109/L, lymphocytes >1 × 109/L, thrombocytes >100 × 109/L and hematocrit 
>30 % and no radiotherapy, chemotherapy or other potentially immunosuppressive therapy 
administered within 4 weeks prior to the immunotherapy. The study was approved by the 
Dutch Central Committee on Human Research (CCMO, https://toetsingo nline.ccmo.nl/
ccmo_search.nsf/dossier number NL14057 000 06) and the medical Ethical Committee of 
the Leiden University Medical Center and the Haga teaching Hospital. Monitoring for ad-
verse events and injection-site reactions, clinical assessments and laboratory tests were per-
formed as described previously [17]. Data were gathered on previous HPV-related disease 
[PHD, defined as surgical or topical treatment of SIL of the cervix or vulvar intraepithelial 
neoplasia (VIN)], atopic constitution and smoking habits. Adverse events were classified 
according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. 
The flu-like syndrome was defined as having two or more of the following complaints: fever, 
chills, head-ache, malaise, fatigue, myalgia, nausea, anorexia, vomiting or diarrhea after 
vaccination. In most patients, the symptoms subsided within 72 h, any symptoms persisting 
longer than 72 h or starting 72 h after vaccination were scored separately.
vaccine and vaccination scheme
The HPV16-synthetic long-peptide vaccine (HPV16-SLP) used in this study consists of two 
separate drug products, together representing the entire sequence of the E6 and E7 oncopro-
teins of HPV16. The clinical grade peptides (9 E6 and 4 E7 peptides of 25–35 amino acids long 
with an over-lap of 10–14 amino acids) were synthesized, vialed and formulated at the GMP 
facility of the department of Clinical Pharmacy and Toxicology of the LUMC as described 
previously [14–18]. Peptides were dissolved in dimethyl sulfoxide (DMSO) and admixed with 
20 mM phosphate buffer (pH 7.5) and Montanide ISA-51 (final volume ratio 20/30/50, respec-
tively), and patients received the vaccine at a dose of 50 μg/peptide. This dose has previously 






been shown to induce HPV16-specific immunity in end-stage cervical cancer patients [17]. 
Patients were assigned to one of the two treatment groups (block size 5). Randomization was 
blinded for patients and the immunomonitoring laboratory. Four out of five patients, in total 
40, were randomized to receive two sequential HPV16-SLP vaccinations at a 3-week interval 
(50 μg/peptide), T = 0 week and T = 3 weeks (Group 1, Fig. 1). They received a mix of nine 
synthetic long HPV16 E6 peptides in the left arm or thigh and four synthetic long HPV16 E7 
peptides in the right arm or thigh. Ten (one out of five) patients were randomized to receive 
phosphate-buffered saline (PBS) in both arms or thighs in the same regime (Group 2). After 
1 year (T = 1 year), a second randomization took place. Half the patients from group 1 were 
randomized to receive a booster vaccination of 50 μg peptide of the HPV16-SLP (group 1A) 
and the other half was randomized to receive PBS (group 1B). Patients in group 2 received PBS 
throughout the study. All vaccinations were performed in the LUMC. Patients stayed at the 
ward for 1–2 h after vaccination during which any experienced local and/or systemic adverse 
events were recorded. Patients recorded any adverse events experienced in the weeks between 
and after vaccinations in a diary or were asked to report any adverse events. Venous blood (70 
ml) for immune monitoring was drawn at five time points; before (T = 0 week), 7 weeks (T = 
7 weeks) and 1 year (T = 1 year) after first vaccination, 3 weeks after booster vaccination (T = 
1 year + 3 weeks) and finally 2 years after first vaccination (T = 2 years; Fig. 1). An extra Pap 
smear was taken before vaccination and at 1 and 2 years after vaccination for histology and 
HPV typing.
hpv-specific t-cell immunity monitoring
In acknowledgment of the minimal information about T-cell assays (MIATAproject.org) 
detailed information about the sample, the assay, the data acquisition, the data analysis and 
the laboratory environment is provided [19, 20]. The peripheral blood mononuclear cells 
(PBMCs) were isolated by Ficoll (prepared by LUMC pharmacy) gradient centrifugation 
within 4 h after blood was drawn (70 mL in 9 mL heparine tubes, kept at room tempera-
ture). The median PBMC numbers obtained were 56 million and ~10 mil-lion cells were 
used directly in the lymphocyte stimulation test (LST) to test for HPV16 specificity. The 
proliferative response accompanying cytokines were measured by the cytometric bead array 
(CBA). The remaining cells were cryopreserved (~5–10 million/vial) in 90 % fetal bovine 
serum and 10 % DMSO in 1 mL cryovials (Greiner) using a controlled freezing apparatus 
and immediately stored in the vapor phase of the liquid nitrogen vessel until used (median 
pre-sample 24 months, post-samples 5 months). Thawed PBMCs were subjected to the 
IFN-γ-Elispot and geared to determine Th type 1 (Th1) responses. The median cell recov-
ery post-thaw was 73.6 % with a median viability of 76.8 %. Cell counts and viability was 
obtained using trypan blue (0.4 %, Sigma) staining and counting using the hemocytometer. 
In this set of complementary T-cell immunomonitoring assays (LST and IFN-γ-Elispot), 
six pools of 22 amino acid long peptides overlapping by 12 amino acids were used. All tests 
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have previously been described, and positive responses have been pre-defined [21]. For all 
T-cell assays, a vaccine-induced response was defined as at least a threefold increase in the 
response after vaccination when compared with the results before vaccination (T = 0 week). 
Similarly, a booster vaccination-enhanced response was defined as an at least threefold 
increase in the immune response after the booster vaccination compared with the HPV-
specific immune response before booster vaccination. The T-cell assays were performed 
in the lab-oratory of the Department of Clinical Oncology (LUMC, Leiden) that operates 
under exploratory research conditions following standard operating procedure (SOPs) and 
using trained staff. This laboratory has participated in all proficiency panels of the CIMT 
Immunoguiding Program (http://www.cimt.eu/workgroups/cip/) as well as in IFNγ-Elispot 
panels of the Cancer Immunotherapy Consortium ( http://www.cancerresearch.org/cic), 
which both aim to harmonize the assays used for T-cell monitoring and the reporting 
thereof. For each different type of immune assay, the strength of the immune response was 
defined as the median-specific spot count (ELISPOT), stimulation index (LST) or amount 
of cytokine production (CBA) obtained for all six different peptide pools of all patients in 
one group. Raw data was stored for verification. Comparisons of the strength of the different 
types of immune responses at different time points within one group of patients were made 
by the non-parametric Wilcoxon matched-pairs signed rank test and between groups by the 
nonparametric Mann–Whitney test using GraphPad InStat Software. For the comparison of 
the immune responses and patients characteristics, patients were divided into two groups 
based on the presence or absence of HPV-specific immune response and calculated using 
the Statistical Package for the Social Sciences (SPSS) software package 17 . All reported P 
values are two-sided and have not been adjusted for multiple comparisons. P ≤ 0.05 was 
considered significant.
hpv testing
DNA was isolated from cervical smears or formalin-fixed, paraffin-embedded biopsy 
samples as previously described [22]. Betaglobin polymerase chain reaction (PCR) was per-
formed using primers RS40 and RS42 to determine whether the isolated DNA was suitable 
for amplification. The DNA was subjected to a short PCR fragment assay using the SPF10 
primer set, according to the manufacturer’s instructions (Innogenetics, Ghent, Belgium). 
Each experiment was performed with separate positive and several negative controls. The 
presence of HPV was established using a microtiter plate–based hybridization assay, and 
SPF10-PCR products from HPV DNA-positive cases were directly genotyped using a reverse 
hybridization line probe assay (Inno-LiPa HPV Genotyping Extra; Innogenetics). With this 
assay, 28 individual HPV genotypes can be identified simultaneously: HPV 6, 11, 16, 18, 26, 
31, 33, 35, 39, 40, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 69, 70, 71, 73, 74 and 82.






r e su lt s
patients and vaccinations
Between May 2007 and March 2010, 99 patients were screened of whom 51 patients were 
accrued for the study (Fig. 1). The average age was 40 years. 47 % of the patients had a 
medical history of PHD (Table 1). The majority (73 %) of the patients was infected by at 
least one high-risk HPV-type (Table 1) and 33 % were infected with HPV16. Patients were 
diagnosed with a LSIL at inclusion or had signs of persistent HPV infection (persistent 
mild cytological cervical abnormalities). The 51 patients were assigned to one of the two 
treatment groups at the start of the study (Table 1; Fig. 1). Group 1 was assigned to receive 
the HPV16-SLP twice at T = 0 week and at T = 3 weeks (n = 41) and Group 2 was to receive 
PBS-placebo (n = 10). The study was temporarily stopped in 2009 and 2010 due to serious 
adverse events in one of the other HPV16-SLP clinical trials. Figure 1 shows the drop-outs 
at the different time points. One year after first vaccination, half of group 1 should have been 
re-vaccinated with the HPV16-SLP (group 1A) and the other half should have received the 
PBS-placebo (group 1B; Fig. 1). As vaccination with PBS is not considered immunogenic, 
patients in group 1A who did not receive a booster vaccination at T = 1 year were grouped 
in group 1C and analyzed together with group 1B at T = 2 years.
adverse events
In total, 40 patients received one or more vaccinations with the HPV16-SLP. Of these, five 
patients discontinued the study pre-maturely because of adverse events four because of local 
adverse events, and one patient (1001) with a history of systemic lupus erythematosus who 
developed an acute exacerbation of cutaneous lupus erythematosus (LE) 3 days after the first 
vaccination. Adverse effects did not exceed grade 2 (Table 2). The most frequent systemic 
adverse event after vaccination was the flu-like syndrome (FLS; 26 %). Fifty-four percent 
of the patients experienced a second flare of systemic and/or local side effects several days 
(5–21 days) after the initial reaction had subsided. In the placebo group, no side effects 
exceeded grade 1 (Table 2). After booster vaccination with the HPV16-SLP, the flu-like 
syndrome (23 %) was the most frequently experienced adverse event, but it did not exceed 
grade 1 (Group 1A). Almost all patients in group 1 had grade 2 or 3 injection-site reactions 
in the weeks following vaccination with swellings beyond 8 cm (Table 2) accompanied by 
redness, pain and/or itching. Patients were evaluated for remaining local adverse events at 
1 and 2 years after vaccination. A painless swelling was still palpable in 41 % of the patients 
after 1 year and in 48 % after 2 years (56 % in group 1A and 41 % in group 1B). Three patients 
developed an ulcer at the site of injection. The first developed the ulcer (<2 cm) 6 months 
after first vaccination. Wound culture revealed a secondary infection with Staphylococcus 
aureus. After 2 years, there was scarring at the site of injection. Two other ulcers developed 
within the second year of the study. Both were sterile ulcers, showing a granulomatous in-
122 Chapter 6

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































fection as seen in foreign body reactions. 
Ulcers took a longtime to resolve with 
periods of healing followed by renewed 
sterile drainage. In one patient, we were 
able to do a skin test that revealed a type 
IV allergic reaction to the montanide.
hpv-specific memory t-cell 
responses are detected at 1 year after 
vaccination
Blood samples were drawn before 
vaccination (T = 0 week), at 7 weeks 
(T = 7 weeks) and 1 year (T = 1 year) 
after the first vaccination for immuno-
monitoring (Fig. 2). Pre-vaccination, 35 
% of the patients in group 1 displayed an 
HPV16-specific T-cell response against 
a median of two peptide pools (out of 
6) as detected by IFNγ-Elispot. At T = 7 
weeks and T = 1 year, this response was 
significantly boosted and 97 % of the 
patients reacted against a median of five 
peptide pools (P value <0.0001; Fig. 2a). 
In the placebo group, no HPV16-specific 
responses were found at T = 0 week or T 
= 7 weeks by IFNγ-Elispot. At T = 1 year, 
two patients in group 2 had developed a 
response (against 1 and 4 peptide pools). 
The proliferation assay (LST) revealed 
an HPV16-specific T-cell response in 
49 % of the patients in group 1 against 
a median of two peptide pools at T = 0. 
After vaccination, all patients (100 %) 
displayed a significantly increased prolif-
erative response against a median of five 
peptide pools at T = 7 weeks and T = 1 
year (P < 0.0001; Fig. 2a). HPV16-specific 
cytokine production was also boosted by 
vaccination (P < 0.0001; Fig. 2a), albeit 
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The occurrence of a flu-like syndrome is correlated 
to the strength of the HPV16-specific T-cell response 
after vaccination
One of the major adverse events seen was the occurrence 
of the flu-like syndrome in group 1. The Mann–Whitney 
test was used to determine the association between the 
FLS and the HPV16-specific response. Patients who had a 
FLS displayed a significantly higher HPV16-specific T-cell 
response by all tests after vaccination at T = 7 weeks than 
patients with no FLS (P < 0.0001; Fig. 3a). Interestingly, 
patients with FLS also displayed a stronger pre-existing 
proliferative response associated with the production of 
cytokines to HPV16. This observation was not made using 
the IFNγ-ELISPOT assay, probably because of the shorter 
assay length. The assay time of the proliferation test and 
associated cytokine production allows low-magnitude 
T-cell response to expand before measurement. The same 
correlations were found with the immune response to 
MRM, suggesting a correlation between the occurrence 
of FLS, a stronger response to vaccination and the overall 
immune status of patients (supplemental figure 2). 
Re-vaccination at 1 year boosts the immune response
One year after first vaccination, 13 patie t  from group 1 
were re-vaccinated with the HPV16-SLP (group 1A) and 
16 received the PBS-placebo (group 1B; Fig. 1). Five 
patients did not receive booster vaccination and were 
grouped into group 1C and analyzed together with group 
1B at T = 2 years (Fig. 1; Table 1, supplemental Figure 3). 
A significant effect of the booster vaccination was seen on 
the HPV16-specific responses as measured by IFNγ-Elispot 
and IL-5 production in the patients in group 1A (Fig. 3b). 
No significant increase was seen after booster vaccination 
on HPV16-specific proliferative responses and the associ-
ated produced cytokines IFNγ, TNFα and IL-10 compared 
with patients in group 1B + 1C (data not shown). Interest-
ingly, analysis of the HPV16-specific cytokine responses 
revealed that patients who received a booster vaccination 
at T = 1 year maintained a Th1 response, but also started 
to develop a Th2 response, indicated by the increased pro-
duction of IL-5. This did not occur in patients who did not 
receive a booster vaccination at 1 year. Patients in group 2 
did not show any significant increase in any of the tests for 
the duration of the study (supplemental Figure 4).
Clinical and virological follow-up
Clinical and virological responses were not endpoints of 
this study but all patients were followed according to stand-
ard clinical practice. HPV typing was performed at three 
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Table 2  Safety and toxicity
ID Systemic toxicitya Local toxicityb
1st 2nd Booster T = 7 weeks T = 1 year Booster T = 2 years
Grade 1 Grade 2 Grade 1 Grade2 Grade 1 Grade2 Swellingc Pigmentation
Group 1a 1035 3, 4 – 4 1 1 – 3 0 2 0 0
1037 – – – 1 13 – 2 0 1 1 0
1040 – – 3 1, 2 1 – 2 1 2 Ulcer 1
1042 11 – – 1, 2 – – 2 0 1 0 0
1015 4 – – 3 3 – 1 0 1 0 0
1012 – 1 – – – – 2 1 1 1 1
1008 – 3 2 – 3, 7 – 2 1 1 1 1
1005 – – – – 4 – 2 0 1 LTF
1013 – – 14 – – – 2 0 1 0 0
1026 – – – – – – 2 1 0 0 0
1028 – – – – – – 2 1 1 1 0
1033 – – 1 – 1, 5 – 2 0 1 0 0
1036 – – – – – – 3 0 1 1 0
1016 7 – – 1 2 2 Ulcer
1029 9 – 1 – 1 Ulcer
1032 9 – 1 – 3 1 1 1
1045 3 – 3 – 2 0
1050 – – – – 2 1 2 1
1049 13 – 2 1
Group 1b 1003 – – – – – – 2 0 LTF LTF
1006 – – – 1, 5 1 – 3 1 0 1 0
1007 – – 6 – – 3 0 0 0 0
1009 – – 3 – – – 2 0 0 0 0
1014 – – – – – – 2 0 0 0 0
1018 1 – 1 6, 8 – – 2 0 0 1 0
1019 4 – 4 – – – 3 0 0 0 1
1020 9 – – 1 – – 2 1 0 1 1
1021 – – – – – – 1 0 0 0 0
1022 3 – – – – – 2 1 0 UK UK
1024 1, 9 – 9 – – – 2 1 0 1 0
1025 – – 9, 11 – – – 1 0 0 1 1
1027 1, 5, 3 – 1 5, 3 4 – 2 0 0 0 0
1034 3, 4 – 4 1 – – 2 0 1 0 0
1038 1 – – – – – 2 1 0 1 1
1041 1 – – – – – 1 1 0 0 0
1044 – – – – 1 1 0 0
1046 – – – – 3 0 0 0




1048 LTF LTF UK
Group 2 1004 – – – – – – 1 0 1 LTF LTF
1010 – – – – – – 0 0 0 0 0
1011 – – – – – – 0 0 0 0 0
1017 – – – – – – 0 0 0 0 0
1023 3 – – – – – 0 0 0 0 0
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regressed to a Pap1, 43 % (16/37) had a Pap2/3a (of whom 
three patients had a LEEP performed after diagnosing 2× 
a CIN2 and 1× a CIN1) and 3 % (1/37) had progressed to 
a Pap3b after two vaccinations (which after LEEP excision 
turned out to be a CIN2) (Table 1). In group 2, 78 % (7/9) 
of the patients had returned to a Pap1 and 22 % (2/9) still 
had a Pap2 at T = 1 year. At 2 years follow-up, 69 % (9/13) 
had a Pap1 in group 1A and 30 % (4/13) a Pap2/3a. In 
group 1B and 1C, 63 % (15/24) had a Pap1 at T = 2 years, 
21 % (5/24) a Pap2/3a and 4 % (1/24) a Pap3b. Four per-
cent (1/24) had undergone a hysterectomy (myoma) and 
8 % (2/24) was not tested. At T = 0 year, nine patients in 
group 1 tested HPV16 positive. In the patients that were 
followed up for 1–2 years, the clearance rate at T = 1 year 
was 3/8 and T = 2 years 5/8. In group 2, two patients 
tested positive at T = 0, the clearance rate was 1/2 and 
1/1 at T = 1 year and T = 2 years, respectively. For com-
parison, six patients in group 1 tested HPV31 positive at 
T = 0 and the clearance rate was 0/6 and 2/4 at T = 1 year 
and T = 2 years. In group 2, one patient tested positive 
for HPV31 at T = 0, the clearance rate was 0/1 and 1/1 at 
T = 1 year and T = 2 years, respectively.
Discussion
In this randomized trial, patients received either a placebo 
or two vaccinations of a therapeutic HPV16-SLP vaccine 
with or without a booster vaccination after 1 year. The dif-
ferences in the HPV16-specific T-cell responses detected 
between the patients in the vaccine and placebo groups 
clearly showed that the HPV16-SLP vaccine is responsible 
for a strong HPV16-specific T-cell response after vaccina-
tion. Furthermore, the study showed that the most immuno-
genic parts of the vaccine are E6 peptide pool two (amino 
acid 41–92), pool four (amino acid 111–158) and E7 pool 
two (amino acid 41–98). These regions are similar to those 
that are recognized by the spontaneously induced HPV16-
specific T-cell response found in healthy volunteers [9, 23].
An important factor for the clinical efficacy of a thera-
peutic vaccine is its capacity to induce a CD4-mediated Th1 
cell response [24]. The first two vaccinations augmented 
the HPV16-specific Th1 response and this response is still 
detected after 1 year, albeit that the strength of the response 
is somewhat lower. The group of patients receiving a 
booster vaccination, not only showed a threefold increase 
in the number of HPV16-specific IFNγ-producing T cells 
as detected by IFNγ-Elispot but also an increase in the 
HPV16-specific production of IL-5 (compare groups 1A vs 
1B/1C). While the combination of HPV16-specific produc-
tion of both IFNγ and IL-5 is commonly found in the spon-
taneous T-cell response to HPV infection in healthy volun-
teers and also in the vaccine-induced response of patients 
clinically responding to HPV16-SLP vaccination [15, 17, 
18], the specific rise in a Th2 type cytokine indicates an 
undesirable polarization toward a Th2 response. The addi-
tion of an adjuvant with the capacity to skew toward a Th1 
response, therefore, seems warranted. Recently, IFNα has 
been used as adjuvant in a clinical trial in which colorec-
tal cancer patients were injected with a p53-SLP vaccine. 
This trial showed that the addition of IFNα enhanced the 
frequency of IFNγ-producing p53-specific T-cells in vacci-
nated patients [25], and thus may also be used as adjuvant 
in HPV16-SLP vaccines.
A second concern about this vaccination scheme in 
patients with pre-cancerous lesions is the adverse events 
observed during vaccination, in particular the delayed local 
reactions at the vaccination sites occurring several weeks 
to months after vaccination. In our other studies using the 
HPV16-SLP and Montanide ISA51, though the adverse 
Up to ID 1014, no diaries were handed out to patient
LTF lost to follow-up, UK unknown
a 1 Flu-like syndrome; 2 rash; 3 fatigue; 4 headache; 5 depression; 6 pruritis; 7 hotflushes; 8 hand and foot syndrome; 9 myalgia; 10 anorexia; 
11 throat ache; 12 constipation; 13 nausea and 14 other
b The swelling shortly after up to 3 weeks after vaccination are noted here. If more than one vaccinations sit reacted, the biggest was recorded. 
Grade 0: no swelling, grade 1: <4 cm; grade: 2 ≥4 cm; grade 3: ≥8 cm
c Swelling <4 cm
Table   continued
ID Systemic toxicitya Local toxicityb
1st 2nd Booster T = 7 weeks T = 1 year Booster T = 2 years
Grade 1 Grade 2 Grade 1 Grade2 Grade 1 Grade2 Swellingc Pigmentation
1030 – – – – – – 0 0 0 0 0
1031 4 – – – – – 0 0 0 0 0
1043 10 – 10 – 0 0
1047 – – 0
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that the levels of cytokines were low in most patients rendering the median level under the 
cutoff value for all cytokines except IL-5 (Fig. 2a, dashed lines). Representative data for the 
responses measured by these assays are shown for one patient in Supplemental figure 1. In 
order to define which of the peptide pools were responsible for the HPV16-SLP-induced 
response in group 1 patients, the response was analyzed with respect to the individual 
peptide pools (Fig. 2b). This showed an HPV16-specific T-cell response that was detected 
against all peptide pools as measured by both IFNγ-Elispot and LST, with peptide pool 
E6.Two being the most immunogenic, and peptide pools E6.1 and E7.2 the least. There was 
no association between pre-existing HPV16-specific T-cell responses and various patient 
characteristics: i.e., HPV16 status at T = 0 (n = 11), PHD, allergic constitution and smoking 
(data not shown). There was no difference in response between patients with or without an 
active HPV16 infection in response to the HPV16-SLP.
The occurrence of a flu-like syndrome is correlated to the strength of the 
hpv16-specific t-cell response after vaccination
One of the major adverse events seen was the occurrence of the flu-like syndrome in group 
1. The Mann–Whitney test was used to determine the association between the FLS and the 
HPV16-specific response. Patients who had a FLS displayed a significantly higher HPV16-
specific T-cell response by all tests after vaccination at T = 7 weeks than patients with no FLS 
(P < 0.0001; Fig. 3a). Interestingly, patients with FLS also displayed a stronger pre-existing 
proliferative response associated with the production of cytokines to HPV16. This observa-
tion was not made using the IFNγ-ELISPOT assay, probably because of the shorter assay 
length. The assay time of the proliferation test and associated cytokine production allows 
low-magnitude T-cell response to expand before measurement. The same correlations were 
found with the immune response to MRM, suggesting a correlation between the occur-
rence of FLS, a stronger response to vaccination and the overall immune status of patients 
(supplemental figure 2).
re-vaccination at 1 year boosts the immune response
One year after first vaccination, 13 patients from group 1 were re-vaccinated with the 
HPV16-SLP (group 1A) and 16 received the PBS-placebo (group 1B; Fig. 1). Five patients 
did not receive booster vaccination and were grouped into group 1C and analyzed together 
with group 1B at T = 2 years (Fig. 1; Table 1, supplemental Figure 3). A significant effect of 
the booster vaccination was seen on the HPV16-specific responses as measured by IFNγ-
Elispot and IL-5 production in the patients in group 1A (Fig. 3b). No significant increase 
was seen after booster vaccination on HPV16-specific proliferative responses and the as-
sociated produced cytokines IFNγ, TNFα and IL-10 compared with patients in group 1B 
+ 1C (data not shown). Interestingly, analysis of the HPV16-specific cytokine responses 
revealed that patients who received a booster vaccination at T = 1 year maintained a Th1 






response, but also started to develop a Th2 response, indicated by the increased production 
of IL-5. This did not occur in patients who did not receive a booster vaccination at 1 year. 
Patients in group 2 did not show any significant increase in any of the tests for the duration 
of the study (supplemental Figure 4).
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figure 2. Strong vaccine-induced T-cell immunity was seen after two vaccinations with HPV16-SLP vaccine 
at 50μg/peptide. (a) HPV16-specific T-cell reactivity was determined using PBMCs before (T=0w), 7 weeks 
(T=7w) and 1 year (T=1y) after vaccination as determined by IFNγ-Elispot, lymphocyte stimulation test (LST) 
and cytometric bead array (CBA). The median (line), interquartile range (boxes) and 10-90% range (bars) of 
the HPV16-specific T-cell responses are shown for patients in group 1 (HPV16-SLP; n=37) and group 2 (PBS-
placebo; n=8). The Wilcoxon matched-pairs signed rank test shows a significant increase after vaccination of 
HPV16-specific responses in all tests at T=7w and T=1y in group 1 (* 0.01 < P < 0.05; ** 0.001 < P < 0.01; *** P 
< 0.001). In group 2 no differences in responses were seen except between T=0 and T=1y in the IFNγ-Elispot. 
(b) Analysis of the individual peptide pools in PBMCs from patients of group 1 shows broad responses with the 
greatest immunogenicity against E6.2, E6.4 and E7.2 and hardly any responses to E6.1.
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clinical and virological follow-up
Clinical and virological responses were not endpoints of this study but all patients were 
followed according to standard clinical practice. HPV typing was performed at three time 
points. At T = 1 year in group 1, 51 % (19/37) had regressed to a Pap1, 43 % (16/37) had a 
Pap2/3a (of whom three patients had a LEEP performed after diagnosing 2× a CIN2 and 
1× a CIN1) and 3 % (1/37) had progressed to a Pap3b after two vaccinations (which after 
LEEP excision turned out to be a CIN2) (Table 1). In group 2, 78 % (7/9) of the patients 
had returned to a Pap1 and 22 % (2/9) still had a Pap2 at T = 1 year. At 2 years follow-up, 
69 % (9/13) had a Pap1 in group 1A and 30 % (4/13) a Pap2/3a. In group 1B and 1C, 63 
% (15/24) had a Pap1 at T = 2 years, 21 % (5/24) a Pap2/3a and 4 % (1/24) a Pap3b. Four 
per-cent (1/24) had undergone a hysterectomy (myoma) and 8 % (2/24) was not tested. At T 
= 0 year, nine patients in group 1 tested HPV16 positive. In the patients that were followed 
up for 1–2 years, the clearance rate at T = 1 year was 3/8 and T = 2 years 5/8. In group 2, two 
patients tested positive at T = 0, the clearance rate was 1/2 and 1/1 at T = 1 year and T = 2 
years, respectively. For comparison, six patients in group 1 tested HPV31 positive at T = 0 
and the clearance rate was 0/6 and 2/4 at T = 1 year and T = 2 years. In group 2, one patient 
tested positive for HPV31 at T = 0, the clearance rate was 0/1 and 1/1 at T = 1 year and T = 
2 years, respectively.
dI s c u s sIon
In this randomized trial, patients received either a placebo or two vaccinations of a thera-
peutic HPV16-SLP vaccine with or without a booster vaccination after 1 year. The differ-
ences in the HPV16-specific T-cell responses detected between the patients in the vaccine 
and placebo groups clearly showed that the HPV16-SLP vaccine is responsible for a strong 
HPV16-specific T-cell response after vaccination. Furthermore, the study showed that 
the most immunogenic parts of the vaccine are E6 peptide pool two (amino acid 41–92), 
pool four (amino acid 111–158) and E7 pool two (amino acid 41–98). These regions are 
similar to those that are recognized by the spontaneously induced HPV16-specific T-cell 
response found in healthy volunteers [9, 23]. An important factor for the clinical efficacy 
of a therapeutic vaccine is its capacity to induce a CD4-mediated Th1 cell response [24]. 
The first two vaccinations augmented the HPV16-specific Th1 response and this response 
is still detected after 1 year, albeit that the strength of the response is somewhat lower. The 
group of patients receiving a booster vaccination, not only showed a threefold increase in 
the number of HPV16-specific IFNγ-producing T cells as detected by IFNγ-Elispot but 
also an increase in the HPV16-specific production of IL-5 (compare groups 1A vs 1B/1C). 
While the combination of HPV16-specific production of both IFNγ and IL-5 is commonly 
found in the spontaneous T-cell response to HPV infection in healthy volunteers and also in 






























































































































































figure 3. (a) Stronger HPV16-specific T-cell responses were seen in patients that had the Flu-like syndrome 
(FLS) after vaccination compared to patients with no FLS in patients of group 1. The median (line), interquartile 
range (boxes) and 10-90% range (bars) of the HPV16-specific T-cell response by IFNγ-Elispot, lymphocyte 
stimulation test (LST) and cytometric bead array (CBA) are shown for both groups. Patients with FLS had sig-
nificantly stronger responses after vaccination by all tests (* 0.01 < P < 0.05; ** 0.001 < P < 0.01; *** P < 0.001). 
This difference was already seen before vaccination in the LST and CBA. (b) A booster vaccination enhanced 
response was defined as a threefold increase in the immune response after the booster vaccination compared to 
the HPV-specific immune response before booster vaccination. Booster vaccination significantly increased the 
response in the IFNγ-Elispot assay and IL-5 production.
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the vaccine-induced response of patients clinically responding to HPV16-SLP vaccination 
[15, 17, 18], the specific rise in a Th2 type cytokine indicates an undesirable polarization 
toward a Th2 response. The addition of an adjuvant with the capacity to skew toward a Th1 
response, therefore, seems warranted. Recently, IFNα has been used as adjuvant in a clinical 
trial in which colorectal cancer patients were injected with a p53-SLP vaccine. This trial 
showed that the addition of IFNα enhanced the frequency of IFNγ-producing p53-specific 
T-cells in vaccinated patients [25], and thus may also be used as adjuvant in HPV16-SLP 
vaccines.
A second concern about this vaccination scheme in patients with pre-cancerous lesions is 
the adverse events observed during vaccination, in particular the delayed local reactions at 
the vaccination sites occurring several weeks to months after vaccination. In our other stud-
ies using the HPV16-SLP and Montanide ISA51, though the adverse events did not exceed 
grade 2, the local injection-site reactions could be severe with large swelling formation with 
itching, redness and pain [14, 16, 17]. Therefore, in this study, a low-dose vaccine (50 μg/
peptide) was administered with Montanide ISA51 as adjuvant. Montanide ISA 51 is not a 
component of any approved human vaccine, but has been used in many previous trials of 
candidate HIV, malaria and cancer vaccines and has been shown to cause severe injection-
site reactions with occasional sterile abscess formation [26–29]. For patients with low-grade 
cervical disease, the short- and long-term local adverse events of the HPV16-SLP vaccine 
are difficult to accept [16]. To be successful in this patient group, the formulation of the 
HPV16-SLP should be changed in such a way that it remains effective, yet with reduction 
in the adverse events. A potential strategy to reach this goal is intradermal vaccination [30] 
or to use SLP formulations were an adjuvant is directly coupled to the peptide allowing 
Montanide to be omitted. Recently, Pam3Cys-conjugated SLP were reported to be highly 
immunogenic and to display low toxicity at the low doses that are still effective in pre-
clinical trials [31].
An interesting finding in this trial was the association between an overall higher active 
immune system - as based on the higher response to recall antigens - the appearance of 
FLS and a stronger response to vaccination. Apparently, such a profile associates with a 
stronger response to vaccination with more adverse events. We did not find this in our 
previous HPV16-SLP vaccination trials in patients with malignant disease, suggesting that 
this phenomenon specifically becomes apparent in patients with low-grade disease with a 
more alert immune system.
In conclusion, vaccination with 50 μg/peptide of HPV16-SLP induces a broad and strong 
immune response in patients with low-grade pre-malignant disorders of the uterine cervix. 
This response remains at a steady state high level for at least 2 years. A booster vaccination 






after 1 year specifically increases Th2 responses. Future use of such a vaccination scheme 
thus may require better adjuvant to steer the immune response toward the desirable Th1 
response. Notably, for this group of patients with pre-malignant lesions of the cervix, the 
often long lasting local adverse events make vaccination with HPV16-SLP as currently for-
mulated inappropriate. The use of other adjuvant, peptide formulations or injection routes 
may overcome these problems.
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Supplemental Figure 1.  Representative immunomonitoring data for patient 1026 is 
shown. Responses are measured by IFNγ- Elispot, proliferation assay (LST) and cytokine 
production (IFNγ, IL-5, IL-10 and TNFa). This patient was allotted to group 1a, receiving 
the HPV16-SLP twice at T=0w and T=3w and again at T=1y. A response is measured in 
the Elispot, LST and Il-5 after vaccination. After booster vaccination (T=1y+3w) a further 
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Supplemental Figure 2.   Box plots of the response to booster vaccination showing the median (line), 
interquartile range (boxes) and 10-90% range (bars) during the second year. Responses are shown for 
time-points T=1y, T=1y+3w and T=2y (except for the IFNγ-Elispot) for group 1A (who received the HPV16-
SLP at T=0, T=3w and T=1y), Group 1B (who received the HPV16-SLP at T=0, T=3w and PBS at T=1y) and 
Group 1C (who received the HPV16-SLP at T=0, T=3w and nothing at T=1y). The results of Group 1B and 1C 
are depicted combined as both patient groups did not receive the HPV16-SLP vaccine. HPV16-specic 
T-cell responses are shown when measured by IFNγ Elispot, proliferation assay (LST) and proliferation 
associated production of IFNγ, IL-5, IL-10 and TNFα. In groups 1B and 1C a certain degree of uctuation 
was seen, although signicant increases in cytokine production were observed more often in group 1A 
after booster vaccination with HPV16-SLP. 








































































































Supplemental figure 3. The HPV16-specific T-cell response for patients in group 
2, who received placebo at all time-points are depicted. No significant changes 
were observed in the immunological tests conducted: IFNγ-Elispot, proliferation 
assay (LST) or cytometric bead array (CBA) for the indicated cytokines.
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a b st r ac t
The aim of this study was to investigate the capacity of an HPV16 E6/E7 synthetic over-
lapping long-peptide vaccine to stimulate the HPV16-specific T-cell response, to enhance 
the infiltration of HPV16-specific type 1 T-cells into the lesions of patients with HPV16+ 
high-grade cervical squamous intraepithelial lesion (HSIL) and HPV clearance. This was 
a placebo controlled randomized phase II study in patients with HPV16 positive HSIL. 
HPV16-specific T-cell responses were determined pre- and post vaccination by ELISPOT, 
proliferation assay and cytokine assays in PBMC and HSIL-infiltrating lymphocytes and 
delayed-type hypersensitivity skin tests. Motivational problems of this patient group to 
postpone treatment of their premalignant lesions affected the inclusion rates and caused 
the study to stop prematurely. Of the accrued patients 4 received a placebo and 5 received 
1-2 vaccinations. Side-effects mainly were flu-like symptoms and injection site reactions. A 
strong HPV-specific IFNg-associated T-cell response was detected by ELISPOT in all vac-
cinated patients. The outcome of the skin tests correlated well with the ELISPOT analysis. 
The cytokine profile associated with HPV16-specific proliferation varied from robust type 1 
to dominant type 2 responses. No conclusions could be drawn on vaccine-enhanced T-cell 
infiltration of the lesion and there was no HPV clearance at the time of LEEP excision. Thus, 
vaccination of HSIL patients results in increased HPV16-specific T-cell immunity. Further 
development of this type of treatment relies on the ability to motivate patients and in the 
reduction of the side effects.






I n t rodu c t Ion
Persisting Human Papillomavirus (HPV) infections, in particular HPV type 16 are associ-
ated with the development of (pre)cancers of the anogenital tract. The risk of progression 
of squamous intraepithelial lesions (SIL) of the cervix is related to the severity of dysplasia 
[1, 2]. Small lesions are easily treated by loop electrosurgical excision procedure (LEEP), 
while larger lesions often require repeated surgery for recurrences [3]. Virus-specific, 
interferon-γ–producing CD4+ T cells and CD8+ cytotoxic T lymphocytes are essential 
components in controlling chronic viral infections [4, 5]. The majority of subjects who clear 
HPV16 display HPV16 E6-specific CD8+ cytotoxic T-lymphocyte (CTL) responses [6, 7], 
and relatively robust proliferative T-cell responses against early viral proteins E2, E6 and 
E7, characterized by CD4+ T cells that produce Interferon-γ (IFNγ) and IL-5 [8-10]. Such 
IFNγ-associated T-cell responses are weak or absent in most patients with HSIL [7, 10-13].
Recently, two studies reported that therapeutic vaccination with an HPV16 E6/E7 protein 
or synthetic long-peptide vaccine (HPV16-SLP) resulted in the complete regression of 
HPV16-induced high grade lesions of the vulva [14, 15]. Clinical success correlated with the 
induction of strong and broad HPV16-specific T-cell responses [14-16]. Non-responders 
had bigger lesions [15] and increased numbers of HPV-specific regulatory T cells [14, 16]. 
The aim of this study was to investigate the capacity of the HPV16-SLP vaccine to stimulate 
the HPV16-specific T-cell response in patients with HPV16+ high grade lesions of the 
cervix.
m at e r Ia l s a n d m et hod s
patients and vaccination
This was a placebo controlled randomized blinded phase II study aiming to include 34 
patients, 17 in each arm. The aim of this study was to investigate the capacity of an HPV16 
E6/E7 synthetic overlapping long-peptide vaccine to stimulate the HPV16-specific T-cell 
response, to enhance the infiltration of HPV16-specific type 1 T-cells into the lesions of 
patients with HPV16+ high-grade cervical squamous intraepithelial lesion (HSIL) and 
HPV clearance.
Patients with histologically proven HPV16+ HSIL were included after oral and written 
informed consent and randomized into two groups. Eligibility required pre-treatment labo-
ratory findings of leukocytes > 3x109/L, lymphocytes > 1x109/L, thrombocytes > 100x109/L 
and haematocrit > 30% and no radiotherapy, chemotherapy or other potentially immu-
nosuppressive therapy administered within 4 weeks prior to the immunotherapy. Patients 
consented to HPV testing and to having an extra biopsy taken for culture of HSIL infiltrat-
ing lymphocytes at colposcopy (Figure 1a). HPV typing was done on paraffin embedded 
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sections of biopsies or smears as published previously [17-19]. Patients either received the 
vaccine at a dose of 300mg per peptide twice with a 3 week interval or a placebo, Phosphate 
Buffered Saline (PBS). Blood was drawn at week 0, 7 and 9-11. Both at screening and LEEP 
excision an extra biopsy was taken for the culture of HSIL infiltrating lymphocytes. A de-
layed type hypersensitivity (DTH) skin test was performed 2-4 weeks after LEEP excision. 
The study was approved by the Dutch Central Committee on Human Research (CCMO, 
https://toetsingonline.ccmo.nl/ccmo_search.nsf/ dossier number NL14015.000.06) and the 
medical ethical committee of the Leiden University Medical Centre and the Haga teaching 
Hospital. Monitoring for adverse events was performed as described previously [20] and 
adverse events were classified according to the Common Terminology Criteria for Adverse 
Events version 3.0 (CTCAE). The vaccine consisted of a mix of 13 overlapping 25-35mer 
peptides representing the entire sequence of the E6 and E7 proteins of HPV16 (HPV16-
SLP) dissolved in dimethylsulfoxide (DMSO) and admixed with 20 mM phosphate buffer 
(pH 7.5) and Montanide ISA-51. The vaccine was produced at the GMP facility of the Leiden 
University Medical Center (LUMC) [15, 16, 20, 21].
t-cell assays, data acquisition, analysis and interpretation
The peripheral blood mononuclear cells (PBMC) were tested for HPV16-specificity by a set 
of complementary T-cell immune monitoring assays including: IFN-γ-ELISPOT, lympho-
cyte proliferation assay (LST) and cytokine bead array (CBA), using pools of 22 amino acid 
long peptides, overlapping by 12 amino acids. All tests have previously been described and 
positive responses have been defined [22]. For all T-cell assays, a vaccine-induced response 
was defined as at least a 3-fold increase in the response after vaccination when compared 
to the results before vaccination. A semi-quantative analysis of local changes in immune 
infiltrate was done on haemotoxyline-eosine stained sections before and after vaccination. 
HSIL-infiltrating lymphocytes were isolated, cultured and tested for HPV16-specific prolif-
eration and cytokine production as described previously [16].
The T-cell assays were performed in the laboratory of the department of Clinical Oncol-
ogy (LUMC, Leiden) that operates under research conditions, following standard operating 
procedure (SOPs) and using trained staff. This laboratory has participated in all proficiency 
panels of the CIMT Immunoguiding Program (http://www.cimt.eu/workgroups/cip/), as 
well as in IFNγ ELISPOT panels of the Cancer Immunotherapy Consortium, which aim is 
to harmonize the reporting and assays used for T-cell monitoring [23-25].
delayed-type hypersensitivity skin tests
Delayed-Type Hypersensitivity reactions can be used as a sensitive and simple method for 
in vivo measurement of HPV-specific cellular immune responses and were used as previ-
ously described [26].






r e su lt s
vaccinations
A total of 47 patients visiting the out-patient department of two hospitals in the Netherlands 
gave informed consent to screening for this study between June 2007 and December 2009. 
Due to the anxiety of patients with a HSIL to postpone the LEEP procedure, accrual proved 
an obstacle. Of the 27 eligible patients only 10 consented, and one patient (placebo group) 
never showed up for vaccination. Within the vaccine group two patients (3006 and 3003) 
did not receive the second vaccination due to side effects and one (3010) due to a study stop 
(Figure 1b)
safety and toxicity
Placebo patients did not display adverse reactions. As expected on the basis of our previ-
ous trials [15,20,21], all 5 patients in the vaccination group displayed adverse reactions not 
exceeding grade 2 according to CTCAE, and included injection site reactions with itching, 
redness, swelling and pain. All patients experienced swellings of more than 8 cm which 
lasted for several days. Systemic reactions consisted of a headache (80% of the patients); 
diarrhea, fatigue and/or dizziness (40% of the patients) and nausea, chills, myalgia, rash, 
fever, uticaria, edema of the limbs or an allergic reaction needing antihistamines (20% of the 
patients). Two patients (3002 and 3007) experienced stronger side effects after the second 
vaccination. In 4 cases there was a renewed reaction to the vaccine 5 to 14 days after vac-
cination consisting of increased injection site reactions with or without systemic reactions. 
The skin test caused mainly itching at the site of the test.
spontaneous and vaccine-induced hpv16 e6- and e7-specific t-cell immunity
Systemic HPV16-specific T-cell reactivity from all three time points was simultaneously 
determined by IFNγ-ELISPOT (Figures 1b and 2a, Online resource 1). Only two of the 
nine patients (3006 and 3007) showed a weak pre-existing HPV16-specific immunity, one 
against E6 and one against E7 (10 and 11 spots per 100,000 PBMC). All vaccinated patients 
showed strong responses to 2-5 of the peptide pools (5/5 patients against E6 peptide pools 
and 4/5 against E7.2) 7 weeks after first vaccination, with reactivity up to 255 HPV-specific 
IFNγ producing cells per 100,000 cells (Figure 1b). Of the patients receiving placebo, 2 
subjects (3004 and 3005) showed a weak IFNg-associated HPV-specific response to one 
peptide pool (13 and 10 spots per 100,000 cells, against E7.2 and E6.1 respectively).
None of the patients tested, displayed an HPV16-specific proliferative response at the start 
of the study. Three of the four patients receiving a placebo (3001, 3004 and 3009) remained 
unresponsive to HPV16 E6 and E7 throughout the duration of the study (Figure 1c, Online 
resource 2). One patient (3005), received a placebo, yet developed a broad proliferative 
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figure 1. Schematic representati n of th  plac bo-controlled randomized trial and summary of immunological 
results. (a) Patients were recruited at colposcopy visit. After informed consent, HPV testing was performed by 
PCR and an extra biopsy was taken for the culture of HSIL infiltrating lymphocytes. Patients with histological 
proven HPV16+ HSIL then consented to the vaccination study at which time blood was drawn for chemistry 
and base-line immunomonitoring. Patients in arm 1 received the vaccine at a dose of 300mg per peptide twice 
with a 3-week interval; patients in arm 2 received a placebo (PBS). Seven weeks after the first vaccination a 
LEEP excision was performed at which time an extra biopsy of the HSIL was taken and blood drawn for immu-
nomonitoring. DTH skin test was performed 2-4 weeks after surgery at which time blood was drawn to measure 
the effect of the LEEP excision on the systemic immune response. (b) Immunological results of all the patients 
using PBMC from three different time-points. Week 0 (pre-vaccination), week 7 (post-vaccination) and week 
9-11 (after LEEP excision). Systemic HPV16-specific T-cell reactivity against six peptide pools (4 E6 and 2 E7 
peptide pools) was determined by IFNγ-ELISPOT. The boxes in grey show the number of HPV-specific IFNγ 
producing T-cells per 100,000 cells. (c) HPV specificity determined by the proliferation assay (LST). The grey 
boxes indicate the (stimulation index) SI of the HPV-specific proliferative responses. The culture at week 0 of 
patient 3006 was not tested due to technical problems. To the right the overall cytokine profile based on the 
outcome of tested supernatants of the LST by cytokine bead array (CBA) is indicated. A Th-0 response indicates 
weak cytokine production inconclusive for a Th-1 or Th-2 response. Patient 3008 was randomised, but never 
showed up for vaccination (NS= Not Started).






9-11). All 5 vaccinated patients developed an HPV16-specific proliferative response after 
vaccination. Patients 3006 and 3007 developed the broadest responses to 5-6 peptide pools 
and the other three patients responded to 1-4 pools (4/5 against E6 peptide pools and 5/5 
against E7 peptide pools) at week 9-11. (Figure 1b and 2b, Online resource 2).
The supernatant of the proliferation assays was tested for the presence of HPV16-specific 
produced cytokines IFNγ, TNFα, IL-10, IL-5, IL-4 and IL-2. Before vaccination, no HPV16-
specific cytokine production was found (Online resource 3 and figure 2c). At the time of 
LEEP treatment HPV16-specific IFNγ production – ranging between 146-1582 pg/mL - 
was found in 3 of the five vaccinated patients (3006, 3007 and 3010). Only in one patient 
(3006) did we find a robust T-helper type 1 response (Online resource 3). Two patients 
displayed a Th-2 response (3002 and 3007) with the production of IL-5 and IL-10. One 
patient (3003) had a weak polarisation (Th-0) with very low amounts of IL-5 production 
and one patient (3010) had a weak mixed Th-1 and Th-2 response producing little amounts 
of IFNγ, TNFα, IL-5 and IL-10 (Online resource 3). Patient 3005 who was not vaccinated 
had a Th-0 response with very low amounts of IFNγ against one pool and IL-5 against 
another, despite a broad proliferative response. This is typical for HPV16-specific immunity 
in patients invasively treated for a persistent or recurrent lesion [13]. IL-4 or IL-2 are most 
likely consumed by T cells during the culture.
systemic immunity to recall antigens
In order to test the general immune status of the patients, the capacity of their T cells to 
proliferate and produce cytokines when stimulated with a mix of recall antigens (MRM) 
was tested. All patients, except 3002, displayed a proliferative response to MRM at all time 
points. MRM-specific IFNγ production was detected in the culture supernatants of patients 
3001, 3003, 3005, 3006 and 3009 and in patient 3010 by IFNγ-ELISPOT. Patient 3004 failed 
to produce MRM-specific cytokines. Patient 3002 and 3007 produced IL-10 (33 pg/mL) and 
IL-5 (53 pg/mL), respectively.
local changes in hsIl biopsies
All patients were diagnosed with HSIL before vaccination. One patient (3001) in the placebo 
group had two biopsies (punch and LEEP) taken before the trial because of a discrepancy 
between the PAP smear (Pap4) and the first biopsy (no dysplasia, the second showed a 
CIN2). In the LEEP specimen after vaccination no dysplasia was found. In none of the other 
patients was a change in the histological and viral disease status found at the time of LEEP. 
A semi-quantative analysis of local changes in immune infiltrate on haemotoxyline-eosine 
stained sections revealed a change from a scattered pattern to a dense immune infiltrate in 3 
(3002, 3003, 3010) of the 5 vaccinated patients. A similar change was observed in one (3004) 
of the three patients in the placebo group.
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We received biopsies from all patients before vaccination for T-cell culture. After vac-
cination we received biopsies from 3 placebo treated patients and 3 vaccinated patients. In 
three of the 9 biopsies taken at the start of the study, enough T cells could be isolated to 
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figure 2. Example of the results from immunomonitoring. The results of patient 3007 who received two vac-
cinations and of whom blood was tested at week 0 (pre-vaccination; white), at week 7 (post-vaccination; black) 
and at week 9-11 (after LEEP excision; grey). The arrows ( ) indicate a pre-existing response and the stars (*) 
indicate a positive reaction during the course of the study. (a) Results of the IFNγ-ELISPOT assay. (b) Results of 
the proliferation assay showed no pre-excising HPV-specific reactivity. (c) Cytokine bead array (CBA) was used 
to test the HPV16-specific production of the indicated cytokines measured in the culture supernatants of the 
proliferation assay. (d) DTH results showing clear redness and swelling of sites injected with E6.1, E6.2, E6.3, 
E6.4 and E7.2. (e) Overview of the IFNg-ELISPOT results compared to the DTH skin test results.






test for the presence of HPV16-specific T cells. Only in the culture of patient 3010 was a 
proliferative response detected against monocytes pulsed with the combined peptide pools 
E6.1 and 2 as well as against monocytes pulsed with protein. After vaccination we received 
6 biopsies for culture (3 from vaccinated patients and 3 from placebo treated patients). Only 
two cultures, both from vaccinated patients (patient 3006 and 3003) had enough T-cells to 
be tested. Neither showed evidence of HPV16-specificity. We did not receive a biopsy after 
vaccination from patient 3010 (who tested positive pre-vaccination).
responses to an hpv16 peptide-based skin test
Skin tests, based on DTH reactions against HPV16 peptides, can be used for in vivo mea-
surement of HPV-specific cellular immunity [26]. Patients receiving placebo showed no 
skin reactions. Patients 3003, 3006 and 3010 who stopped after one vaccination did not 
receive the skin test. Patients 3002 and 3007 showed strong DTH reactivity after two vac-
cinations matching the results of the IFNγ-ELISPOT assay (Figure 2de).
dI s c u s sIon
Therapeutic HPV vaccination is a promising strategy for HPV-induced pre-cancerous le-
sions and cancer as shown for patients with high grade VIN lesions by us and others [14, 
15]. The aim of this study was to examine the systemic and local HPV16-specific T-cell 
responses after HPV16-SLP vaccination in patients with HPV16-induced HSIL. We were 
able to identify enough patients within 18 months, yet we experienced problems in accrual, 
due to patient anxiety at having to postpone standard surgical treatment. The study was 
extended in time, however, the accrual stayed extremely low and it was decided to stop the 
study prematurely. These problems have been described before in other attempts to test 
potential vaccines in patients with HSIL [27, 28]. Overall, the inclusion rate in this study 
was 19%. This was quite unexpected as the inclusion rate in our previous trials in which this 
vaccine was tested in patients with cancer or VIN was well over 60% [15, 20]. In contrast to 
patients with VIN3 - for whom treatment is mutilating, disfiguring and of which the effects 
are mostly transient as recurrences are high [15, 20, 29] - this is not the case for patients 
with HSIL as they have no symptoms of their lesion and can be treated relatively easily by 
surgery. The side effects including amongst others swellings of 8cm of the injection site and 
flu-like symptoms, were expected on the basis of our earlier trials [15, 20, 21]. However, 
though they did not bear much impact on the study in patients with VIN3, it did cause 
a high drop out of patients in this trial. This clearly shows that strong disparities in the 
side effects and benefit between the standard of care and new therapies may outweigh the 
potential benefits of newly tested therapeutic modalities and affect clinical testing.
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This was the first placebo controlled trial with this HPV16 SLP vaccine. Although the 
numbers were small it allowed us to show that the standard care, which includes a biopsy, 
can induce a broad and strong HPV16-specific response. However, this response was nei-
ther associated with the production of IFNg nor with a positive skin test. In contrast to the 
placebo group, all vaccinated subjects displayed a strong vaccine-induced IFNγ-associated 
T–cell response as measured by ex-vivo IFNg-ELISPOT. This placebo-controlled trial thus 
sustains our notion to use the IFNγ-ELISPOT assay to determine vaccine-induced HPV16-
specific T-cell reactions. The skin test assay may be an alternative as the pattern of skin 
reactions found in the 2 vaccinated and 4 placebo treated patients tested matched well the 
results of the IFNγ-ELISPOT assay, confirming our previous observations that they have 
quite similar detection rates [26]. Notably, IFNg-ELISPOT reactivity correlated with clinical 
responsiveness in our previous study in patients with vulvar lesions [15]. Only 1 vaccinated 
patient (3006) showed a robust Th-1 profile at week 7 after receiving only one vaccination.
An earlier randomized blinded placebo-controlled study with E6 and E7 protein in IS-
COMATRIX in HSIL patients reported stronger HPV16-specific T-cell responses in immu-
nized subjects than in placebo recipients. No clinical effects were observed [27]. In addition, 
a recent report on the use of an encapsulated plasmid DNA vaccine revealed that about half 
of the patients mounted a transient HPV-specific CD8 T-cell response [30]. Furthermore, 
HSIL patients vaccinated with a MVA viral vector expressing HPV16 E6 and E7 as well as 
IL-2 displayed some clinical efficacy at six months but the correlation with vaccine-induced 
T-cell reactivity was not assessed [28].
Overall, our placebo-controlled study shows that the HPV16-SLP vaccine is capable of 
increasing the numbers of circulating IFNg-producing HPV16-specific T cells in patients 
with HSIL. These responses can be reliably detected using a DTH skin test. Importantly, 
motivational problems and the local and systemic side-effects of the HPV16-SLP vaccine in 
HSIL patients must be taken into account when considering further studies in patients with 
pre-malignant lesions for whom an effective treatment is available. Future efforts should 
be focused on the development of a well tolerated formulation, capable of inducing strong 
immune responses in patients with premalignant HPV-induced disease.
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Supplementary fig 1. Phenotype of in vitro differentiated DC and M2 macrophages.
(A) Monocytes were cultured for 6 days with GM-CSF+IL-4 to obtain imm DC or M-CSF to obtain M2 macrophages and 
analyzed by flowcytometry for the expression of phenotypical markers. M2-differentiated macrophages typically display 
high expression of  the scavenger receptor CD163 and the mannose receptor CD206. In contrast to monocyte derived DC 
M2-macrophages express all FcγReceptors (CD32, CD64 and CD16). (B+C) Stimulation of TSN-M2 for 48 hr with (B) 
indicated TLR-ligands and (C) Th1 cells or CD40-L cells results in a lowered expression of CD14 and CD163 as detected 
by flowcytometry.
















































































































































Online Resouce 2. Immunomonitoring by proliferation assay (LST). The top four patients received a placebo and the 
bottom five patients received the vaccine. The proliferative responses were measured after 7 days of culture by [3H]-
thymidine incorporation for the last 24 hours and are displayed as count per minute (CPM). The results are shown for 
week 0 (pre-vaccination), week 7 (post-vaccination) and week 9-11 (after LEEP excision). The data of patient 3006 at 






































































































































































































































































































Online Resource 3. Immunomonitoring by cytokine bead array (CBA). Supernatants of the 7-day proliferative cultures 
(LST) were  harvested at day 6 and  subjected to CBA to measure the production of IFN   (light blue), TNFα (dark green), 
IL-10 (pink), IL-5 (red), IL-4 (brown) IL-2 (dark blue).  The results are shown for the three time points. The upper 4 
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Conventional therapies like surgery, radiotherapy and chemotherapy, are of essential clini-
cal value in the combat against cervical cancer. Yet, recurrent and metastatic disease are still 
often incurable due to limitations of toxicity and loss of efficacy of treatment. Based on new 
insights, novel immune-based therapies are gaining a undisputed place in the treatment of 
many cancers. Understanding the mechanisms underlying the generation of tumour im-
munity is vital if immunotherapeutic strategies are to join ranks in standard cancer therapy. 
This thesis contributed to the ongoing research into the role of the immune system during 
the development of cervical cancer and the search for effective and innovative immuno-
therapeutic strategies to combat it.
Previous studies in healthy individuals show that systemic HPV16 specific T-cell responses 
are frequently present in the healthy population (+-80%) (1, 2) indicating that a successful 
defence against HPV16 infection is commonly associated with the presence of a systemic 
effector T-cell response against these viral antigens. Our studies revealed that the HPV-
specific T cell response is different at multiple levels in patients with HPV induced disease 
(systemically and locally), varying from no response, or a dysfunctional response, to an anti-
inflammatory response in the presence of Tregs. In patients with cervical cancer, HPV16 
specific systemic immune responses are detected in only about half of all patients (3) and 
are predominantly not associated with the production of pro-inflammatory cytokines. We 
found that this immune failure against HPV starts earlier and is already present at the time 
of pre-cancerous disease (HSIL) (chapter 2). We found an HPV 16 specific proliferative 
T-cell response against HPV16 in a minority of patients, and similar to cervical cancer 
patients, these T-cell responses mostly lacked a pro-inflammatory signature.
Tumours can mediate systemic and local effects in their effort to escape the immune 
system. Circulating HPV-specific lymphocytes have to home to the lesion and overcome 
the often hostile anti-inflammatory tumour microenvironment. Previous in situ immuno-
histochemical studies suggest that CD8+ T cells fail to migrate into the tumour cell nests 
and when they did this it usually coincided with the infiltration of regulatory CD4+ T cells 
(4). Yet immunohistochemistry cannot define the tumour specificity of these infiltrating 
lymphocytes. TIL cultures suggest that only 50-60% of the HPV16 or 18-positive cervical 
carcinoma, and 4 out of 7 HSIL, contain no HPV specific T cells in the tumour or its drain-
ing lymph nodes ((5) chapter 2). When HPV specific T cells were found they comprised not 
only HPV-specific effector cells but also HPV-specific regulatory T cells ((6); chapter 2). In 
the face of developing therapeutic vaccination strategies, it is important to gain a better and 
more complete understanding of the local tumour environment and the preexisting local 
anti-tumour response. This led to our in depth analysis of the spontaneous local tumour-
specific immune response whereby we dissected the HPV E6- and E7-specific CD4+ and 
CD8+ T-cell responses down to the level of the percentage, specificity, cytokine polarization 
and number of different responding T-cells (chapter 3). We discovered that large polyclonal 







repertoires of HPV-specific T cells can be present in tumours. At that time, we called these 
T-cells poised and non-functional yet in retrospect many tumours do contain HPV-specific 
T cells that seem well polarized and are able to produce IFNγ and IL-2 when stimulated 
ex vivo with their cognate antigen. This again shows the diversity of local HPV-specific 
responses varying from no HPV-specific T-cells, to regulatory T-cells, to dysfunctional or 
poised T-cells. Overcoming this immune failure is the key to successful immunotherapy 
and we found that the effector function of infiltrating T-cells could be enhanced when 
cultured in the presence of TLR ligands, such as PAM3CSK4 or poly(I:C) (chapter 3). The 
use of immune activating compounds, like TLR ligands, could have beneficial effects for 
therapeutic strategies. Imiquimod, which is used in the clinic for the treatment of genital 
warts and VIN, is an immune response modifier which triggers the TLR7 receptor. In 
patients with VIN the majority that responded to treatment had a pre-existing systemic 
HPV specific T-cells response (7). Although the local HPV specific T cell response was 
not investigated it deems plausible that this pre-existing HPV-specific T-cell response was 
activated in response to treatment.
It is clear that the tumour microenvironment is a precarious balance between tumour 
cells, infiltrating immune cells and the cytokines they produce. One of the hallmarks of can-
cer is the influx of myeloid cells which can be found infiltrating tumours in great numbers. 
In chapter 4 we aimed to improve our current understanding of the local microenvironment 
in cervical carcinomas. We focused on the constitution of tumour-infiltrating myeloid cells 
(TIM) and their relationship to other tumour-infiltrating immune cells, tumour character-
istics and the disease-specific survival of patients with cervical cancer. Extensive literature 
demonstrates that high numbers of TAM facilitate tumour growth, disease progression and 
poor prognosis in various cancer types as reviewed by Heusinkveld et al (8). However, in 
CxCa, TAMs were never associated with clinical parameters or clinical outcome (9-11). 
Quantification of myeloid cell populations revealed a large variety between patients in 
type and amount of TIM, varying from no myeloid cells, to an abundance of mature or 
immature M1 and M2 macrophages. Analysis showed that a strong intraepithelial infiltra-
tion of matured M1 macrophages (CD14+CD33−CD163−), is associated with significantly 
improved disease-specific survival and is an independent prognostic factor as determined 
by multivariate analysis. Moreover, analysis with the CTL/Foxp3 ratio revealed a substantial 
increase in survival in the group of patients with tumours displaying dense intraepithelial 
matured M1 macrophage infiltrate and a high CD8+/Foxp3+ T-cell ratio. This work shows 
the importance of taking the whole tumour microenvironment into account and offers a 
profound insight on the important role of myeloid cells in the microenvironment and how 
they can work side by side with T cells to control tumours. Extensive studies in colorectal 
cancer have accentuated the importance of the number, function and location of infiltrating 
immune cells in the tumour microenvironment, leading to the development an immune 
score with a strong correlation to survival (12-14). Indeed in colorectal tumors B and T 
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cell infiltration can be linked to the production of IL-15, which in turn can be traced back 
to chromosomal changes in the tumor, underling the fact that multiple mechanisms can be 
involved in the creation of the tumour microenvironment. We succeeded in finding immu-
nological fingerprints for cervical cancer by performing unsupervised clustering using 40 
different immune parameters of the tumour microenvironment. The main determinants for 
a better survival were the presence of matured M1 macrophages and a high CD8+/Foxp3+ 
T-cell ratio, both independent prognostic factors. We found that the tumour-infiltrating 
T-cells are less able to exert a proper antitumour effect within a tumour microenvironment 
that does not allow the accumulation of high numbers of M1 macrophages. Patients with a 
better survival often have tumours that are infiltrated with relatively high numbers of M1 
macrophages and displayed a high CD8/Treg ratio.
In view of our findings, selective inhibition of M2 macrophages together with the stimula-
tion of M1 macrophages would seem a possible beneficial therapy in cervical cancer. In 
order to explore this possibility we analysed the effect of tumour cells on myeloid cell differ-
entiation in order to explore the possibilities of reprogramming the abundantly present M2 
macrophages toward an M1 phenotype. Our vitro analysis in chapter 5 shows that cancer 
cells can hamper DC differentiation and function and can induce M2-like macrophages by 
the production of IL-6 and PGE2. Blocking these two cytokines during the differentiation 
period of the monocyte prevented the differentiation of monocytes to M2 macrophages. 
Furthermore, fully polarized M2 macrophages could switch to M1 macrophages when 
interacting with Th1 cells. A combination therapy consisting of COX inhibition, IL-6 block-
ing, and the induction of a strong Th1 T cell response could be a promising form of im-
munotherapy for the treatment of CxCa. COX-inhibiting drugs and mAbs to IL-6 receptor 
are used in the clinic for treatment of autoimmune diseases and further exploration of their 
use in the treatment of cancer is underway in our group. HPV-specific Th1 T-cell responses 
can be elicited by therapeutic vaccination.
Vaccination is a powerful method to induce humoral and cellular adaptive immune 
responses. The treatment of cancer strongly depends on the activation of antigen-specific 
CD4 and CD8 T cells with the ultimate aim of destroying the tumour cells. The capacity 
of the immune system to combat cancer is shown by the approval of a cell-based vaccine 
for the treatment of prostate cancer (Provenge) and an aspecific T-cell stimulating thera-
peutic antibody for the treatment of melanoma (Ipilimumab). Synthetic peptide vaccines 
were initially developed in order to elicit tumour-specific CTL responses and consisted of 
short peptides. These early vaccine were able to elicit CTL responses able to protect against 
tumour challenge in preclinical studies, yet in time after an initial expansion phase could 
result in functional deletion of the antigen-specific T cells, leading to enhanced tumour 
outgrowth (15). The discovery that long peptides prevented tolerance induction, induced 
CD4 helper responses and increased the diversity of the anti-tumour response, which could 
help reduce selective tumour antigen-loss during treatment (16), led to the development of 







an HPV16 overlapping long synthetic peptide vaccine consisting of the whole length of the 
oncogenic proteins E6 and E7 emulsified in Montanide (17). Montanide ISA-51 is a water 
in oil emulsion that is frequently used with peptide vaccines as adjuvants. It’s main function 
is a depot formation which inhibits immediate systemic bio-distribution of the peptides 
(which can lead to the cytokine release syndrome) and improves uptake by APCs. The group 
previously reported that vaccination with HPV16-SLP (25–35 amino acids) was highly im-
munogenic in end-stage cervical cancer patients (18, 19) and could result in complete and 
durable regression of human papilloma virus-induced premalignant lesions of the vulva 
by induction of a strong and broad multifunctional CD4 and CD8 T-cell reaction (20, 21).
Our first placebo-controlled study was in a group of patients with HSIL (CIN3 trial). 
Vaccination in patients with precancerous lesions has a distinct advantage as the develop-
ment of cancer can be prevented. The study was set up to evaluate the local response after 
vaccination, but we ran into motivational problems in this patient group for whom there is 
a treatment available. Furthermore the patients experienced considerable systemic (flu-like 
symptoms) and local side effects (redness, swelling, itching and pain) which caused drop-
out leading to premature closure of the study. The side effects had been expected as they 
were seen in our previous trials, yet in this group they seemed more severe and were less 
well accepted in the light of the fact that patients with a HSIL experience no symptoms of 
their lesions and have an available therapy. However, this was the first placebo-controlled 
trial with the HPV16-SLP vaccine and although the numbers were small, it allowed us to 
show that vaccination compared to the standard care, which includes a biopsy, can induce 
a broad and strong HPV16-specific response associated with the production of IFNγ, as 
measured by ex vivo IFNγ-ELISPOT and it showed that the responses are detectable by a 
skin test.
Our second randomized controlled trial included patients with low grade lesions of the 
cervix (CIN1 trial). The purpose of this trial was to study the long term memory response 
to the vaccine. In addition, as in this trial a lower vaccine dose was used it also allowed us 
to evaluate if this would lead to less side-effects without loss of immunogenicity. The differ-
ences in the HPV16-specific T-cell responses detected between the patients in the vaccine 
and placebo groups clearly showed that the lower dose HPV16-SLP vaccine is responsible 
for a strong HPV16-specific T-cell response after vaccination. This response, still detectable 
after one year, was boosted by re-vaccination. However a rise in Th2 type cytokines were 
seen, possibly warranting the addition of a polarizing adjuvants. Though less severe than in 
the HSIL group, the side-effects found is some patients were still difficult to accept. Espe-
cially the delayed local reactions at the vaccination sites, which included sterile abscesses, 
occurring several weeks to months after vaccination are cause for concern. Montanide 
ISA 51 is not a component of any approved human vaccine, but has been used in many 
previous trials. Recently more reports have been published outing concern about severe 
injection-site reactions with occasional sterile abscess formation (22-24) These side-effects 
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may be acceptable in the treatment of patients with (recurrent) cancer, yet to patients with 
pre-clinical lesions they are unacceptable. Based on these data, new clinical trials have been 
set up to test the immunogenicity of the HPV16-SLP when injected intradermally without 
montanide, and a trial in which the vaccine peptides are conjugated to a TLR2 ligand and 
injected intradermally.
So what is the way forward for immunotherapy in cervical cancer? Our and other studies 
on the mechanisms underlying the generation of anti-tumour responses and the immune 
evasion by tumours have underscored that multiple mechanisms restrain the host’s immune 
system to rise to the challenge of combating the tumour. On the other hand favourable 
immune profiles have been highlighted that need boosting in order to keep the balance in 
favour of tumour eradication. Therapy should combine various synergistic approaches, and 
old and new therapies should be used side by side in order to enhance vaccination efficacy 
and counteract tumour suppression. In order to boost the T cell response to CxCa one 
should put further effort in the combination with better adjuvants, delivered separately or 
conjugated to a vaccine. Continued research in pre-clinical and clinical settings within our 
group is investigating the possibilities of using HPV16 SLP vaccination in combination with 
other adjuvants such as IFNα (25) and Imiquimod (TLR 7), or a TLR2 ligand conjugated 
to the HPV16-SLP (unpublished data). Based on a study where healthy individuals showed 
an HPV 16 specific T-cell response after placement of a skin test, intradermal injection or 
delivery by tattoeage are being further investigated as a possibility of avoiding the use of 
Montanide. Preliminary data within our group show that tocilizumab, used in the treatment 
of rheumatoid arthritis, can functionally block the IL-6 receptor in patients with ovarian 
cancer. As cervical carcinoma, similar to ovarian cancer, produces IL-6 which is linked 
to a worse survival (26, 27) further research to its use in cervical cancer patients is war-
ranted. Current studies within our group show alterations in the number and phenotype of 
circulating and local myeloid cells in both an animal model for CxCa and in patients with 
CxCa when compared to controls. The current standard therapy (carboplatin + paclitaxel) 
normalizes the myeloid cell population as well as synergizes with therapeutic vaccination 
(Welters & van der Sluis & van Meir, in preparation) Alternatively, one could enhance the 
number of tumour-specific T cells via adoptive cell transfer of ex-vivo cultured tumour-
infiltrating lymphocytes as we showed in chapter 3. Current studies show it is feasible and a 
phase 1 clinical trial is being discussed. Other possibilities lie in the blocking of inhibitory 
receptors. In cervical carcinoma PD-1 is brought to expression in about half of the infiltrat-
ing CD8 T cells (28, 29), suggesting that the blocking of PD-1 or its ligand PD-1L could 
have therapeutic benefits. Agonistic antibodies to co-stimulatory receptors can also be 
considered. We showed that CD40 can stimulate a shift from M2 to M1 in the presence of 
IFNγ. Combining a monoclonal antibody to CD40 with a vaccine or other standard treat-
ments e.g. surgery, radiation or chemotherapy are being investigated in clinical trials in 
patients with melanoma, haematological malignancies, pancreatic and prostate cancer as 







reviewed by Khong et al (30) and VonderHeide et al (31) and should be further investigated 
in cervical cancer.
Our ongoing research has led to new insights into the role of the immune system in HPV 
induced disease and to various immunotherapeutic options which are being tested in pre-
clinical and clinical trials. A future of possibilities lies ahead, all new immunotherapeutic 
strategies and combinations of therapies need extensive and accurate exploration as to 
dose optimisation, interaction, timing of delivery and feasibility. We should proceed with 
optimism, yet with great care.
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e ng l I sh sum m a ry
Cervical Cancer
Cervical cancer is preceded by pre-malignant dysplastic changes in the epithelium known as 
cervical intraepithelial neoplasia (CIN) or squamous intraepithelial lesions (SIL). Affected 
cells comprising of more than one-third of the epithelium are called CIN 2/ 3 or high-grade 
SIL (HSIL). HSIL is caused by persistent infection with the human papillomavirus (HPV), 
a DNA virus infecting the basal cells of the cervical epithelium. There are over 100 types of 
HPV, which can be divided into low-risk (non-oncogenic) and high-risk (oncogenic) HPV. 
HPV is the most common sexually transmitted virus with a lifetime risk of infection of 80%. 
In the majority of cases infection is controlled after approximately 2 years, but persistence 
of infection occurs in about 10% of the women. These women are at risk of developing 
CIN, but other areas can be infected as well (vagina, anus, vulva, penis and/or head and 
neck) with risk of progression to invasive squamous(adeno)carcinoma. The HPV genome 
importantly encodes the two oncoproteins, the early antigens 6 (E6) and 7 (E7), which are 
expressed in HSIL and tumour cells which are required for the onset and maintenance of 
the malignant transformation.
Immunology
Keratinocytes are the first line of defense against invading pathogens. They express among 
other pathogen receptors, Toll-like receptor (TLR)-9, which can recognize HPV DNA. 
Activation of TLR9 should lead to activation of NF-kB, which results in the up regulation of 
proinflammatory cytokines (e.g. GM-CSF, IL-1b, TNF-a, IL-10, Il-12) and chemokine’s, in-
ducing the migration and the activation of antigen-presenting cells (APC’s) e.g. Langerhans 
cells (LC’s), Dendritic cells (DC’s) and macrophages. Cues in the microenvironment will 
evoke APC to differentiate and migrate to the local lymphoid organs in order to present an-
tigens to locally present naive T cells. Depending on different co-stimulatory or -inhibitory 
molecules and cytokine production (e.g., IL-12 or IL-10), a T-cell response will be induced 
which may comprise various CD8+ cytotoxic T cells (CTLs), CD4+ helper T cells (Th cells) 
and/or CD25+FoxP3+ regulatory T cells (Tregs). As HPV proteins are foreign to the body 
they should be able to trigger a strong immune reaction when presented in the cervical 
epithelium.
In the circulation of healthy individuals HPV-16 specific Th1, Th2 cells and CTLs are often 
detected against HPV. The importance of the adaptive immune system is shown by the high 
incidence of HPV infections, HSIL and cervical cancer in immune suppressed individuals. 
A broad HPV specific T-cell response, consisting of Th1, Th2 and CTLs, seems desired for 
viral control, yet in patients with HPV induced disease this response is often not present. It 
deems logical that restoration of this profile is one of the aims of immunotherapeutic strate-
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gies. Failure of immune system to control infection is reflected by the fact that only one 
third of cervical cancer patients display a detectable systemic HPV-specific response against 
HPV, and when it is present, the response is generally not associated with the production of 
IFN-γ and consists of mostly Th2 cells, non-polarized T cells or Tregs. In the course of HPV 
infection to cervical cancer, various factors seem to play an important role. Pathogen rec-
ognition receptor (PPR) signaling in keratinocytes is suppressed, human leukocyte antigen 
(HLA) expression (important for the recognitions of cancer cells by lymphocytes) is down 
regulated, immunosuppressive cytokines are produced, Tregs are induced, while Th cells 
and CTLs may be rendered dysfunctional via the expression of co-inhibitory molecules. 
Furthermore, APC’s are hampered in their function.
Immunotherapy of cancer
With all evidence pointing in the direction that failure of the immune system leads to the 
development of cervical cancer, restoration of an effective anti-tumour immunity seems the 
logical way forward. Various modalities have been developed with limited success, affecting 
often a minority of patients with progressive disease. As discussed above a multitude of 
mechanisms can be responsible for the tumours escape from the hosts’ immune system. 
Therefore successful immunotherapy probably lies in multiple therapeutic strategies aiming 
at the enhancement of immune-mediated tumour destruction as well as simultaneously 
counteracting the tumour-induced immune suppression. Three main modalities have been 
developed to achieve this goal, therapeutic vaccination, antibody or cytokine therapy and 
adoptive cell transfer, but it is likely that this arsenal will increase tremendously in the com-
ing years.
This Thesis
In the face of developing therapeutic vaccination strategies, it is of vital importance to gain 
a better understanding of the local tumour environment and the pre-existing local anti-
tumour response. This thesis firstly investigates the natural immune response against HPV 
in patients with (pre-) cancerous lesions of the cervix with an emphasis on the tumour 
microenvironment. The last two chapters describe two clinical trials in which patients with 
pre-cancerous lesions of the cervix are vaccinated with an HPV16 E6/E7 synthetic overlap-
ping long-peptide vaccine (HPV16-SLP).
In Chapter 2 we show that failure of the immune system is already present in a pre-cancerous 
phase. Only a minority of the patients with HPV16+ HSIL have an IFNγ associated HPV16 
specific T cell response. Proliferative responses were found more often, especially in patients 
with persisting infections after previous surgical treatment. Moreover, we showed that these 








ter formed a good basis for the design and interpretation of immunotherapeutic vaccine 
approaches as treatment modality for HPV-induced in CIN.
In Chapter 3 we comprehensively analyzed the spontaneous tumour-specific immune 
response in patients with cervical cancer. We describe a large repertoire of HPV-specific T 
cells present in the tumour and lymph nodes of cervical cancer patients, whereby we dis-
tinguished four different cytokine signatures. This work shows lymphocytes can be isolated 
and cultured from tumour tissue for use in adoptive cell transfer.
A tumour is surrounded by stroma which is made up of, among others, fibroblasts, blood and 
lymph vessels and various immune cells. The tumour cells, immune cells and the cytokines 
they produce form a precarious balance, which is called the tumour microenvironment. The 
focus of Chapter 4 was to further improve our knowledge of the local microenvironment. 
We show an important role for myeloid cells, whereby, a strong intraepithelial infiltration 
with CD14+CD33-CD163- myeloid cells is associated with a large influx of intraepithe-
lial T lymphocytes and an improved disease-specific survival. Furthermore we identified 
various immune fingerprints by analyzing 40 different immune parameters in the tumour 
microenvironment which are associated with the survival of patients. Chapter 5 further 
investigates the influence of human cervical cancer cells on myeloid cell (monocyte) dif-
ferentiation. It shows that cancer cells can either hamper monocyte to DC differentiation, 
or skew their differentiation towards M2-like (immune suppressive) macrophages. Block-
ing studies revealed that M2-differentiation is caused by tumour-produced PgE2 and IL-6. 
Furthermore, upon CD40 activation or interaction with Th1 cells, these tumour-induced 
M2-macrophages could be switched back to activated M1-like macrophages. Blocking of 
Il-6 or PGE2 (through COX inhibitors) together with vaccination aimed at the induction 
of HPV specific Th1 cells could be beneficial in changing the tumour microenvironment 
towards an pro-inflammatory tumour rejecting profile.
The last two chapters describe two clinical studies testing the HPV16 synthetic long peptide 
vaccine (SLP) in patients with CIN. Chapter 6 describes a placebo controlled randomized 
phase II study in patients with HPV16 positive high grade CIN (CINII/III). The aim of the 
study was to investigate the capacity of the HPV16-SLP vaccine to stimulate the HPV16-
specific T-cell response and to enhance the infiltration of HPV16-specific type 1 T-cells 
into the lesions and HPV clearance. Vaccination of HSIL patients resulted in increased Th1 
HPV16-specific T-cell immunity, yet encountered problems of accrual and unacceptable 
local side-effects. Chapter 7 investigates the capacity of a low dose of HPV16-SLP vaccine 
to induce an HPV16-specific T-cell response in patients with low grade abnormalities of 
the cervix, to determine the long term memory response after vaccination and to evaluate 
the need and potency of a booster vaccination after one year. We concluded that two low 
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dose injections of HPV16-SLP can induce a strong and stable HPV16-specific Th1 T-cell 
response that lasts at least for 1 year. The booster injection resulted in increased Th2 re-
sponses. In order to further develop the HPV16-SLP in this group of patients it is essential 
to reduce the side-effects.
The future of immunotherapy in cervical cancer
So what is the way forward for immunotherapy in cervical cancer? Our and other studies 
on the mechanisms underlying the generation of anti-tumour responses and the immune 
evasion by tumours have underscored that multiple mechanisms restrain the host’s immune 
system to rise to the challenge of combating the tumour. On the other hand favorable 
immune profiles have been highlighted that need boosting in order to keep the balance 
in favor of tumour eradication. Therapy should combine various synergistic approaches, 
and old and new therapies should be used side by side in order to enhance vaccination 
efficacy and counteract tumour suppression. Continued research in pre-clinical and clinical 
settings within our group is investigating the possibilities of using HPV16 SLP vaccina-
tion in combination with other adjuvants such as IFNα and Imiquimod, or a TLR2 ligand 
conjugated to the HPV16-SLP. Furthermore intradermal injection or delivery by tattooing 
are being further investigated as a possibility of avoiding the use of Montanide. Preliminary 
data within our group show that Tocilizumab, can functionally block the IL-6 receptor 
in patients with ovarian cancer. IL-6 is produced in cervical cancer affecting myeloid cell 
populations, further research to its use in cervical cancer patients is warranted. Preliminary 
results within the group shows that the current standard therapy (carboplatin + paclitaxel) 
for cervical cancer, normalizes the myeloid cell population as well as synergizes with thera-
peutic vaccination. Alternatively, one could enhance the number of tumour-specific T cells 
via adoptive cell transfer of ex-vivo cultured tumour-infiltrating lymphocytes as we showed 
in chapter 3. Current studies show it is feasible and a phase 1 clinical trial is being discussed. 
Other possibilities lie in the blocking of inhibitory receptors. In cervical carcinoma PD-1 
is brought to expression in about half of the infiltrating CD8 T cells, suggesting that the 
blocking of PD-1 or its ligand PD-1L could have therapeutic benefits. Agonistic antibodies 
to co-stimulatory receptors can also be considered. We showed that CD40 can stimulate a 
shift from M2 to M1 in the presence of IFN-γ. Combining a monoclonal antibody to CD40 
with a vaccine or other standard treatments e.g. surgery, radiation or chemotherapy should 
be further investigated in cervical cancer.
Our ongoing research has led to new insights into the role of the immune system in HPV 
induced disease and to various immunotherapeutic options which are being tested in pre-
clinical and clinical trials. A future of possibilities lies ahead, all new immunotherapeutic 
strategies and combinations of therapies need extensive and accurate exploration as to dose 










n e de r l a n d se s a m e n vat t I ng
Immunologie en Immunotherapie van premaligne afwijkingen en kanker van de baar-
moederhals
Baarmoederhalskanker
Baarmoederhalskanker (het cervixcarcinoom) wordt veroorzaakt door een virus, het hu-
maan papillomavirus (HPV). Er zijn meer dan 100 verschillende soorten HPV ingedeeld in 
laag-risico (niet-oncogene) virussen en hoog-risico (oncogene) virussen. Voordat er sprake 
is van een maligniteit, kan er jaren lang sprake zijn van premaligne veranderingen in het 
epitheel van de baarmoedermond, beter bekend als Cervicale Intra-epitheliale Neoplasie 
(CIN). HPV is de meest voorkomende seksueel overdraagbare aandoening, ongeveer 80% 
van alle vrouwen zal ooit geïnfecteerd raken. De meerderheid van de infecties zal binnen 
twee jaar geklaard worden, echter in 10% van de gevallen zal het virus persisteren, met 
kans op het ontstaan van CIN. Het HPV brengt twee oncogene eiwitten tot expressie (E6 en 
E7). Deze eiwitten, die aanwezig zijn in alle hooggradige CIN (CIN II/III) en kankercellen, 
zorgen voor een maligne transformatie van de cellen, maar kunnen ook als markers op 
de cellen gebruikt worden om de kwaadaardige cellen te herkennen tussen de omliggende 
gezonde cellen.
Immunologie
Het immuunsysteem beschermt het lichaam tegen virussen, bacteriën en parasieten, maar 
ruimt ook afvalstoffen en zieke cellen (zoals kankercellen) op. Keratinocyten (epitheel 
cellen) zijn de eerstelijns verdediging tegen indringers doordat ze receptoren tot expressie 
brengen (Toll-like receptoren, TLR) die pathogenen, zoals HPV, kunnen herkennen. Als 
ze in aanraking komen met een pathogeen wordt de TLR geactiveerd, wat een cascade in 
de cel teweegbrengt, met als doel de productie van allerlei afweer stimulerende cytokinen 
(b.v. GM-CSF, IL-1b, TNF-a, IL-10, IL-12) en chemokinen die zorgen voor het aantrekken 
van antigeen-presenterende cellen (APC’s) o.a. Langerhans cellen (LC), Dendritische cellen 
(DC’s) en Macrofagen. De APC’s reageren op signalen in de omgeving en zullen daardoor 
op een bepaalde manier differentiëren en migreren naar de lymfeklieren, om daar de an-
tigenen te presenteren aan naïeve T-cellen (lymfocyten). Afhankelijk van co-stimulatoire 
of inhibitoire moleculen (bv IL-12 vs. IL-10) zal een T-cel reactie geïnduceerd worden 
bestaande uit CD8+ cytotoxische T-cellen (CTLs), CD4+ helper T-cellen (Th cellen) en/ of 
CD25+FoxP3+ regulatoire T-cellen.
Het belang van een goede T-cel respons in de verdediging tegen HPV, wordt evident 
bij immuun gecomprimeerde personen, waar een hoge incidentie van CIN II/III en baar-
moederhalskanker wordt gevonden. In de circulatie van gezonde individuen wordt vaak 
een breed HPV specifiek Th1, Th2 en CTL immuun respons gevonden wat gepaard gaat 
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met de productie van pro-inflammatoire cytokinen (bv Interferon (IFN-)γ). Een breed 
HPV-specifiek respons lijkt essentieel om het virus onder controle te krijgen. Het falen 
van het immuunsysteem om HPV onder controle te krijgen wordt gezien in patiënten met 
baarmoederhalskanker, waarbij maar in een derde van de patiënten een systemische HPV-
specifieke T-cel respons tegen de HPV E6 en E7 wordt gevonden. Een minderheid van die 
responsen gaat gepaard met de productie van IFN-γ en word er voornamelijk Th2 cellen, 
niet-gepolariseerde cellen en regulatoire T cellen gevonden.
In de loop van een HPV infectie zijn er meerdere mechanismen die een rol lijken te spelen 
in het ontwijken van het immuunsysteem. Zo wordt in keratinocyten de cascade na activatie 
van TLR onderdrukt. Het HLA expressie (humaan leukocytenantigen, belangrijk voor de 
herkenning van kanker cellen door, en de activatie van lymfocyten) wordt onderdrukt en 
er worden immunosuppressieve cytokinen geproduceerd. Regulatoire T-cellen worden 
geactiveerd terwijl Th cellen en CTLs dysfunctioneel worden gemaakt door de expressie 
van co-inhibitoire moleculen. Tot slot worden de APC’s ondermijnd in hun functie.
Immunotherapie bij kanker
Het falen van het immuunsysteem kan dus leiden tot het ontstaan van kanker. Logisch-
erwijs is het herstellen van een goed immuun profiel één van de belangrijke doelen van 
immunotherapeutische strategieën. Verschillende therapieën zijn in de loop van de jaren 
ontwikkeld, vaak met gelimiteerd succes, waarbij maar een kleine gedeelte van de patiënten 
baat lijkt te hebben. Dit zou dit kunnen liggen aan het feit dat er meerdere mechanis-
men betrokken bij het ontwijken van de tumor aan het immuunsysteem (tumor escape). 
Een succes ligt dan waarschijnlijk ook in een gecombineerde aanpak waarbij meerdere 
therapeutische strategieën worden gecombineerd. Enerzijds moet het immuun-gemedieerd 
tumorvernietiging bevorderd worden en anderzijds moet het tumor-gemedieerde immuun 
suppressie uitgeschakeld worden. Er zijn grofweg drie immunotherapeutische strategieën: 
therapeutisch vaccineren, antilichaam- of cytokinetherapie en adoptieve T cel therapie. De 
verwachting is dat het aantal strategieën in de komende jaren sterk zal toenemen.
dit proefschrift
In de zoektocht naar effectieve en innovatieve immunotherapeutische behandelingen van 
baarmoederhalskanker, is het essentieel om meer te weten over de bestaande anti-tumorale 
immuniteit in het bloed en in de tumor zelf. Dit proefschrift draagt bij aan lopend onderzoek 
naar de rol van het immuunsysteem in het ontstaan van baarmoederhalskanker met nadruk 
op het lokale tumor micromilieu en een verdere ontwikkeling van een therapeutisch vaccin.
In Hoofdstuk 2 laten we zien dat het falen van het immuunsysteem reeds in de premaligne 










III laesies, heeft een IFN-γ geassocieerde immuunrespons tegen HPV16. Dysfunctionele 
proliferatieve responsen worden vaker gevonden bij patiënten met persisterende infectie na 
chirurgische behandeling. Ook hebben we HPV16 specifieke regulatoire T-cellen kunnen 
kweken uit CINII/III laesies. Dit onderzoek laat zien dat er ruimte is voor immunotherapie 
bij premaligne afwijkingen van de baarmoedermonden en het heeft de basis gelegd voor het 
ontwikkelen van een therapeutisch vaccin voor patiënten met CIN.
Hoofdstuk 3 beschrijft een uitgebreide onderzoek naar de lokale HPV16 E6 en E7 spe-
cifieke T-cellen, gekweekt uit baarmoederhalstumoren en de drainerende lymfeklieren. 
Grote repertoires aan HPV specifieke T-cellen kunnen aanwezig zijn die ingedeeld kunnen 
worden in verschillende cytokine profielen. De cellen zijn goed te geïsoleerd en te kweken 
en zouden gebruikt kunnen worden in adoptieve T-cel therapie voor patiënten met baar-
moederhalskanker.
Een tumor is omgeven door een stroma opgebouwd uit o.a. fibroblasten, bloed- en lymfe-
vaten en immuun cellen. Er bestaat een precaire balans tussen tumor cellen, infiltrerende 
immuun cellen en de cytokinen die geproduceerd worden. Dit wordt het tumor micromilieu 
genoemd. In hoofdstuk 4 brengen wij het tumor micromilieu verder in kaart bij patiënten 
met baarmoederhalskanker. Wij laten een belangrijke rol zien voor myloide cellen. Intra-
epitheliale CD14+CD33-CD163- myloide cellen worden geassocieerd met een sterkte intra-
epitheliale toename van T cellen en een verbeterde overleving van de patiënten. Tevens 
brengen we 40 bekende immuun parameters van het tumor micromilieu in kaart, waarbij 
we verschillende immuun profielen vinden, die geassocieerd zijn met de overleving van 
patiënten. In hoofdstuk 5 gaan we dieper in op het tumor micromilieu en laten we zien hoe 
baarmoederhalskanker cellen de myeoide cellen kunnen beïnvloeden door de differentiatie 
van monocyten tot DC te verstoren tot anti-inflammatoire macrofagen (M2). Wij identifi-
ceren twee cytokinen, geproduceerd door de kankercellen, die hiervoor verantwoordelijk 
zijn (PgE2 en Il-6). Wij zijn vervolgens op zoek gegaan naar manieren om dit proces weer 
terug te draaien en laten zien dat dit bereikt kan worden door het blokkeren van PgE2 en 
IL-6, maar ook door CD40 activatie door interactie met geactiveerde T cellen. Bij patiënten 
met baarmoederhalskanker zou het blokkeren van Il-6 en/of PgE2 (door COX-inhibitoren) 
samen met de inductie van sterk geactiveerde T cellen (door bv. vaccinatie) kunnen leiden 
tot een veranderde pro-inflammatoir tumor micromilieuIn de laatste twee hoofdstukken 
beschrijven we twee klinische studies, waarin een HPV16 synthetisch lange peptide (SLP) 
vaccin in een Montanide adjuvant, getest wordt bij patiënten met CIN. Hoofdstuk 6 be-
schrijft een placebo gecontroleerde fase II studie waarin het HPV16 SLP wordt getest bij 
patiënten met een CIN II/III. Het doel van de studie was de immuniciteit van het vaccin 
in deze patiëntengroep, de capaciteit van het vaccin om T cellen te laten migreren naar de 
laesie en de klaring van het virus. Vaccinatie van patiënten met CIN II/III liet een sterke 
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toename in Th1 HPV16 specifieke immuniteit zien, echter stuitte het onderzoek op inclusie 
problemen en onacceptabele bijwerkingen ter plekke van de vaccinatie plek. Hoofdstuk 7 
onderzoekt de capaciteit van een lage dosering van het HPV16 SLP om een HPV16 speci-
fieke response te initiëren in patiënten met een afwijkend uitstrijkje of CIN I. Ook wilden 
we de lange termijn respons en de noodzaak tot een herhaling van het vaccin na 1 jaar te 
bekijken. Aan de hand dit onderzoek kunnen we concluderen dat twee lage doseringen van 
het HPV16 SLP een sterke immuunrespons kan induceren en dat deze respons langer dan 
een jaar intact blijft. Het revaccineren na 1 jaar initieerde voornamelijk een Th2 respons. 
Om het HPV16 SLP vaccin verder te ontwikkelen in deze patiënten groep is een reductie in 
de lokale bijwerkingen essentieel. Lopend onderzoek zal moeten uitwijzen of het intrader-
maal injecteren van het HPV16 SLP, eventueel geconjugeerd aan TLR2 zonder Montanide, 
de bijwerkingen kan verminderen zonder verlies van effectiviteit.
de toekomst van immunotherapie bij baarmoederhalskanker?
Ons onderzoek benadrukt dat er meerdere mechanismen zijn die voorkomen dat het im-
muun systeem erin slaagt een tumor te bestrijden. Wij laten echter ook zien dat er gunstige 
immuun profielen bestaan die versterkt of nagebootst kunnen worden om het balans weer in 
het voordeel van tumor destructie te drijven. Het antwoord tot succes ligt waarschijnlijk in 
het gebruik van meerdere synergistische therapieën en het combineren van oude en nieuwe 
therapieën, om de effectiviteit te vergroten en immuun suppressieve werking van de tumor 
tegen te gaan. Preklinische en klinische studies binnen onze onderzoeksgroep richten zich 
op het optimaliseren van het HPV16 SLP vaccin en het ontwikkelen van nieuwe therapieën. 
Om de bijwerkingen van het vaccin te verminderen en de effectiviteit te vergroten, wordt het 
gebruik van andere adjuvanten bekeken (bv IFNα, Imiquimod, TLR2) en andere methodes 
van vaccineren (bv tatoeage) ontwikkelt. Een onderzoek in patiënten met eierstokkanker 
laat zien dat Tocilizumab de productie van Il-6 kan onderdrukken. Gezien het effect van 
Il-6 op myeloide cellen, beschreven in hoofdstuk 5, moet dit verder onderzocht worden in 
patiënten met baarmoederhalskanker. De standaard chemotherapie tegen baarmoederhals-
kanker is Carboplatin en Taxol. Recente resultaten van onze onderzoeksgroep laten zien dat 
behandeling met Carboplatin en Taxol de myeloide populaties in patiënten normaliseert en 
dat het een synergistische werking heeft op het HPV16-SLP vaccin. Een ander alternatief 
is het versterken van het aantal tumor specifieke T cellen door middel van adoptieve T 
cel therapie, zoals beschreven in hoofdstuk 3. Een fase 1 studie wordt momenteel opgezet. 
Stimulatie van CD40 in het bijzijn van IFN-γ kan een shift van M2 naar M1 cellen te-
weegbrengen, zoals beschreven in hoofdstuk 5. Een monoclonale antilichaam tegen CD40, 
gecombineerd met een vaccin of standaard therapieën zoals chirurgie, chemotherapie of 
radiotherapie, moet verder onderzocht worden in patiënten met baarmoederhalskanker. 
Een andere mogelijkheid is het blokkeren van inhiberende receptoren bijvoorbeeld PD-1. 










infiltrerende CD8+ T cellen in baarmoederhalskanker. Het blokkeren van PD-1, of zijn 
ligand PD-1L, zou therapeutische consequenties kunnen hebben voor patiënten met baar-
moederhalskanker.
Ons onderzoek geeft nieuw inzicht in de rol van het immuun systeem in HPV geïnduceerde 
ziekten en in verschillende immunotherapeutische opties die verder worden uitgewerkt 
in lopende studies. De toekomst van de immunotherapie staat voor ons open. We dienen 
alle nieuwe behandelingen, en combinaties van behandelingen, nauwkeurig te testen op 











l I st of a bbr e v Iat Ion s
ACT Adoptive cell transfer
APC Antigen-presenting cells
CD cluster of differentiation
CIN Cervical intraepithelial neoplasia
CTL Cytotoxic T cells
CTLA-4 Cytotoxic T-Lymphocyte Antigen 4
CxCa Cervical cancer
CXCL chemokine (C-X-C motif) ligand
DC Dendritic cells
E Early antigen
GM-CSF Granulocyte-macrophage colony-stimulating factor







M1 Macrophage type 1
M2 Macrophage type 2
mAbs Monoclonal antibodies
MICA MHC class I chain related molecule A
NF-kB nuclear factor kappa-light-chain-enhancer of activated B cells
NK Natural Killer
NKG2D natural-killer group 2, member D
PD-1 Program death 1
PD-L Program death ligand
PPR Pathogen recognition receptor
SIL Squamous intraepithelial lesions
SLP Synthetic long-peptide
TAM Tumour associated macrophages
TGF Transforming growth factor
Th T helper
TIL Tumour infiltrating T cells
TIM Tumour infiltrating myeloid cell
TIM-3 T cell immunoglobulin mucin-3
TLR Toll-like receptor
TNF Tumor Necrosis Factor
Treg Regulatory T cells
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